10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001193125-18-160263.txt : 20180511 0001193125-18-160263.hdr.sgml : 20180511 20180511093655 ACCESSION NUMBER: 0001193125-18-160263 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 18825201 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d766736d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of Common Shares, without par value, outstanding as of May 11, 2018 was 7,416,814.

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	March 31, 2018 (unaudited)			June 30, 2017
ASSETS
Current Assets:
Cash and cash equivalents	$	3,541		$	10,494
Restricted cash		0			1,000
Receivables – net		5,884			5,906
Inventory		1,974			2,159
Prepaid expense and other assets		3,083			3,062

Total current assets		14,482			22,621
Property, plant and equipment, at cost		30,103			28,609
Less accumulated depreciation		19,559			18,319

Property, plant and equipment – net		10,544			10,290

Noncurrent Assets:
Intangible assets – net		1,500			1,587
Income tax receivable		296			0
Other noncurrent assets		969			838

Total noncurrent assets		2,765			2,425

TOTAL ASSETS	$	27,791		$	35,336

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,254		$	1,571
Current maturities of long-term debt, net of debt issuance costs		258			6,710
Accrued payroll and related taxes		2,381			2,098
Due to third party payors		293			658
Other accrued expenses		1,099			1,277

Total current liabilities		5,285			12,314
Long-Term Liabilities
Long-term debt, net of debt issuance costs		2,863			0
Noncurrent liability for professional liability risks		752			1,040
Other noncurrent liabilities		304			289

Total long-term liabilities		3,919			1,329
Commitment and Contingencies

Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 7,417 shares at March 31, 2018 and 9,163 at June 30, 2017		3,708			4,581
Additional paid-in capital		11,009			13,103
Retained earnings		4,197			4,336
Accumulated other comprehensive loss		(327	)		(327	)

Total Shareholders’ Equity		18,587			21,693

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	27,791		$	35,336

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(unaudited)


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Operating revenues (net of contractual allowances)	$	13,550		$	13,883		$	41,021		$	41,321
Less provision for bad debts of Healthcare Facilities segment		133			184			363			321

Net revenues		13,417			13,699			40,658			41,000
Costs and Expenses
Cost of goods sold		5,073			5,523			14,623			15,592
Salaries, wages and benefits		6,045			5,872			17,697			17,476
Provision for bad debts of Pharmacy segment		237			126			445			342
Supplies		448			455			1,361			1,373
Purchased services		672			692			2,021			2,113
Other operating expenses		1,052			1,194			3,639			4,015
Rent and lease expense		157			142			471			409
EHR incentive payments		0			0			(21	)		0
Depreciation and amortization		464			466			1,332			1,376

Operating Loss		(731	)		(771	)		(910	)		(1,696	)
Other Income (Expense):
Gain on sale of assets		183			2			181			3,019
Gain on economic damages claim, net		0			0			944			0
Loss on extinguishment of debt		0			0			(238	)		(243	)
Interest expense, net		(56	)		(129	)		(302	)		(507	)

Earnings (Loss) from Continuing Operations before income taxes		(604	)		(898	)		(325	)		573
Income Tax Benefit		0			(8	)		(296	)		(236	)

Earnings (Loss) from Continuing Operations		(604	)		(890	)		(29	)		809
Earnings (Loss) from Discontinued Operations, net of tax		16			(135	)		(110	)		4,287

Net Earnings (Loss)		(588	)		(1,025	)		(139	)		5,096
Other comprehensive income		0			0			0			0

Comprehensive Earnings (Loss)	$	(588	)	$	(1,025	)	$	(139	)	$	5,096

Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	(0.08	)	$	(0.10	)	$	(0.00	)	$	0.09

Diluted	$	(0.08	)	$	(0.10	)	$	(0.00	)	$	0.09

Discontinued Operations:
Basic	$	0.00		$	(0.01	)	$	(0.01	)	$	0.46

Diluted	$	0.00		$	(0.01	)	$	(0.01	)	$	0.45

Net Earnings (Loss):
Basic	$	(0.08	)	$	(0.11	)	$	(0.02	)	$	0.54

Diluted	$	(0.08	)	$	(0.11	)	$	(0.02	)	$	0.54

Weighted-Average Common Shares Outstanding:
Basic		7,417			9,334			8,564			9,408

Diluted		7,417			9,334			8,564			9,429

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended March 31,
	2018			2017
Net Cash Used in Operating Activities	$	(33	)	$	(4,999	)

Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment – continuing operations		(1,502	)		(1,097	)
Proceeds from sale of other assets		412			4,942
Proceeds from sale of hospital		0			14,620

Net Cash Provided by (Used in) Investing Activities		(1,090	)		18,465

Cash Flows Used in Financing Activities:
Repurchase of common shares		(2,974	)		(640	)
Payments on long-term debt – continuing operations		(3,856	)		(3,850	)
Receipt (Deposit) of restricted cash		1,000			(1,000	)

Net Cash Used in Financing Activities		(5,830	)		(5,490	)


Net increase (decrease) in Cash and Cash Equivalents		(6,953	)		7,976
Cash and Cash Equivalents Beginning of Period		10,494			3,261

Cash and Cash Equivalents End of Period	$	3,541		$	11,237


Supplemental Disclosure of Cash Flow Information:
Cash Paid for:
Interest	$	269		$	458

Income taxes	$	0		$	141

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED MARCH 31, 2018

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. – Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2018 and for the three and nine month periods ended March 31, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines.

The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets.

The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines.

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation for approximately $410. A pre-tax gain of $183 on the sale of these assets is included in the results for the three months ended March 31, 2018.

Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Net Revenues:
Chestatee Hospital	$	0		$	0		$	0		$	2,369
Other Sold Hospitals		77			(68	)		71			(288	)

	$	77		$	(68	)	$	71		$	2,081

Earnings (Loss) before income taxes:
Chestatee Hospital	$	0		$	(104	)	$	(38	)	$	83
Other Sold Hospitals		61			(69	)		45			(304	)
Life sciences and engineering		(36	)		(37	)		(108	)		(112	)
Gain (Loss) on sale of Chestatee Hospital		(9	)		0			(9	)		7,270

Earnings (Loss) before income taxes		16			(210	)		(110	)		6,937
Income tax expense		0			(75	)		0			2,650

Earnings (Loss) from discontinued operations	$	16		$	(135	)	$	(110	)	$	4,287

Chestatee Hospital – On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. A purchase price adjustment of $328 is due to the Company from the hospital buyer as a post-closing adjustment to the purchase price as confirmed by a binding decision of an independent accountant rendered pursuant to the purchase agreement. Chestatee retained certain liabilities, including certain employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds was used for the repayment of debt.

Other Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The earnings (loss) before income taxes of the Other Sold Hospitals results primarily from prior year Medicare and Medicaid cost report settlements.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2018 and 2017.

The components of pension expense for the three and nine months ended March 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Interest Cost	$	14		$	13		$	42		$	39
Expected return on assets		(9	)		(8	)		(27	)		(24	)
Amortization of prior service cost		31			32			93			97

Net pension expense	$	36		$	37		$	108		$	112

SunLink contributed $105 to the plan in the nine months ended March 31, 2018 and expects to contribute an additional $35 during the last fiscal quarter of the fiscal year ending June 30, 2018.

Note 4. – Economic Damages Claim

The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the nine months ended March 31, 2018.

Note 5. – Restricted Cash

Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt), a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan.

Note 6. – Shareholders’ Equity

Common Share Purchase Tender Offer – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,794, excluding fees and expenses relating to the Offer.

Stock-Based Compensation – For the three months ended March 31, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2018 and 2017, the Company recognized $7 and $59, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2018 and 2017, respectively.

Note 7. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues by payor were as follows for the three and nine months ended March 31, 2018 and 2017:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Healthcare Facilities Segment:
Medicare	$	2,485		$	2,079		$	7,167		$	6,447
Medicaid		2,091			2,285			6,328			7,185
Self-pay		91			86			532			356
Managed Care & Other Insurance		793			871			2,278			2,248
Other		330			364			1,091			1,139

Revenues before provision for doubtful accounts		5,790			5,685			17,396			17,375
Provision for doubtful accounts		(133	)		(184	)		(363	)		(321	)

Healthcare Facilities Segment Net Revenues		5,657			5,501			17,033			17,054
Pharmacy Segment Net Revenues		7,760			8,198			23,625			23,946

Total Net Revenues	$	13,417		$	13,699		$	40,658		$	41,000

The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss).

Summary information for accounts receivable is as follows:


	March 31, 2018			June 30, 2017
Accounts receivable (net of contractual allowances)	$	6,453		$	6,458
Less allowance for doubtful accounts		(569	)		(552	)

Patient accounts receivable – net	$	5,884		$	5,906

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and nine months ended March 31, 2018 and 2017:


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2018
Balance at January 1, 2018	$	326		$	219		$	545
Additions recognized as a reduction to revenues:
Continuing Operations		133			237			370
Discontinued Operations		(4	)		0			(4	)
Accounts written off, net of recoveries		(82	)		(260	)		(342	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2018
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		363			445			808
Discontinued Operations		2			0			2
Accounts written off, net of recoveries		(320	)		(473	)		(793	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2017
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		0			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2017
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			0			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710

New Accounting Pronouncement for Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on July 1, 2018 and is currently implementing its plan for adoption and evaluating the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. A significant element of executing this plan is the process of reviewing sources of revenue and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. The Company is currently evaluating the appropriate portfolios to apply in its collectability analysis and is considering the impact of applying the new standard when its patient accounts are evaluated in those portfolios. The Company expects this process will be completed later in 2018.

Additionally, the adoption of the new accounting standard will impact the presentation on the Company’s statement of operations for a significant component of its provision for bad debts. After adoption of the new standard, the majority of what is currently classified as the provision for bad debts will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenue. The Company will continue to evaluate certain changes in collectability on its self-pay patient accounts receivable resulting from certain credit and collection issues not assessed at the date of service, including bankruptcy, and recognize such amounts in the provision for bad debts included in operating expenses on the statement of operations. The Company cannot reasonably estimate at this time the quantitative impact that the adoption of this accounting standard will have on the financial statements of the Company.

Note 8. – Intangible Assets

Intangibles consist of the following, net of amortization:


	March 31, 2018			June 30, 2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,392	)		(1,305	)

Net Intangibles	$	1,500		$	1,587

Amortization expense was $29 and $35 for the three months ended March 31, 2018 and 2017, respectively. Amortization expense was $87 and $106 for the nine months ended March 31, 2018 and 2017, respectively.

Note 9. – Long-Term Debt

Long-term debt consisted of the following:


	March 31, 2018			June 30, 2017
Trace RDA Loan	$	3,347		$	7,191
Capital lease obligations and other		0			12

Total		3,347			7,203
Less unamortized debt issuance costs		(226	)		(493	)
Less current maturities		(258	)		(6,710	)

Long-term Debt	$	2,863		$	0

Trace RDA Loan – Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced to $39 per month, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.75% at March 31, 2018) and certain loan covenants were modified. The Modification also included a waiver of covenant violations for the quarters ended June 30 and September 30, 2017. Trace was in compliance with the amended financial covenants at March 31, 2018. In connection with the modification and prepayment, an existing deposit of $1,000 in a blocked, interest bearing account with the lender was released. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

Note 10. – Income Taxes

Income tax benefit of $0 ($0 federal tax and $0 state tax expense) and income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) was recorded for continuing operations for the three months ended March 31, 2018 and 2017, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) was recorded for continuing operations for the nine months ended March 31, 2018 and 2017, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) 118 on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available.

At March 31, 2018, consistent with the above processes, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $8,071 against all other net deferred tax asset items at March 31, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

The principal negative evidence that led us to determine at March 31, 2018 that $8,071 of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate.

For Federal income tax purposes, at March 31, 2018, the Company had approximately $13,400 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date.

Note 11. – Commitments and Contingencies

Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2018 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	258	$	574	$	172
2 years		296		423		173
3 years		315		340		155
4 years		333		132		136
5+ years		2,145		4		355

	$	3,347	$	1,473	$	991

On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH“) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements; however the nursing home anticipates further surveys to evaluate its implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the nine months ended March 31, 2018. The CMP was paid January 18, 2018.

Note 12. – Related Party Transactions

A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $25 and $109 for legal services to this law firm in the three months ended March 31, 2018 and 2017, respectively. The Company expensed an aggregate of $215 and $481 for legal services to this law firm in the nine months ended March 31, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2018 and June 30, 2017 is $12 and $38, respectively, of amounts payable to this law firm.

Note 13. – Sale of Assets

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $183 is included in the results for the three months ended March 31, 2018.

Note 14. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2018 and 2017 and for the three and nine months then ended is as follows:


	Healthcare Facilities			Pharmacy			Corporate and Other			Total
As of and for the three months ended March 31, 2018
Net revenues from external customers	$	5,657		$	7,760		$	0		$	13,417
Operating profit (loss)		114			(367	)		(478	)		(731	)
Depreciation and amortization		167			297			0			464
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		167			263			0			430

As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,501		$	8,198		$	0		$	13,699
Operating profit (loss)		(146	)		(324	)		(301	)		(771	)
Depreciation and amortization		176			289			1			466
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		25			264			0			289

As of and for the nine months ended March 31, 2018
Net revenues from external customers	$	17,033		$	23,625		$	0		$	40,658
Operating profit (loss)		118			285			(1,313	)		(910	)
Depreciation and amortization		485			845			2			1,332
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		980			522			0			1,502

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	17,054		$	23,946		$	0		$	41,000
Operating profit (loss)		146			(511	)		(1,331	)		(1,696	)
Depreciation and amortization		563			810			3			1,376
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		358			739			0			1,097

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, or other terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, and pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions, and capital improvements at existing healthcare and pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and

•

fluctuations in the market value of equity securities including SunLink common shares.

Operational Factors

•

ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists, and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

changes in interest rates under lending agreements and other indebtedness;

•

the ability or inability to refinance existing indebtedness and existing or potential defaults under existing indebtedness;

•

restrictions imposed by existing or future lending agreements or other indebtedness;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self-insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Services and Pharmacy segments;

•

changes in wages as a result of inflation or competition for physician, nursing, pharmacy, management and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality of or costs with respect to our information systems for our Healthcare Services and Pharmacy segments and our corporate office, including both software and hardware;

•

the availability of and competition from alternative drugs or treatments to those provided by our Pharmacy segment; and

•

the restrictions, processes, and conditions relating to our Pharmacy segment imposed by pharmacy benefit providers, drug manufacturers, and distributors.

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees, disposition agreements, and other obligations relating to discontinued operations, including claims from sold or leased Facilities, retained liabilities or retained subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general, and other claims which may be asserted against us; and

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage, and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate our remaining hospital (Mississippi) and two remaining nursing homes (Georgia and Mississippi) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Services and Pharmacy Segments; and

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy Facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding and other reforms).

Dispositions, Acquisition and Renovation Related Matters

•

the ability to dispose of underperforming Facilities and business segments;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement Facilities; and

•

competition in the market for acquisitions of hospitals, nursing homes, pharmacy Facilities, and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions, will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for $410. A pre-tax gain on the sale of the assets of $183 is included in the results for the three months ended March 31, 2018.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2017 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; and

•

Accounting for income taxes

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Services and Pharmacy.


	Three Months Ended March 31,									Nine Months Ended March 31,
	2018			2017			% Change			2018			2017			% Change
Net Revenues – Healthcare Services	$	5,657		$	5,501			2.8	%	$	17,033		$	17,054			-0.1	%
Net Revenues – Pharmacy		7,760			8,198			-5.3	%		23,625			23,946			-1.3	%

Total Net Revenues		13,417			13,699			-2.1	%		40,658			41,000			-0.8	%
Costs and expenses		(14,148	)		(14,470	)		-2.2	%		(41,568	)		(42,696	)		-2.6	%

Operating profit (loss)		(731	)		(771	)		-5.2	%		(910	)		(1,696	)		-46.3	%
Interest expense – net		(56	)		(129	)		-56.6	%		(302	)		(507	)		-40.4	%
Loss on extinguishment of debt		0			0			NA			(238	)		(243	)		-2.1	%
Gain on economic damages claim, net		0			0			NA			944			0			NA
Gain (Loss) on sale of assets		183			2			NA			181			3,019			-94.0	%

Earnings (Loss) from continuing operations before income taxes	$	(604	)	$	(898	)		-32.7	%	$	(325	)	$	573			-156.7	%

Healthcare Facilities Segment:
Hospital and Nursing Home Admissions		196			154			27.3	%		518			399			29.8	%
Hospital and Nursing Patient Days		13,876			14,561			-4.7	%		42,749			45,268			-5.6	%

Results of Operations

Healthcare Services Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Services segment for the periods indicated:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Source:
Medicare		42.9	%		36.6	%		41.2	%		37.1	%
Medicaid		36.1	%		40.2	%		36.4	%		41.4	%
Managed Care Insurance & Other		19.4	%		21.7	%		19.4	%		19.4	%
Self-pay		1.6	%		1.5	%		3.0	%		2.1	%

		100.0	%		100.0	%		100.0	%		100.0	%

The Healthcare Services segment in the current year is composed of two nursing homes, one hospital, a subsidiary which provides information technology (“IT”) services to outside customers and SunLink subsidiaries, two leased medical office buildings, and unimproved land at three locations. Healthcare Services net revenues increased $156, or 3%, for the three months ended March 31, 2018 compared to the prior year period. Increased nursing home Medicaid revenues and decreased provision for bad debts resulted in the increased net revenues. Healthcare Services net revenues decreased $21, or less than 1%, for the nine months ended March 31, 2018 compared to the prior year period. Decreased nursing home Medicaid revenues, partially offset by increased physician clinic and nursing home Medicare revenues, resulted in the decreased net revenues. The net revenues of the Healthcare Services Segment included increases of $35 and $299 resulting from prior years’ Medicare positive cost report settlements for the three and nine months ended March 31, 2018, and $38 and $385 resulting from prior years’ Medicare positive cost report settlements for the three and nine months ended March 31, 2017.

Pharmacy Segment Net Revenues

Pharmacy segment net revenues for the three months ended March 31, 2018 decreased $438, or 5%, from the three months ended March 31, 2017. The decrease was a result of a 13% decrease in Retail Pharmacy net revenues, a 3% decrease in Institutional Pharmacy net revenues and a 4% decrease in Durable Medical Equipment (“DME”) net revenues. The decrease in Retail Pharmacy is primarily due to the sale of a retail pharmacy operation in early January 2018. Pharmacy segment net revenues for the nine months ended March 31, 2018 decreased $321, or 1%, from the nine months ended March 31, 2017. The decrease was a result of a 5% decrease in Retail Pharmacy net revenues and a 3% decrease in Institutional Pharmacy net revenues partially offset by a 3% increase in DME net revenues. DME net revenues for the nine months ended March 31, 2018 increased primarily due to increased Medicare reimbursement realized from the implementation of the provisions of the 21^st Century Cures Act. The Company expects that the increased revenues from the 21^st Century Cures Act will not continue in material amounts this fiscal year. Scripts fulfilled volume has decreased for all Pharmacy Segment product areas for both the three and nine months ended March 31, 2018 compared to the prior year periods.

Healthcare Services Segment Cost and Expenses

Costs and expenses for our Healthcare Services Segment, including depreciation and amortization, were $5,543 and $5,647 for the three months ended March 31, 2018 and 2017, respectively. Costs and expenses for our Healthcare Services segment, including depreciation and amortization, were $16,915 and $16,908 for the nine months ended March 31, 2018 and 2017, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2018			2017			2018			2017
Salaries, wages and benefits		66.8	%		69.0	%		67.7	%		65.6	%
Supplies		7.4	%		7.6	%		7.5	%		7.5	%
Purchased services		7.0	%		7.0	%		6.8	%		7.0	%
EHR incentive payments		0.0	%		0.0	%		-0.1	%		0.0	%
Other operating expenses		12.9	%		14.9	%		13.7	%		15.0	%
Rent and lease expense		0.9	%		0.9	%		1.0	%		0.7	%
Depreciation and amortization expense		3.0	%		3.2	%		2.8	%		3.3	%

Salaries, wages and benefits increased as a percent of net revenue for the nine months ended March 31, 2018 due to increased employee medical claims when compared to same period last year, but decreased as a percent of net revenue for the three months ended March 31, 2018 due to better labor management in the nursing homes this year. Supplies and Other operating expenses decreased this year because last year’s expenses included expenses related to a hospital that ceased operations in June 2016. Depreciation and amortization expense decreased $78 for the nine months ended March 31, 2018, as compared to the same period last year as a result of the sale of a medical office building last year.

Pharmacy Segment Cost and Expenses

Cost and expenses for our Pharmacy segment, including depreciation and amortization, were $8,127 and $8,522 for the three months ended March 31, 2018 and 2017, respectively. Cost and expenses for our Pharmacy segment, including depreciation and amortization, were $23,340 and $24,457 for the nine months ended March 31, 2018 and 2017, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2018			2017			2018			2017
Cost of goods sold		65.4	%		67.4	%		61.9	%		65.1	%
Salaries, wages and benefits		23.7	%		22.8	%		22.6	%		23.4	%
Provision for bad debts		3.0	%		1.5	%		1.9	%		1.4	%
Supplies		0.4	%		0.4	%		0.3	%		0.4	%
Purchased services		3.4	%		3.5	%		3.5	%		3.7	%
Other operating expenses		3.9	%		3.9	%		3.9	%		3.7	%
Rent and lease expense		1.1	%		1.0	%		1.1	%		1.0	%
Depreciation and amortization expense		3.8	%		3.5	%		3.6	%		3.4	%

Cost of goods sold as a percent of net revenues decreased in the three and nine month period ended March 31, 2018 as compared to the comparable period of the prior year due to changes in sales product mix, primarily decreased Institutional Pharmacy revenues, and increased discounts from their venders. Salaries, wages and benefits as a percent of net revenues in the three month period ended March 31, 2018 as compared to the comparable period of the prior year increased due to the lower sales in this year’s third fiscal quarter. Provision for bad debts increased for the three months ended March 31, 2018 as compared to last year due to lower than anticipated collections from private payors.

Operating Profit and Loss

The Company reported an operating loss of $731 for the three months ended March 31, 2018 compared to an operating loss of $771 for the three months ended March 31, 2017. The operating loss for the three months ended March 31, 2018 compared to the operating loss for the prior year’s three month period improved as a result of increased operating profit of the Healthcare Facilities segment. The Company reported an operating loss of $910 for the nine months ended March 31, 2018 compared to operating loss of $1,696 for the nine months ended March 31, 2017. The operating loss last year included expenses related to a hospital that ceased operations in June 2016.

Gain on economic damages claim

Interest Expense

Interest expense was $56 and $129 for the three months ended March 31, 2018 and 2017, and $302 and $507 for the nine months ended March 31, 2018 and 2017, respectively. The decrease in interest expense resulted from lower debt outstanding in the current fiscal year, primarily because debt was reduced $3,856 in the nine months ended March 31, 2018 and $3,985 last fiscal year with no additional debt undertaken.

Income Taxes

The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB” 118) on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available.

Gain on Sale of Assets

On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of $183 is included in the results for the three and nine months ended March 31, 2018.

In December 2016, a subsidiary sold a medical office building complex, comprised of land and three buildings in Ellijay, GA (“Ellijay MOB”) for $4,900. A gain of $2,819 was reported on the sale.

Earnings (Loss) from Continuing Operations before Income Tax

Loss from continuing operations before income tax was $604 for the three months ended March 31, 2018 compared to a loss from continuing operations before income tax of $898 for the three months ended March 31, 2017. Loss from continuing operations before income tax was $325 for the nine months ended March 31, 2018 compared to earnings from continuing operations before income tax of $573 for the nine months ended March 31, 2017. The loss from continuing operations for the nine months period ended March 31, 2018 as compared the earnings from continuing operation for the nine month period last year results from a significant gain on the sale of assets last year.

Earnings (Loss) After Taxes

Loss from continuing operations were $604 (or a loss of $0.08 per fully diluted share) for the three months ended March 31, 2018 compared to a loss from continuing operations of $890 (or a loss of $0.10 per fully diluted share) for the three months ended March 31, 2017. The reduced loss in the three months ended March 31, 2018 compared to the same period last year resulted from the gain on the sale of certain retail pharmacy assets in January 2018. Loss from continuing operations were $29 (or a loss $0.00 per fully diluted share) for the nine months ended March 31, 2018 compared to earnings from continuing operations of $809 (or $0.09 per fully diluted share) for the nine months ended March 31, 2017. The loss for the nine months period ended March 31, 2018 as compared the earnings for the nine month period last year results from a significant gain on the sale of assets last year.

Net loss for the three months ended March 31, 2018 was $588 (or a loss of $0.08 fully diluted share) compared to a net loss of $1,025 (or a loss of $0.11 earnings per fully diluted share) for the three months ended March 31, 2017. Net loss for the nine months ended March 31, 2018 was $139 (or a loss of $0.02 fully diluted share) compared to net earnings of $5,096 ($0.54 earnings per fully diluted share) for the nine months ended March 31, 2017. Net earnings last year included $4,287 of earnings from discontinued operations which primarily resulted from the gain on the sale of a hospital in August 2016.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally

accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges, we refer to such measurement as “Adjusted EBITDA”, which we report on a Company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Services segment Adjusted EBITDA and Pharmacy segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three and nine months ended March 31, 2018 and 2017, respectively, is shown below.


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2018			2017			2018			2017
Healthcare Services Adjusted EBITDA	$	281		$	30		$	603		$	709
Pharmacy Adjusted EBITDA		(70	)		(35	)		1,130			299
Corporate overhead costs		(478	)		(300	)		(1,311	)		(1,328	)
Taxes and interest expense		(56	)		(121	)		(6	)		(271	)
Other non-cash expenses and net change in operating assets and liabilities		25			(659	)		(449	)		(4,408	)

Net cash used in operations	$	(298	)	$	(1,085	)	$	(33	)	$	(4,999	)

Liquidity and Capital Resources

Overview

Our primary source of liquidity is unrestricted cash on hand of $3,541 at March 31, 2018. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We nevertheless periodically seek options to obtain financing for the liquidity needs of the Company or individual subsidiaries. The Company and its subsidiaries currently are funding working capital needs primarily from cash on hand and from the sale of assets. See “Subsidiary Loans” below.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Trace RDA Loan – Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced to $39 per month, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.75% at March 31, 2018) and certain loan covenants were modified. The Modification also included a waiver of covenant violations for the quarters ended June 30 and September 30, 2017. Trace was in compliance with the amended financial covenants at March 31, 2018. In connection with the modification and prepayment, an existing deposit of $1,000 in a blocked, interest bearing account with the lender was released. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	258	$	574	$	172
2 years		296		423		173
3 years		315		340		155
4 years		333		132		136
5+ years		2,145		4		355

	$	3,347	$	1,473	$	991

At March 31, 2018, we had outstanding long-term debt of $3,347 under the Trace RDA Loan.

On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH“) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements. The nursing home will be subject to future DCH surveys from time to time to evaluate compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs including its continued implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the nine months ended March 31, 2018. The CMP was paid January 18, 2018.

Discontinued Operations

Chestatee Hospital – On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. A purchase price adjustment of $328 is due to the Company from the hospital buyer as a post-closing adjustments to the purchase price as confirmed by a binding decision of an independent accountant rendered pursuant to the purchase agreement. Chestatee retained certain liabilities, including certain employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds was used for the repayment of debt.

Related Party Transactions

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of March 31, 2018.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2018.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended March 31, 2018 in our internal control over financial reporting that materially affected, or is likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1.

LEGAL PROCEEDINGS

On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH“) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements. The nursing home will be subject to future DCH surveys from time to time to evaluate compliance with federal and state program requirements for nursing homes participating in Medicare and/or Medicaid programs including its continued implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the nine months ended March 31, 2018. The CMP was paid January 18, 2018.

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2017. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS


Exhibits:

31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended March 31, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and June 30, 2017, (ii) Condensed Consolidated Statements of Operations for the three and nine months ended March 31, 2018 and 2017 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three and nine months ended March 31, 2018 and 2017 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: May 11, 2018

EX-31.1 2 d766736dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2018 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of March 31, 2018 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d766736dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2018 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d766736dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2018, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

May 11, 2018

EX-32.2 5 d766736dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2018, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:

/s/ Mark J. Stockslager

Mark J. Stockslager

Chief Financial Officer

May 11, 2018

EX-101.INS 6 ssy-20180331.xml XBRL INSTANCE DOCUMENT

1.60

7416814

1.60

0.055

732000

400000

332000

710000

38133000

11237000

12678000

11519000

13936000

388000

322000

545000

219000

326000

569000

293000

14482000

19559000

11009000

1254000

6453000

-327000

27791000

3541000

7417000

3708000

8071000

2381000

296000

1500000

1974000

27791000

3919000

5285000

3347000

258000

2863000

2765000

1099000

13400000

969000

304000

2000000

3083000

10544000

30103000

5884000

4197000

18587000

226000

752000

4293000

9104000

14394000

0.0575

3347000

1000000

9975000

333000

296000

258000

3347000

315000

2145000

136000

173000

172000

991000

155000

355000

132000

423000

574000

1473000

340000

4000

1089000

623000

1180000

328000

35000

12000

196000

1392000

1500000

2892000

373000

991000

3261000

367000

624000

552000

658000

22621000

18319000

13103000

1571000

6458000

-327000

35336000

12000

10494000

9163000

4581000

2098000

1587000

2159000

35336000

1329000

12314000

7203000

6710000

2425000

1277000

838000

289000

2000000

3062000

10290000

28609000

5906000

1000000

4336000

21693000

493000

1040000

7191000

1089000

623000

1180000

38000

224000

1305000

1587000

2892000

328000

296000

7270000

15000000

1745751

2017-12-21

2794000

3725656

39000

0.01

Prime rate plus 1% with a floor of 5.5%

3548000

410000

2025

59000

1322000

106000

7976000

5096000

-221000

15592000

2113000

-15000

1376000

6937000

4287000

0.54

2650000

0.54

-243000

321000

3019000

809000

0.09

0.46

141000

573000

0.09

0.45

-236000

507000

458000

17476000

18465000

-5490000

-4999000

5096000

-1696000

409000

4015000

640000

1097000

14620000

4942000

-1000000

342000

3850000

41000000

1373000

9429000

9408000

41321000 1097000 0

3000

-1331000

810000

-511000

739000

23946000

563000

146000

358000

17054000

2081000

-304000

-288000

7270000

83000

2369000

-112000

356000 2248000 1139000 7185000 6447000

24000

39000

97000

112000

72000

481000

321000

23946000

342000

1001000

321000

17054000

17375000

321000

378000

663000

378000

false

7000

793000

87000

<div> Note 11. – Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2018 were as follows:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">258</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">574</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">172</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">296</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">423</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">173</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">315</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">333</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,145</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">355</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,473</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> On September 8, 2017, the Georgia Survey agency of the Georgia Department of Community Health (“DCH“) conducted a Complaint Investigation survey to determine whether our nursing home in Ellijay, Georgia was in compliance with federal program requirements for nursing homes participating in Medicare and/or Medicaid programs. As a result of this survey, the nursing home received from the DCH a notice of deficiencies which were identified as posing an immediate jeopardy to resident health and safety and which had to be corrected immediately. DCH also notified the nursing home of its intent to recommend civil monetary penalties. In response to the survey findings, the nursing home adopted a succession of plans to remedy the matters identified. On November 6, 2017, DCH advised the nursing home that its latest plan of correction was accepted and on November 20, 2017, DCH advised the nursing home that it was in substantial compliance with its long-term care requirements; however the nursing home anticipates further surveys to evaluate its implementation of the plans of correction. A Civil Money Penalty (“CMP”) was imposed by the Department of Health & Human Services Centers for Medicare and Medicaid Services on January 4, 2018 which resulted in $170 expensed in the nine months ended March 31, 2018. The CMP was paid January 18, 2018. </div>

-6953000

-139000

-296000

14623000

2021000

<div> Contractual obligations, commitments and contingencies related to outstanding debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2018 were as follows:   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">258</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">574</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">172</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">296</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">423</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">173</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">315</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">333</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,145</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">355</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,473</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

--06-30

1332000

-110000

<div> Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,081</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(108</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gain (Loss) on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(210</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,937</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,650</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(135</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,287</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Chestatee Hospital – On August 19, 2016, Southern Health Corporation of Dahlonega, Inc., (“Chestatee”), a wholly owned subsidiary of the Company, sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,270 is subject to adjustment for various purchase price adjustments. A purchase price adjustment of $328 is due to the Company from the hospital buyer as a post-closing adjustment to the purchase price as confirmed by a binding decision of an independent accountant rendered pursuant to the purchase agreement. Chestatee retained certain liabilities, including certain employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds was used for the repayment of debt. Other Sold Hospitals – Subsidiaries of the Company sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. The earnings (loss) before income taxes of the Other Sold Hospitals results primarily from prior year Medicare and Medicaid cost report settlements. Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2018 and 2017.   The components of pension expense for the three and nine months ended March 31, 2018 and 2017, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">108</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> SunLink contributed $105 to the plan in the nine months ended March 31, 2018 and expects to contribute an additional $35 during the last fiscal quarter of the fiscal year ending June 30, 2018. </div>

Q3 2018 10-Q

-0.02

2018-03-31

-0.02

SUNLINK HEALTH SYSTEMS INC 0000096793 Smaller Reporting Company

944000

-238000

363000

181000

-29000

0.00

-0.01

<div> Note 10. – Income Taxes Income tax benefit of $0 ($0 federal tax and $0 state tax expense) and income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) was recorded for continuing operations for the three months ended March 31, 2018 and 2017, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) was recorded for continuing operations for the nine months ended March 31, 2018 and 2017, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) 118 on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available. At March 31, 2018, consistent with the above processes, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $8,071 against all other net deferred tax asset items at March 31, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at March 31, 2018 that $8,071 of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at March 31, 2018, the Company had approximately $13,400 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date. </div>

-325000

0.00

-0.01

-296000

302000

<div> Note 8. – Intangible Assets Intangibles consist of the following, net of amortization:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,392</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,305</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense was $29 and $35 for the three months ended March 31, 2018 and 2017, respectively. Amortization expense was $87 and $106 for the nine months ended March 31, 2018 and 2017, respectively. </div>

269000

17697000

<div> Note 9. – Long-Term Debt Long-term debt consisted of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,203</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(226</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(493</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(258</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,710</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,863</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan – Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. On December 26, 2017, the Fifth Amendment to Loan Agreement, Modification of Note and Waiver (“Modification”) was entered into by Trace and the bank. Under the Modification, Trace made a $3,548 prepayment on the Trace RDA Loan. The monthly principal and interest payments on the RDA Loan were reduced to $39 per month, the interest rate was reduced to the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.75% at March 31, 2018) and certain loan covenants were modified. The Modification also included a waiver of covenant violations for the quarters ended June 30 and September 30, 2017. Trace was in compliance with the amended financial covenants at March 31, 2018. In connection with the modification and prepayment, an existing deposit of $1,000 in a blocked, interest bearing account with the lender was released. The Trace RDA Loan is collateralized by real estate and equipment of Trace in Houston, MS, and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash, including from operating activities and asset sales. If Trace is unable to generate sufficient cash to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. </div>

<div> Note 4. – Economic Damages Claim The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the nine months ended March 31, 2018. </div>

<div> Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets. The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines. On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation for approximately $410. A pre-tax gain of $183 on the sale of these assets is included in the results for the three months ended March 31, 2018.   Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations. </div>

-1090000

-5830000

-33000

-139000

-910000

<div> New Accounting Pronouncement for Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on July 1, 2018 and is currently implementing its plan for adoption and evaluating the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. A significant element of executing this plan is the process of reviewing sources of revenue and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. The Company is currently evaluating the appropriate portfolios to apply in its collectability analysis and is considering the impact of applying the new standard when its patient accounts are evaluated in those portfolios. The Company expects this process will be completed later in 2018. Additionally, the adoption of the new accounting standard will impact the presentation on the Company’s statement of operations for a significant component of its provision for bad debts. After adoption of the new standard, the majority of what is currently classified as the provision for bad debts will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenue. The Company will continue to evaluate certain changes in collectability on its self-pay patient accounts receivable resulting from certain credit and collection issues not assessed at the date of service, including bankruptcy, and recognize such amounts in the provision for bad debts included in operating expenses on the statement of operations. The Company cannot reasonably estimate at this time the quantitative impact that the adoption of this accounting standard will have on the financial statements of the Company. </div>

<div> Note 1. – Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2018 and for the three and nine month periods ended March 31, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

471000

3639000

2974000

1502000

412000

1000000

445000

3856000

<div> Note 12. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $25 and $109 for legal services to this law firm in the three months ended March 31, 2018 and 2017, respectively. The Company expensed an aggregate of $215 and $481 for legal services to this law firm in the nine months ended March 31, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2018 and June 30, 2017 is $12 and $38, respectively, of amounts payable to this law firm. </div>

<div> Note 5. – Restricted Cash Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt), a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan. </div>

<div> Revenues by payor were as follows for the three and nine months ended March 31, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,485</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,167</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,447</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,091</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,285</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,185</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">532</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">793</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,278</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">330</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">364</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,091</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,139</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,790</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,396</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,375</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(133</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(184</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(363</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,501</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,033</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,054</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,760</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,625</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,417</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,658</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

40658000

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,453</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,458</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(569</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(552</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable – net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,884</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,369</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,081</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(104</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(38</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">83</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(304</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(108</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gain (Loss) on sale of Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,270</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(210</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,937</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(75</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,650</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(135</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,287</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2018 and 2017 and for the three and nine months then ended is as follows:   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,657</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,760</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,417</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(367</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(478</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(731</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">297</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">464</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,394</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,791</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">263</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">430</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,501</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,198</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(146</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(324</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(301</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(771</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">176</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,936</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,678</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">264</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the nine months ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,033</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,625</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">118</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,313</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(910</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">485</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">845</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,332</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,394</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,791</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">980</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">522</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,502</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the nine months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,054</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(511</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,331</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,696</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">563</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,376</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,936</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,678</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">358</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">739</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,097</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

<div> Note 14. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy.   We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of March 31, 2018 and 2017 and for the three and nine months then ended is as follows:   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,657</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,760</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,417</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">114</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(367</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(478</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(731</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">297</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">464</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,394</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,791</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">167</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">263</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">430</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the three months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,501</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,198</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(146</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(324</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(301</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(771</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">176</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,936</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,678</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">264</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">289</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the nine months ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,033</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,625</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,658</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">118</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,313</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(910</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">485</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">845</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,332</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,394</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,293</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,791</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">980</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">522</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,502</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> As of and for the nine months ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,054</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,946</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(511</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,331</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,696</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">563</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">810</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,376</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,936</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,519</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,678</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,133</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">358</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">739</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,097</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div>

<div> Note 6. – Shareholders’ Equity Common Share Purchase Tender Offer – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,794, excluding fees and expenses relating to the Offer. Stock-Based Compensation – For the three months ended March 31, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2018 and 2017, the Company recognized $7 and $59, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2018 and 2017, respectively. </div>

1361000

SSY

8564000

41021000 1502000 21000 <div> The components of pension expense for the three and nine months ended March 31, 2018 and 2017, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(27</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">108</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">112</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,180</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">623</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,892</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,392</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,305</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Net Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and nine months ended March 31, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(260</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(342</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">196</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nine Months Ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">363</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">445</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">808</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(320</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(473</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(793</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">196</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">126</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">310</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(138</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(318</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nine Months Ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,001</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,322</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 7. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.   Revenues by payor were as follows for the three and nine months ended March 31, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,485</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,079</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,167</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,447</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,091</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,285</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,185</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">86</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">532</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">793</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">871</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,278</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,248</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">330</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">364</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,091</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,139</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,790</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,685</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,396</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,375</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(133</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(184</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(363</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,657</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,501</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,033</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,054</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,760</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,198</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,625</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,946</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,417</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,658</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss). Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,453</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,458</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(569</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(552</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable – net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,884</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Services Segment and the Pharmacy Segment for the three and nine months ended March 31, 2018 and 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at January 1, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">326</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">545</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(260</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(342</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">196</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nine Months Ended March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">328</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">552</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">363</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">445</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">808</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(320</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(473</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(793</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">373</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">196</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">569</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at January 1, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">332</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">400</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">126</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">310</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(138</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(318</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Services</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Nine Months Ended March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">321</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">342</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,001</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(321</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,322</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">710</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> New Accounting Pronouncement for Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on July 1, 2018 and is currently implementing its plan for adoption and evaluating the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. A significant element of executing this plan is the process of reviewing sources of revenue and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. The Company is currently evaluating the appropriate portfolios to apply in its collectability analysis and is considering the impact of applying the new standard when its patient accounts are evaluated in those portfolios. The Company expects this process will be completed later in 2018. Additionally, the adoption of the new accounting standard will impact the presentation on the Company’s statement of operations for a significant component of its provision for bad debts. After adoption of the new standard, the majority of what is currently classified as the provision for bad debts will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenue. The Company will continue to evaluate certain changes in collectability on its self-pay patient accounts receivable resulting from certain credit and collection issues not assessed at the date of service, including bankruptcy, and recognize such amounts in the provision for bad debts included in operating expenses on the statement of operations. The Company cannot reasonably estimate at this time the quantitative impact that the adoption of this accounting standard will have on the financial statements of the Company. </div> <div> Long-term debt consisted of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,191</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,347</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,203</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(226</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(493</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(258</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,710</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Long-term Debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,863</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 170000

2000

-1313000

845000

285000

522000

23625000

485000

118000

980000

17033000

P15Y

2012-07-05

71000

45000

71000

-9000

-38000

-108000

532000 2278000 1091000 6328000 7167000

27000

42000

93000

108000

105000

<div> Note 13. – Sale of Assets On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $183 is included in the results for the three months ended March 31, 2018. </div>

84 100 66

215000

473000

944000

23625000

445000

320000

363000

17033000

17396000

363000

2000

808000

2000

0.50 1.00

5000

318000

35000

-1025000

-32000

5523000

692000

24000

466000

-210000

-135000

-0.11

-75000

-0.11

184000

2000

-890000

-0.10

-0.01

-898000

-0.10

-0.01

-8000

129000

5872000

-1025000

-771000

142000

1194000

289000

126000

13699000

455000

9334000

13883000 0

1000

-301000

289000

-324000

264000

8198000

176000

-146000

25000

5501000

-68000

-69000

-68000

-104000

-37000

86000 871000 364000 2285000 2079000

8000

13000

32000

37000

109000

138000

8198000

126000

180000

184000

5501000

5685000

184000

-14000

310000

-14000

1000

342000

29000

-588000

5073000

672000

464000

16000

-0.08

133000

183000

-604000

-0.08

0.00

-604000

-0.08

0.00

56000

6045000

-588000

-731000

157000

1052000

430000

237000

13417000

448000

7417000

13550000 0

-478000

297000

-367000

263000

7760000

167000

114000

167000

5657000

77000

61000

77000

-9000

-36000

91000 793000 330000 2091000 2485000

9000

14000

31000

36000

183000

25000

260000

7760000

237000

82000

133000

5657000

5790000

133000

-4000

370000

-4000

3 0000096793 2012-07-03 2014-12-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-03-31 0000096793 ssy:PharmacySegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:ManagementMember 2018-01-01 2018-03-31 0000096793 ssy:CarmichaelsCashwayPharmacyIncMember 2018-01-01 2018-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2018-01-01 2018-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2018-01-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2018-01-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2018-01-01 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2018-01-01 2018-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0000096793 2018-01-01 2018-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0000096793 ssy:PharmacySegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:ManagementMember 2017-01-01 2017-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2017-01-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-01-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-01-01 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-03-31 0000096793 2017-01-01 2017-03-31 0000096793 us-gaap:LatestTaxYearMember 2017-07-01 2018-03-31 0000096793 us-gaap:EarliestTaxYearMember 2017-07-01 2018-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2018-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2017-07-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2017-07-01 2018-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2017-07-01 2018-03-31 0000096793 ssy:PharmacySegmentMember 2017-07-01 2018-03-31 0000096793 ssy:PharmacySegmentMemberstpr:LA 2017-07-01 2018-03-31 0000096793 us-gaap:ManagementMember 2017-07-01 2018-03-31 0000096793 ssy:NursingHomeMemberssy:HealthcareServicesSegmentMemberstpr:MS 2017-07-01 2018-03-31 0000096793 ssy:NursingHomeMemberssy:HealthcareServicesSegmentMemberstpr:GA 2017-07-01 2018-03-31 0000096793 ssy:CommunityHospitalMemberssy:HealthcareServicesSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2017-07-01 2018-03-31 0000096793 ssy:CarmichaelsCashwayPharmacyIncMember 2017-07-01 2018-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2017-07-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2017-07-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2017-07-01 2018-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2017-07-01 2018-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2017-07-01 2018-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-07-01 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-07-01 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-07-01 2018-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-07-01 2018-03-31 0000096793 2017-07-01 2018-03-31 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2017-03-31 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2017-03-31 0000096793 ssy:PharmacySegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:ManagementMember 2016-07-01 2017-03-31 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2016-07-01 2017-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-07-01 2017-03-31 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-07-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-07-01 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2016-07-01 2017-03-31 0000096793 2016-07-01 2017-03-31 0000096793 2017-07-01 2017-12-31 0000096793 ssy:CarmichaelsCashwayPharmacyIncMember 2018-01-11 2018-01-11 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 2017-12-26 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-12-21 2017-12-21 0000096793 ssy:ChestateeHospitalMemberssy:AssetPurchaseAgreementMember 2016-08-19 2016-08-19 0000096793 ssy:ChestateeHospitalMember 2016-08-19 2016-08-19 0000096793 us-gaap:ScenarioForecastMemberssy:LaterThanMember 2022-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:PharmacySegmentMember 2017-06-30 0000096793 us-gaap:ManagementMember 2017-06-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2017-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-06-30 0000096793 2017-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-06-30 0000096793 ssy:PharmacySegmentMember 2016-06-30 0000096793 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2018-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2018-03-31 0000096793 ssy:PharmacySegmentMember 2018-03-31 0000096793 us-gaap:ManagementMember 2018-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2018-03-31 0000096793 ssy:ChestateeHospitalMember 2018-03-31 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2018-03-31 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2018-03-31 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2018-03-31 0000096793 ssy:OperatingLeasesMember 2018-03-31 0000096793 ssy:InterestOnOutstandingDebtMember 2018-03-31 0000096793 us-gaap:LongTermDebtMember 2018-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2018-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2018-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2018-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2018-03-31 0000096793 2018-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-12-31 0000096793 ssy:PharmacySegmentMember 2017-12-31 0000096793 2017-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2017-03-31 0000096793 ssy:PharmacySegmentMember 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2017-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2017-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2017-03-31 0000096793 2017-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-12-31 0000096793 ssy:PharmacySegmentMember 2016-12-31 0000096793 2016-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2017-12-26 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-12-21 0000096793 2018-05-11 0000096793 ssy:CommonSharePurchaseTenderOfferMember 2017-11-21 iso4217:USD shares shares pure iso4217:USD ssy:Segment ssy:Bed ssy:Services ssy:Hospital

EX-101.SCH 7 ssy-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Economic Damages Claim link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Restricted Cash link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Sale of Assets link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Revenue Recognition and Accounts Receivables (Policies) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Economic Damages Claim - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Intangible Assets - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Sale of Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accrued Liabilities, Current Due to third party payors Accrued penalty expense. Accrued penalty expense Accrued penalties expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts [Table Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset purchase agreement. Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Assets Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Assets, Noncurrent [Abstract] Noncurrent Assets: Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Capital Lease Obligations Capital lease obligations and other Carmichael's Cashway Pharmacy, Inc. Carmichael's Cashway Pharmacy, Inc [Member] Carmichael's Cashway Pharmacy, Inc [Member] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in Cash and Cash Equivalents Chestatee hospital. Chestatee Hospital [Member] Chestatee Hospital [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common share purchase tender offer. Common Share Purchase Tender Offer [Member] Common Share Purchase Tender Offer [Member] Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 7,417 shares at March 31, 2018 and 9,163 at June 30, 2017 Community hospital. Community Hospital [Member] Community Hospital [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings (Loss) Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate and Other [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument interest rate, basis spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument Floor Interest Rate Debt Instrument Floor Interest Rate Debt instrument, interest rate floor Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment Monthly principal and interest payment of loan Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Federal alternative minimum tax, tax credits Deferred Tax Assets, Valuation Allowance Deferred income tax valuation allowance Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year Expected contribution to pension plan during the remaining fiscal year Defined Benefit Plan, Expected Return (Loss) on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Net pension expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain (Loss) on sale Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (Loss) before income taxes: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Earnings (Loss) before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (Loss) from discontinued operations Earnings (Loss) from Discontinued Operations, net of tax Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Income tax expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Group Name [Domain] Disposal Group Name [Domain] Disposal groups, including discontinued operations, sale of assets. Disposal Groups, Including Discontinued Operations, Sale of Assets Disclosure [Text Block] Sale of Assets Divestiture of businesses purchase price adjustment receivable. Divestiture Of Businesses Purchase Price Adjustment Receivable Purchase price adjustment due to from hospital buyer Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earliest Tax Year [Member] For tax years beginning after March 31, 2018 and before January 1, 2022 [Member] Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings (Loss): Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Revenue from Financial and Health Care Services Financial And Healthcare Services Revenue Net revenues Operating revenues (net of contractual allowances) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] GEORGIA Georgia [Member] Gain (Loss) Related to Litigation Settlement Gain on economic damages claim, net Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Gain (Loss) on Disposition of Assets for Financial Service Operations Gain on sale of assets Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. Health Care Organization, Medicare and Medicaid Electronic Health Records Incentives, Gain (Loss) EHR incentive payments Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Healthcare services segment. Healthcare Services Segment [Member] Healthcare Services Segment [Member] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Earnings (Loss) from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings (Loss) from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Statement Equity Method Investments [Line Items] Income Statement Equity Method Investments [Line Items] Income Statement Equity Method Investments [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Taxes Receivable, Noncurrent Income tax receivable Income Tax Expense (Benefit) Income Tax Benefit Income tax expense (benefit) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Total Interest bearing covenant deposit. Interest Bearing Covenant Deposit Interest bearing deposit under financial covenant Interest Expense Interest expense, net Interest on outstanding debt. Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory LOUISIANA Louisiana [Member] Labor and Related Expense Salaries, wages and benefits Later Than [Member] Later Than [Member] Later Than [Member] Latest Tax Year [Member] For the 2021 tax year [Member] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Loans Payable RDA Loan Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt, net of debt issuance costs Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt, net of debt issuance costs Total Long-term debt, excluding current maturities, total Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Contingencies Disclosure [Text Block] Economic Damages Claim Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medicare license. Medicare License [Member] Medicare License [Member] Medicare. Medicare [Member] Medicare [Member] Mortgages [Member] Mortgages [Member] MISSISSIPPI Mississippi [Member] Nature of Operations [Text Block] Business Operations EX-101.PRE 11 ssy-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 11, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		7,416,814

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Current Assets:
Cash and cash equivalents	$ 3,541	$ 10,494
Restricted cash	0	1,000
Receivables - net	5,884	5,906
Inventory	1,974	2,159
Prepaid expense and other assets	3,083	3,062
Total current assets	14,482	22,621
Property, plant and equipment, at cost	30,103	28,609
Less accumulated depreciation	19,559	18,319
Property, plant and equipment - net	10,544	10,290
Noncurrent Assets:
Intangible assets - net	1,500	1,587
Income tax receivable	296	0
Other noncurrent assets	969	838
Total noncurrent assets	2,765	2,425
TOTAL ASSETS	27,791	35,336
Current liabilities:
Accounts payable	1,254	1,571
Current maturities of long-term debt, net of debt issuance costs	258	6,710
Accrued payroll and related taxes	2,381	2,098
Due to third party payors	293	658
Other accrued expenses	1,099	1,277
Total current liabilities	5,285	12,314
Long-Term Liabilities
Long-term debt, net of debt issuance costs	2,863	0
Noncurrent liability for professional liability risks	752	1,040
Other noncurrent liabilities	304	289
Total long-term liabilities	3,919	1,329
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 7,417 shares at March 31, 2018 and 9,163 at June 30, 2017	3,708	4,581
Additional paid-in capital	11,009	13,103
Retained earnings	4,197	4,336
Accumulated other comprehensive loss	(327)	(327)
Total Shareholders' Equity	18,587	21,693
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 27,791	$ 35,336

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	7,417,000	9,163,000
Common shares, outstanding	7,417,000	9,163,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Operating revenues (net of contractual allowances)	$ 13,550	$ 13,883	$ 41,021	$ 41,321
Less provision for bad debts of Healthcare Facilities segment	133	184	363	321
Net revenues	13,417	13,699	40,658	41,000
Costs and Expenses
Cost of goods sold	5,073	5,523	14,623	15,592
Salaries, wages and benefits	6,045	5,872	17,697	17,476
Provision for bad debts of Pharmacy segment	237	126	445	342
Supplies	448	455	1,361	1,373
Purchased services	672	692	2,021	2,113
Other operating expenses	1,052	1,194	3,639	4,015
Rent and lease expense	157	142	471	409
EHR incentive payments	0	0	(21)	0
Depreciation and amortization	464	466	1,332	1,376
Operating Loss	(731)	(771)	(910)	(1,696)
Other Income (Expense):
Gain on sale of assets	183	2	181	3,019
Gain on economic damages claim, net	0	0	944	0
Loss on extinguishment of debt	0	0	(238)	(243)
Interest expense, net	(56)	(129)	(302)	(507)
Earnings (Loss) from Continuing Operations before income taxes	(604)	(898)	(325)	573
Income Tax Benefit	0	(8)	(296)	(236)
Earnings (Loss) from Continuing Operations	(604)	(890)	(29)	809
Earnings (Loss) from Discontinued Operations, net of tax	16	(135)	(110)	4,287
Net Earnings (Loss)	(588)	(1,025)	(139)	5,096
Other comprehensive income	0	0	0	0
Comprehensive Earnings (Loss)	$ (588)	$ (1,025)	$ (139)	$ 5,096
Continuing Operations:
Basic	$ (0.08)	$ (0.10)	$ 0.00	$ 0.09
Diluted	(0.08)	(0.10)	0.00	0.09
Discontinued Operations:
Basic	0.00	(0.01)	(0.01)	0.46
Diluted	0.00	(0.01)	(0.01)	0.45
Net Earnings (Loss):
Basic	(0.08)	(0.11)	(0.02)	0.54
Diluted	$ (0.08)	$ (0.11)	$ (0.02)	$ 0.54
Weighted-Average Common Shares Outstanding:
Basic	7,417	9,334	8,564	9,408
Diluted	7,417	9,334	8,564	9,429

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement of Cash Flows [Abstract]
Net Cash Used in Operating Activities	$ (33)	$ (4,999)
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(1,502)	(1,097)
Proceeds from sale of other assets	412	4,942
Proceeds from sale of hospital	0	14,620
Net Cash Provided by (Used in) Investing Activities	(1,090)	18,465
Cash Flows Used in Financing Activities:
Repurchase of common shares	(2,974)	(640)
Payments on long-term debt - continuing operations	(3,856)	(3,850)
Receipt (Deposit) of restricted cash	1,000	(1,000)
Net Cash Used in Financing Activities	(5,830)	(5,490)
Net increase (decrease) in Cash and Cash Equivalents	(6,953)	7,976
Cash and Cash Equivalents Beginning of Period	10,494	3,261
Cash and Cash Equivalents End of Period	3,541	11,237
Cash Paid for:
Interest	269	458
Income taxes	$ 0	$ 141

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1. – Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2018 and for the three and nine month periods ended March 31, 2018 and 2017 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2017 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on September 28, 2017. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2018 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Business Operations	9 Months Ended
Business Operations	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Operations	Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84-bed community hospital and a 66-bed nursing home in Mississippi, a 100-bed nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines. The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries’ underperforming assets. The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines. On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation for approximately $410. A pre-tax gain of $183 on the sale of these assets is included in the results for the three months ended March 31, 2018. Throughout these notes to the consolidated financial statements, all references to “SunLink,” “we,” “our,” “ours,” “us” and the “Company” refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to “we,” “our,” “ours,” and “us” in such context refer to the operations.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Mar. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Net Revenues:
Chestatee Hospital	$	0		$	0		$	0		$	2,369
Other Sold Hospitals		77			(68	)		71			(288	)

	$	77		$	(68	)	$	71		$	2,081

Earnings (Loss) before income taxes:
Chestatee Hospital	$	0		$	(104	)	$	(38	)	$	83
Other Sold Hospitals		61			(69	)		45			(304	)
Life sciences and engineering		(36	)		(37	)		(108	)		(112	)
Gain (Loss) on sale of Chestatee Hospital		(9	)		0			(9	)		7,270

Earnings (Loss) before income taxes		16			(210	)		(110	)		6,937
Income tax expense		0			(75	)		0			2,650

Earnings (Loss) from discontinued operations	$	16		$	(135	)	$	(110	)	$	4,287

The components of pension expense for the three and nine months ended March 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Interest Cost	$	14		$	13		$	42		$	39
Expected return on assets		(9	)		(8	)		(27	)		(24	)
Amortization of prior service cost		31			32			93			97

Net pension expense	$	36		$	37		$	108		$	112

SunLink contributed $105 to the plan in the nine months ended March 31, 2018 and expects to contribute an additional $35 during the last fiscal quarter of the fiscal year ending June 30, 2018.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Economic Damages Claim	9 Months Ended
Economic Damages Claim	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Economic Damages Claim	Note 4. – Economic Damages Claim The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys’ fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the nine months ended March 31, 2018.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Restricted Cash	9 Months Ended
Restricted Cash	Mar. 31, 2018
Receivables [Abstract]
Restricted Cash	Note 5. – Restricted Cash Under the Fourth Amendment to the Trace RDA Loan dated January 7, 2017 (see Note 9. Long-Term Debt), a deposit of $1,000 in a blocked interest bearing account was held by the lender. Under the Fifth Amendment to the Trace RDA Loan dated December 26, 2017, the blocked account was eliminated and a prepayment was made on the Trace RDA loan.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Mar. 31, 2018
Equity [Abstract]
Shareholders' Equity	Note 6. – Shareholders’ Equity *Common Share Purchase Tender Offer* – On November 21, 2017, SunLink commenced a tender offer for the purchase of a portion of its common shares at a price of $1.60 per share (the “Offer”). The offer expired on December 21, 2017 with 3,725,656 common shares tendered. In accordance with the terms and conditions of the Offer, the Company accepted for payment a total of approximately 1,745,751 shares at a price of $1.60 per share for a total cost of approximately $2,794, excluding fees and expenses relating to the Offer. *Stock-Based Compensation* – For the three months ended March 31, 2018 and 2017, the Company recognized $1 and $5, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2018 and 2017, the Company recognized $7 and $59, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 0 and 72,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2018 and 2017, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables

9 Months Ended

Mar. 31, 2018

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 7. – Revenue Recognition and Accounts Receivables

Revenues by payor were as follows for the three and nine months ended March 31, 2018 and 2017:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Healthcare Facilities Segment:
Medicare	$	2,485		$	2,079		$	7,167		$	6,447
Medicaid		2,091			2,285			6,328			7,185
Self-pay		91			86			532			356
Managed Care & Other Insurance		793			871			2,278			2,248
Other		330			364			1,091			1,139

Revenues before provision for doubtful accounts		5,790			5,685			17,396			17,375
Provision for doubtful accounts		(133	)		(184	)		(363	)		(321	)

Healthcare Facilities Segment Net Revenues		5,657			5,501			17,033			17,054
Pharmacy Segment Net Revenues		7,760			8,198			23,625			23,946

Total Net Revenues	$	13,417		$	13,699		$	40,658		$	41,000

Summary information for accounts receivable is as follows:


	March 31, 2018			June 30, 2017
Accounts receivable (net of contractual allowances)	$	6,453		$	6,458
Less allowance for doubtful accounts		(569	)		(552	)

Patient accounts receivable – net	$	5,884		$	5,906


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2018
Balance at January 1, 2018	$	326		$	219		$	545
Additions recognized as a reduction to revenues:
Continuing Operations		133			237			370
Discontinued Operations		(4	)		0			(4	)
Accounts written off, net of recoveries		(82	)		(260	)		(342	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2018
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		363			445			808
Discontinued Operations		2			0			2
Accounts written off, net of recoveries		(320	)		(473	)		(793	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2017
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		0			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2017
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			0			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710

New Accounting Pronouncement for Revenue Recognition

XML 24 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 8. – Intangible Assets

Intangibles consist of the following, net of amortization:


	March 31, 2018			June 30, 2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,392	)		(1,305	)

Net Intangibles	$	1,500		$	1,587

XML 25 R14.htm IDEA: XBRL DOCUMENT

Long-Term Debt

9 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt

Note 9. – Long-Term Debt

Long-term debt consisted of the following:


	March 31, 2018			June 30, 2017
Trace RDA Loan	$	3,347		$	7,191
Capital lease obligations and other		0			12

Total		3,347			7,203
Less unamortized debt issuance costs		(226	)		(493	)
Less current maturities		(258	)		(6,710	)

Long-term Debt	$	2,863		$	0

XML 26 R15.htm IDEA: XBRL DOCUMENT

Income Taxes	9 Months Ended
Income Taxes	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. – Income Taxes Income tax benefit of $0 ($0 federal tax and $0 state tax expense) and income tax benefit of $8 ($32 federal tax benefit and $24 state tax expense) was recorded for continuing operations for the three months ended March 31, 2018 and 2017, respectively. Income tax benefit of $296 ($296 federal tax benefit and $0 state tax expense) and income tax benefit of $236 ($221 federal tax benefit and $15 state tax benefit) was recorded for continuing operations for the nine months ended March 31, 2018 and 2017, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. The Tax Cut and Jobs Act (“TCJA”) was enacted on December 22, 2017. Under ASC 740, the impact of changes in tax law must be recorded in the financial statements in the reporting period that included the date of enactment. However, the SEC and the FASB both recognize that the magnitude of this law change will require extensive analysis and calculations to conform to the new provisions. The SEC issued Staff Accounting Bulletin (‘SAB”) 118 on December 22, 2017. SAB 118 provides registrants with guidance on when and how to report the impact of the law change when not all necessary information is available. At March 31, 2018, consistent with the above processes, we evaluated the need for a valuation allowance against our deferred tax assets and determined that it was more likely than not that only our federal alternative minimum tax (“AMT”) tax credits of $296 would be realized. The AMT credit represents a provisional amount that will be finalized upon the filing of the Company’s federal income tax return for the year ended June 30, 2017. The filing of this return will occur prior to the Company’s fiscal year end which is within the measurement period. Under TCJA, AMT tax credits will now become refundable in conjunction with the repeal of the corporate AMT. For tax years beginning after December 31, 2017 and before January 1, 2022, the AMT credit is refundable in an amount equal to 50% (100% for the 2021 tax year) of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. This results in the Company receiving its entire AMT credit of $296 as a refund no later than fiscal 2022 and as such a valuation allowance is no longer needed for the AMT credit carryforward. However, in accordance with ASC 740, we recognized a valuation allowance of $8,071 against all other net deferred tax asset items at March 31, 2018. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at March 31, 2018 that $8,071 of the net deferred tax assets resulting from non-AMT credit carryforwards should have full valuation allowances was the three-year cumulative pre-tax loss as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at March 31, 2018, the Company had approximately $13,400 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire in 2025. With the enactment of TCJA, Federal net operating loss carryforwards generated in taxable years ending after December 31, 2017 now have no expiration date.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. – Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	258	$	574	$	172
2 years		296		423		173
3 years		315		340		155
4 years		333		132		136
5+ years		2,145		4		355

	$	3,347	$	1,473	$	991

XML 28 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $25 and $109 for legal services to this law firm in the three months ended March 31, 2018 and 2017, respectively. The Company expensed an aggregate of $215 and $481 for legal services to this law firm in the nine months ended March 31, 2018 and 2017, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2018 and June 30, 2017 is $12 and $38, respectively, of amounts payable to this law firm.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Sale of Assets	9 Months Ended
Sale of Assets	Mar. 31, 2018
Carmichael's Cashway Pharmacy, Inc [Member]
Sale of Assets	Note 13. – Sale of Assets On January 11, 2018, Carmichael’s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $183 is included in the results for the three months ended March 31, 2018.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Financial Information by Segment

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Financial Information by Segment

Note 14. – Financial Information by Segment


	Healthcare Facilities			Pharmacy			Corporate and Other			Total
As of and for the three months ended March 31, 2018
Net revenues from external customers	$	5,657		$	7,760		$	0		$	13,417
Operating profit (loss)		114			(367	)		(478	)		(731	)
Depreciation and amortization		167			297			0			464
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		167			263			0			430

As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,501		$	8,198		$	0		$	13,699
Operating profit (loss)		(146	)		(324	)		(301	)		(771	)
Depreciation and amortization		176			289			1			466
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		25			264			0			289

As of and for the nine months ended March 31, 2018
Net revenues from external customers	$	17,033		$	23,625		$	0		$	40,658
Operating profit (loss)		118			285			(1,313	)		(910	)
Depreciation and amortization		485			845			2			1,332
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		980			522			0			1,502

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	17,054		$	23,946		$	0		$	41,000
Operating profit (loss)		146			(511	)		(1,331	)		(1,696	)
Depreciation and amortization		563			810			3			1,376
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		358			739			0			1,097

XML 31 R20.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Policies)	9 Months Ended
Revenue Recognition and Accounts Receivables (Policies)	Mar. 31, 2018
Receivables [Abstract]
New Accounting Pronouncement for Revenue Recognition	New Accounting Pronouncement for Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on July 1, 2018 and is currently implementing its plan for adoption and evaluating the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows. A significant element of executing this plan is the process of reviewing sources of revenue and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. The Company is currently evaluating the appropriate portfolios to apply in its collectability analysis and is considering the impact of applying the new standard when its patient accounts are evaluated in those portfolios. The Company expects this process will be completed later in 2018. Additionally, the adoption of the new accounting standard will impact the presentation on the Company’s statement of operations for a significant component of its provision for bad debts. After adoption of the new standard, the majority of what is currently classified as the provision for bad debts will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenue. The Company will continue to evaluate certain changes in collectability on its self-pay patient accounts receivable resulting from certain credit and collection issues not assessed at the date of service, including bankruptcy, and recognize such amounts in the provision for bad debts included in operating expenses on the statement of operations. The Company cannot reasonably estimate at this time the quantitative impact that the adoption of this accounting standard will have on the financial statements of the Company.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

9 Months Ended

Mar. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Net Revenues:
Chestatee Hospital	$	0		$	0		$	0		$	2,369
Other Sold Hospitals		77			(68	)		71			(288	)

	$	77		$	(68	)	$	71		$	2,081

Earnings (Loss) before income taxes:
Chestatee Hospital	$	0		$	(104	)	$	(38	)	$	83
Other Sold Hospitals		61			(69	)		45			(304	)
Life sciences and engineering		(36	)		(37	)		(108	)		(112	)
Gain (Loss) on sale of Chestatee Hospital		(9	)		0			(9	)		7,270

Earnings (Loss) before income taxes		16			(210	)		(110	)		6,937
Income tax expense		0			(75	)		0			2,650

Earnings (Loss) from discontinued operations	$	16		$	(135	)	$	(110	)	$	4,287

Components of Pension Expense

The components of pension expense for the three and nine months ended March 31, 2018 and 2017, respectively, were as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Interest Cost	$	14		$	13		$	42		$	39
Expected return on assets		(9	)		(8	)		(27	)		(24	)
Amortization of prior service cost		31			32			93			97

Net pension expense	$	36		$	37		$	108		$	112

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Tables)

9 Months Ended

Mar. 31, 2018

Receivables [Abstract]

Summary of Revenues

Revenues by payor were as follows for the three and nine months ended March 31, 2018 and 2017:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2018			2017			2018			2017
Healthcare Facilities Segment:
Medicare	$	2,485		$	2,079		$	7,167		$	6,447
Medicaid		2,091			2,285			6,328			7,185
Self-pay		91			86			532			356
Managed Care & Other Insurance		793			871			2,278			2,248
Other		330			364			1,091			1,139

Revenues before provision for doubtful accounts		5,790			5,685			17,396			17,375
Provision for doubtful accounts		(133	)		(184	)		(363	)		(321	)

Healthcare Facilities Segment Net Revenues		5,657			5,501			17,033			17,054
Pharmacy Segment Net Revenues		7,760			8,198			23,625			23,946

Total Net Revenues	$	13,417		$	13,699		$	40,658		$	41,000

Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:


	March 31, 2018			June 30, 2017
Accounts receivable (net of contractual allowances)	$	6,453		$	6,458
Less allowance for doubtful accounts		(569	)		(552	)

Patient accounts receivable – net	$	5,884		$	5,906

Summary of Allowance for Doubtful Accounts


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2018
Balance at January 1, 2018	$	326		$	219		$	545
Additions recognized as a reduction to revenues:
Continuing Operations		133			237			370
Discontinued Operations		(4	)		0			(4	)
Accounts written off, net of recoveries		(82	)		(260	)		(342	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2018
Balance at July 1, 2017	$	328		$	224		$	552
Additions recognized as a reduction to revenues:
Continuing Operations		363			445			808
Discontinued Operations		2			0			2
Accounts written off, net of recoveries		(320	)		(473	)		(793	)

Balance at March 31, 2018	$	373		$	196		$	569


	Healthcare Services			Pharmacy			Total
Three Months Ended March 31, 2017
Balance at January 1, 2017	$	332		$	400		$	732
Additions recognized as a reduction to revenues:
Continuing Operations		184			126			310
Discontinued Operations		(14	)		0			(14	)
Accounts written off, net of recoveries		(180	)		(138	)		(318	)

Balance at March 31, 2017	$	322		$	388		$	710


	Healthcare Services			Pharmacy			Total
Nine Months Ended March 31, 2017
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		321			342			663
Discontinued Operations		378			0			378
Accounts written off, net of recoveries		(1,001	)		(321	)		(1,322	)

Balance at March 31, 2017	$	322		$	388		$	710

XML 34 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangibles consist of the following, net of amortization:


	March 31, 2018			June 30, 2017
Pharmacy Segment Intangibles
Trade Name (non-amortizing)		1,180			1,180
Customer Relationships		1,089			1,089
Medicare License		623			623

		2,892			2,892
Accumulated Amortization		(1,392	)		(1,305	)

Net Intangibles	$	1,500		$	1,587

XML 35 R24.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

9 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:


	March 31, 2018			June 30, 2017
Trace RDA Loan	$	3,347		$	7,191
Capital lease obligations and other		0			12

Total		3,347			7,203
Less unamortized debt issuance costs		(226	)		(493	)
Less current maturities		(258	)		(6,710	)

Long-term Debt	$	2,863		$	0

XML 36 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	258	$	574	$	172
2 years		296		423		173
3 years		315		340		155
4 years		333		132		136
5+ years		2,145		4		355

	$	3,347	$	1,473	$	991

XML 37 R26.htm IDEA: XBRL DOCUMENT

Financial Information by Segment (Tables)

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Segment Information


	Healthcare Facilities			Pharmacy			Corporate and Other			Total
As of and for the three months ended March 31, 2018
Net revenues from external customers	$	5,657		$	7,760		$	0		$	13,417
Operating profit (loss)		114			(367	)		(478	)		(731	)
Depreciation and amortization		167			297			0			464
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		167			263			0			430

As of and for the three months ended March 31, 2017
Net revenues from external customers	$	5,501		$	8,198		$	0		$	13,699
Operating profit (loss)		(146	)		(324	)		(301	)		(771	)
Depreciation and amortization		176			289			1			466
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		25			264			0			289

As of and for the nine months ended March 31, 2018
Net revenues from external customers	$	17,033		$	23,625		$	0		$	40,658
Operating profit (loss)		118			285			(1,313	)		(910	)
Depreciation and amortization		485			845			2			1,332
Assets		14,394			9,104			4,293			27,791
Expenditures for property, plant and equipment		980			522			0			1,502

As of and for the nine months ended March 31, 2017
Net revenues from external customers	$	17,054		$	23,946		$	0		$	41,000
Operating profit (loss)		146			(511	)		(1,331	)		(1,696	)
Depreciation and amortization		563			810			3			1,376
Assets		13,936			11,519			12,678			38,133
Expenditures for property, plant and equipment		358			739			0			1,097

XML 38 R27.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 11, 2018 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2018 USD ($) Segment Bed Services	Mar. 31, 2017 USD ($)
Business And Organization [Line Items]
Number of segments \| Segment				2
Proceeds from sale				$ 0	$ 14,620
Earnings (Loss) before income taxes		$ 16	$ (210)	$ (110)	$ 6,937
Carmichael's Cashway Pharmacy, Inc [Member]
Business And Organization [Line Items]
Proceeds from sale	$ 410
Earnings (Loss) before income taxes		$ 183
Pharmacy Segment [Member] \| Louisiana [Member]
Business And Organization [Line Items]
Number of material service lines \| Services				4
Healthcare Services Segment [Member] \| Community Hospital [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary \| Bed				84
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Mississippi [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary \| Bed				66
Healthcare Services Segment [Member] \| Nursing Home [Member] \| Georgia [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary \| Bed				100

XML 39 R28.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 19, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ 16	$ (210)	$ (110)	$ 6,937
Income tax expense		0	(75)	0	2,650
Earnings (Loss) from discontinued operations		16	(135)	(110)	4,287
Chestatee Hospital [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	$ 7,270
Discontinued Operations, Disposed of by Sale [Member]
Net Revenues:
Net revenues		77	(68)	71	2,081
Discontinued Operations, Disposed of by Sale [Member] \| Chestatee Hospital [Member]
Net Revenues:
Net revenues		0	0	0	2,369
Earnings (Loss) before income taxes:
Gain (Loss) on sale		(9)	0	(9)	7,270
Earnings (Loss) before income taxes		0	(104)	(38)	83
Discontinued Operations, Disposed of by Sale [Member] \| Other Sold Hospitals [Member]
Net Revenues:
Net revenues		77	(68)	71	(288)
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		61	(69)	45	(304)
Discontinued Operations, Disposed of by Sale [Member] \| Life Sciences and Engineering [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes		$ (36)	$ (37)	$ (108)	$ (112)

XML 40 R29.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Additional Information (Detail) $ in Thousands		3 Months Ended		9 Months Ended		30 Months Ended
	Aug. 19, 2016 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2014 Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale				$ 0	$ 14,620
Earnings (Loss) before income taxes		$ 16	$ (210)	(110)	$ 6,937
Number of Hospitals Sold \| Hospital						3
Chestatee Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earnings (Loss) before income taxes	$ 7,270
Purchase price adjustment due to from hospital buyer		328		328
Chestatee Hospital [Member] \| Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 15,000
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan				105
Expected contribution to pension plan during the remaining fiscal year		$ 35		$ 35

XML 41 R30.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 14	$ 13	$ 42	$ 39
Expected return on assets	(9)	(8)	(27)	(24)
Amortization of prior service cost	31	32	93	97
Net pension expense	$ 36	$ 37	$ 108	$ 112

XML 42 R31.htm IDEA: XBRL DOCUMENT

Economic Damages Claim - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Loss Contingencies [Line Items]
Gain on economic damages claim, net	$ 0	$ 0	$ 944	$ 0
Pharmacy Segment [Member]
Loss Contingencies [Line Items]
Gain on economic damages claim, net			$ 944

XML 43 R32.htm IDEA: XBRL DOCUMENT

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 0	$ 1,000
Trace RDA Loan [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 1,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 21, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Nov. 21, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, amount recognized		$ 1	$ 5	$ 7	$ 59
Common Share Purchase Tender Offer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common share purchase price per share	$ 1.60					$ 1.60
Number of shares tendered	3,725,656
Number of shares purchased	1,745,751
Total cost of share purchased	$ 2,794
Share purchase program expiration date	Dec. 21, 2017
2011 Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted				0	72,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 13,550	$ 13,883	$ 41,021	$ 41,321
Provision for doubtful accounts	(133)	(184)	(363)	(321)
Net revenues	13,417	13,699	40,658	41,000
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	5,790	5,685	17,396	17,375
Provision for doubtful accounts	(133)	(184)	(363)	(321)
Net revenues	5,657	5,501	17,033	17,054
Healthcare Facilities Segment [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,485	2,079	7,167	6,447
Healthcare Facilities Segment [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,091	2,285	6,328	7,185
Healthcare Facilities Segment [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	91	86	532	356
Healthcare Facilities Segment [Member] \| Managed Care & Other Insurance [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	793	871	2,278	2,248
Healthcare Facilities Segment [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	330	364	1,091	1,139
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 7,760	$ 8,198	$ 23,625	$ 23,946

XML 46 R35.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 6,453		$ 6,458
Less allowance for doubtful accounts	(569)	$ (545)	(552)	$ (710)	$ (732)	$ (991)
Patient accounts receivable - net	$ 5,884		$ 5,906

XML 47 R36.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	$ 545	$ 732	$ 552	$ 991
Accounts written off, net of recoveries	(342)	(318)	(793)	(1,322)
Ending balance	569	710	569	710
Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	370	310	808	663
Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(4)	(14)	2	378
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	326	332	328	624
Accounts written off, net of recoveries	(82)	(180)	(320)	(1,001)
Ending balance	373	322	373	322
Healthcare Facilities Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	133	184	363	321
Healthcare Facilities Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	(4)	(14)	2	378
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	219	400	224	367
Accounts written off, net of recoveries	(260)	(138)	(473)	(321)
Ending balance	196	388	196	388
Pharmacy Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	237	126	445	342
Pharmacy Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	$ 0	$ 0	$ 0	$ 0

XML 48 R37.htm IDEA: XBRL DOCUMENT

Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Indefinite-lived Intangible Assets [Line Items]
Total	$ 1,500	$ 1,587
Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	2,892	2,892
Accumulated Amortization	(1,392)	(1,305)
Total	1,500	1,587
Trade Name [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,180	1,180
Customer Relationships [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 623	$ 623

XML 49 R38.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 29	$ 35	$ 87	$ 106

XML 50 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Debt Instrument [Line Items]
Capital lease obligations and other	$ 0	$ 12
Total	3,347	7,203
Total	3,347	7,203
Less unamortized debt issuance costs	(226)	(493)
Less current maturities	(258)	(6,710)
Total Long-term debt, excluding current maturities, total	2,863	0
Trace RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	$ 3,347	$ 7,191

XML 51 R40.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Dec. 26, 2017	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Prepayment of loan		$ 3,856	$ 3,850
Trace RDA Loan [Member]
Debt Instrument [Line Items]
Debt instrument maturity period		15 years
Prepayment of loan	$ 3,548
Monthly principal and interest payment of loan	$ 39
Debt instrument description	Prime rate plus 1% with a floor of 5.5%
Debt instrument interest rate, basis spread	1.00%
Debt instrument, interest rate floor	5.50%
Effective interest rate		5.75%
Interest bearing deposit under financial covenant		$ 1,000
Trace RDA Loan [Member] \| Mortgages [Member]
Debt Instrument [Line Items]
Loan agreement amount		$ 9,975
Date of loan agreement		Jul. 05, 2012

XML 52 R41.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2022
Schedule of Income Taxes [Line Items]
Income tax expense (benefit)	$ 0	$ (8)		$ (296)	$ (236)
Federal tax expense (benefit)	0	(32)		(296)	(221)
State tax expense (benefit)	0	$ 24		0	$ (15)
Deferred income tax valuation allowance	8,071			8,071
Net operating loss carry-forward	$ 13,400			$ 13,400
Net operating loss carryforward expiration year			2025
For tax years beginning after March 31, 2018 and before January 1, 2022 [Member]
Schedule of Income Taxes [Line Items]
Percentage of AMT credit refundable				50.00%
For the 2021 tax year [Member]
Schedule of Income Taxes [Line Items]
Percentage of AMT credit refundable				100.00%
Later Than [Member] \| Scenario, Forecast [Member]
Schedule of Income Taxes [Line Items]
Federal alternative minimum tax, tax credits						$ 296

XML 53 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Mar. 31, 2018 USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 258
Payments due in 2 years	296
Payments due in 3 years	315
Payments due in 4 years	333
Payments due in 5+ years	2,145
Contractual obligations, commitments and contingencies	3,347
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	574
Payments due in 2 years	423
Payments due in 3 years	340
Payments due in 4 years	132
Payments due in 5+ years	4
Contractual obligations, commitments and contingencies	1,473
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	172
Payments due in 2 years	173
Payments due in 3 years	155
Payments due in 4 years	136
Payments due in 5+ years	355
Contractual obligations, commitments and contingencies	$ 991

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	9 Months Ended
	Mar. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Accrued penalties expense	$ 170

XML 55 R44.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Related Party Transaction [Line Items]
Legal services to these law firms	$ 25	$ 109	$ 215	$ 481
Amount payable to law firms	$ 12		$ 12		$ 38

XML 56 R45.htm IDEA: XBRL DOCUMENT

Sale of Assets - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 11, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement Equity Method Investments [Line Items]
Proceeds from sale				$ 0	$ 14,620
Earnings (Loss) before income taxes		$ 16	$ (210)	$ (110)	$ 6,937
Carmichael's Cashway Pharmacy, Inc [Member]
Income Statement Equity Method Investments [Line Items]
Proceeds from sale	$ 410
Earnings (Loss) before income taxes		$ 183

XML 57 R46.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	9 Months Ended
	Mar. 31, 2018 Segment
Segment Reporting [Abstract]
Number of segments	2

XML 58 R47.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 13,417	$ 13,699	$ 40,658	$ 41,000
Operating profit (loss)	(731)	(771)	(910)	(1,696)
Depreciation and amortization	464	466	1,332	1,376
Assets	27,791	38,133	27,791	38,133	$ 35,336
Expenditures for property, plant and equipment	430	289	1,502	1,097
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,657	5,501	17,033	17,054
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,657	5,501	17,033	17,054
Operating profit (loss)	114	(146)	118	146
Depreciation and amortization	167	176	485	563
Assets	14,394	13,936	14,394	13,936
Expenditures for property, plant and equipment	167	25	980	358
Operating Segments [Member] \| Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	7,760	8,198	23,625	23,946
Operating profit (loss)	(367)	(324)	285	(511)
Depreciation and amortization	297	289	845	810
Assets	9,104	11,519	9,104	11,519
Expenditures for property, plant and equipment	263	264	522	739
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	0	0	0	0
Operating profit (loss)	(478)	(301)	(1,313)	(1,331)
Depreciation and amortization	0	1	2	3
Assets	4,293	12,678	4,293	12,678
Expenditures for property, plant and equipment	$ 0	$ 0	$ 0	$ 0

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

)Q*$KLCBF>BL/ O"CQTFID*X'??-JW/)S: M<-:W6 .;TP//Y?12S/B+J&5>KG6/WA!6#P1V@?!4%@):9[JD:JK&O%_;X;>N M0#Y[QQG%I>)V((5V*,?81E7QQ;@>A6R6-O4U2*W#OVN'3G@]#X@]OO#^RPX< M:NO"LA(/3HIR8Y!*GMB<"!IM#2*NHL%JQ-:1HT_2<^Z+2?XM.MRA2+([TB G M+P-G1K@ Q?;<782<^#/WZ$13SN8FKN\'G#_AU'/UYU5T68]A^51I'E=0O)CL M%O+WFJN$AJ@J1>-A%4;'5JT,013S5:2HS-Q5_5<'76L@"7W 7M=!E=)%O@O: M%2]8/:$K]313[0_25BJ*N*,BA7(6L^56M1?.=N'MJFJ)AA(S!6OUM5,O9&;9 M")+*]H/-X5PVF4?H>:$;11>W$LP;)%Y(7]CZ!$S2&6Y[]8(6),%038.7-4$! M_'%7M'H*KW55L=N7E&%/UFX56A#57#*,7T9F%Y_!/P(G @Z9;,'UAZ#$1GX" MDY9082':NY0[2'$K$2;GBKN8E-TQ]=)AJ FB8LD#WI0&0S2=!KS55S3>-,"6 M&@P&($D,QA%B*5QB/1:;Y%_#MJL$(&,/T2Z :J ML-0?9R42)6R9OVQ(0'>V7;@=BXNXW&#-$VX9?;'7Z_&J@1N<+DA\5Q<5WM*' M Z.KB))B@A*,6P OE8IAO(!'>8I#H 5Z4\-KW]TB&+7&:55H)7VS7#"] '@5 M5M'!&VR@J-2*%,6RB6,[8S(-=R9W7$6QOL)J_P3YW(CPJ 8^6.^YL@DS9 M2,F*F91JF#1R?FF6GZR7'<\KD6B@7_D@U%*U@2#U!KRH&T M699Y2Q8U7M85 ML3L8"$)OV =J@?*BF7+Q2*PV-_(A/]3L_5'"9@O&\"YIZ@:G/_L38#U+H>=FU'2&4EYB*(I%$='?;<=#6L6Q-S?^-R>*B\-XCLDO #;'3T;"R>F'5^2!P*JY#/P'!X-@88/KVC3RMYD* M+QY@E"R5/=%MQJ&JSDX_$NLB;V]"P@-\ZXE3NX6F9 MN5,BDRPBF11M%9FVP'1E81ZL.KE5'F&=_D/,L5#$BL66!WW;A5(RODCXW?'\ M@.;ML)4'IG!Q%);6\YU$4W11X@G-;+N\M3H%N8E]V>0M!=3!:+*#U(KMEE-8 MD%AX9@>YE<=P+\EU0J2B^=WGBKJS['J):*_L;=R48P14OTL9E2L06 JHIBOO M58X\-Q4V!IYP+(6.Y^&N1@I%=S.W'(U6]ZO$"($N9?#9=WX HC&V(IL\52J- M7"PY@*OA+^*(6=UV.*46SYB,N\]_#S%E@LE\D'36*'(>:,&11DXHXFTH6M'A MOSE.&]%BZ'BV-VH^+=!!QJM*J3+#YDAM1(PT[*/AQ$!:**9I;D*+"IR6:)%M M;XU<_UCW:>DPN@!VJ1Q2@G+#\<**G;RHE1"K@+ZBVM,+%[MDG3JG M6"FX./=$<04[T)+@X14\$.\6M1N/FS(&AMJ5/#5KL:AD$&KYQ,^D;S<27Q/1 M%2O*V*U HA1@&0=A#OT@B^*^F.S44:-&(:YCZX52..6+F%1C?N-;([!I W* MGBN'H(!B]?N6W,,(.W7 *XH@\9:D]GA].# 'DM4=BMH04\J9C2$*IEY)AI?1 M.F*D;8V<@%$Y"JVTM4^.4OX%='A?3'+%N;8(P*\1<1E+KRCE$F/KT%B-:\6G>DU59:0D::"0?%8$O(358CYW@8&;[)'0:41:J9A6$>XB4O\@ MSOT4BS(\@ IS3WXL9G>85I9W%.[6P&0ETLL.T3WPI1U,E%+5\BUQVH@@2V\= M*ASEL.3 )B&*8&Q"CFJ,LJR86'3;+N@U[!1_A#52X\C5>)$T9GF 4 MMZ"-@Z(/Z"&K'6L,"A/AT]LYS8YO*M=-"#2=#V T'TB)K)T-BC&1:S7*XZYU M^$?5#U,];5/T);KVC5(R[BNO_M>A TH#56RR,'@5NJ!PT$ME'9HC(5Z'5;#@ MH&PJVN:F:*V"8Y\B:)M2061A#UJCU(;7H0.-S]ORY.TUY48]9$&Y(9=B2!HK M-VKB% W#3P15>5ENH.'2=\*Y']KN[X&_F*?!TY4A8]GK%Y/8:[37>@(Q:C[1 M_XJ[EKC=)%M)Q(,;VMO&R&S_/=%N?,YFF;[YNG:RKA\S.TQ">FO8I5PH\N#1 MTSH;Q,]UTQM3K27#J)&_$S]%/&WT:^A-K7BT!I[>O>+E1C2FA[_&IA4O=R?- M2E-?H2C5S]]'/=6A M[3)D$_M *(9B:H?1B/5^U]*Q\INJ&%U>40<&;VK= =\5!_UN7^D+ ]EBNI^$ M-H*VZ[%/3:315%-6S!I)(R5JL:083:>-ACW?:J0-%7X8YB3*9M-I8P B4HVT M4>*-01<-M>&T :$M&'*-M%&1-MBK6E'T76B3>;@FV 8N3E9"OP5NH1@]=46B M1>!=>'AMOQSW ^UMUF"H]"V1'^JRSBM=W>2[0[W/ZX:D][IB3] TC4EAU"5* M]N 66+Y$GR1Q""-P3X4B0D4EXW5XO42#8L'#2]CP@YC+\&W6YN!4: -[=BG* M=C=\7Z(9Z*=)P>CXZBEQ$/;.+*N+&Z)8\GU65DVU@L#V[FE]ENYS]DCL8+6P MP.P%:XO\.SP8A5\]]J$M6ZLMTU"59 6;JV$QW.U+JV]41#:127J1?$<@1#G6 M,VVE]7P##X?VB'YA1N-"+R:Y:_M0L+[V82RPRB@>:6Z!Y:O4Y*VQ>YA)#_/, MY1HX.Y7HK4-[.@!E-M*6M-BIEIUR[J@N;4;)PU;S+=.)_E94VNP(ULF.C6(V MZPXE)*$$Y9#S?0C1<)+JBG),DHI)E,HK4O. 4NWH'M1HTM[=!Q!KKUS^ MK$8348]/QXY:$>UP1]FUDD7?ZN2ZIFVP'M1IS0A9W\FCT@R9S>A4\S;( F-V MTZR:OPU6D/3XVR"+N9+U71I/-IJD]7$EB_K62F%K;XB$Q^="^4A<.";.9PN, M]C$:[D/7WCYUS4@22Y;<#CV];PVT'M_31 6/^73>$@8"WU4!+PE$O:9B0R3Q M[,L$Z$/^^FD)EEKZ\Z3P'ZT_CXP> 7UIXIK6GFL7-!RS[0&LJKQAFH)6, (%K2*_:S-X6#0%U3+&L!R1N3^W8U^'3L/_WX? M_0J0XZ\Y%T;/+OGM;&8']X['1_[\LS"/?N7BWW=^%/DS=FD" /.A\R_R6<"YESD(A_&\'-9R&.PA#H4$?QX@LOC%)81'\[M$?GL^8^! M/:??]WR/'^$:='&M45+@6WB+\]/R,RZM7H- P+>84C.#H%>*!3"SZLG)4=A"2AP#O#WW!Z/D]^/SCB:_G9F*#^?<7=^,"8! MO1Q#U;VXZ@^N^-[%MV_6Y?7@<_+'6@XHL\L99\/T>[^=818D"?)L'@7Y'^,$ M&LWX^2SEX6ACR-;S;V>Y=5U>-5QQG7"5PHRQ=7))/!?PR=!W =I_ M8]4@?F7D_*R:YX**KXR=<.[:SY\=SW4\4@)[/8I+4CQ)6>#&"P)2YO,:$?W2 MK-.7LA5?7/LO<),ML1X_3(EZ;XE$C!BJJ],V)\S;;?$CERY2J.SC-+TN[N'E#U84_\ MMUYO,!@.SPXF_T1AI0 $:;:[M(LON6024;*365&=XY.+.^AT(O=,[*!6L84W M?]J()^.? 58^H:])JE'Y8FE?>=VEM =^JJZ\:?Q$73H&?D?3:$YQ14MT18>U M+^DM]YOEM6UJI\'[^R*J2/+[0%34CX)HNZ.O7?_RB:Y_653?Q[*0%>%]("JJ M1YG1=K?/K7;E5%>[_%XV0?DH*F\3$3V*_M;N]FO7O_K_G:@ D#JB\DXV_!.Q MZ?<6Z?5N][G%,G_Z=<6ZS7^C!A+NR#-G8[#I,^=/\C<_8#S)W YH9"K>PSA; M#)M^YEB*%OP0@!H15R6?#9Q$\'IT.''.+JC)PYBX6% M$9.&%A@0^\D/8(2DKT4R:'C.62%GP\CAPHT8 9TP1HJ1.O\-"@,&O -1: 0M M/@"$@Q$\'[Y-<(0QF0 4T)P1F$..,V=A3&V.+N3O,K0@"6I F&]!] M/F?PN:%/0<2/PRAEQ!!N)PIIS#!\D7X=PYH)AC,[#X[+S7R/1';P#"_/B0< M 7;GP L(YMS'U YX"8>-&6+BT "GL)*(]MB?4\:"ITO 2 ]R:+@"Y#-B.4K@2D] (9C4XV?)@. MR58RDQXQ.<(B/6"9<#W*!]^!#YZY2\H"ST4)TOM^F?WL@P0!;!&=&7 Z$.6. MS6=1)C%)5-H \7_<'PL0B5R20HH2B,;CL86?7]G9HDX>QLGZF^TM@%VSD146 MP0X#L77#ECPN%H_[2=0%CK"T'GJ!4A9%&;!]- TY6 =TW:P(BS_G;N %P)]. M\!QA6?J^:,3/+F]7<3)&EF^R70Y)*?_$#J?X$OP'2X?#A.,P!TJOVRO]9J,V M3R+M4\1KIEI,0MH&K:6$G'*GXZ3+<;WX;]2G2;Z55-J#IUAK:PT2)6P7 39I M'K+-$V['V6IQ,:6:9]PR^F*OU^-50]=Y11A+7%U$? JK%*AUD2DL!Z.4,IG+X)= MR9W7L.5@F[%O_NA4>%0J%%O9"(_R;*;I8Q=I]M@0I+GM_@^Q@^]VM A -[\> M3.SWMJ$NS;AKH%)4AL*XS;AKDVX:Q/NWD+ 7IMPUR3\VH2[-@2_ M3;AK.._O'7_;)MRU(?AMPMU2K%R;W.(M@EW;<+= MYNI^FW#WQM!L$^[V.LQH$XG:.6GGI)V3S>:D3;AK$^[>*(9MPMW>0JA-(FIG MI9V5=E9VTR:6$NZJ$B+V")[->NDD0>7IBP-OW,=TF(.%UVJZ+@WZ\(IEJ :O M2 .1-TQ5YTW1ZHJF,E U0[H5L14RSPL:+PNLL242)6R!&"Q>EHPODFA9EOKPS0_#8>#/*A_I RMX]Y=3 M.R07B[B9=)=,_"#.FZ@_[T/5!H+4&_"B;JC8:DGF+5F$R=<5L3L8"$)OV+^E MG7=X;"95(-;Q:' \8C<[NT8Z,IFKTW+@];D?VN[O@;^8AS"TN\!PM,I1C]LG M2.]U55GNF[PI=[N\@F+*ZADFK\N6.1 56;4&_1<3 +Y;5[]__<%W+VYN+KY_ MYN@^,KSX<<-??_U_@\^@7E"<9E%*.[1A;#5QD??V"8:>+#S>"_;_BO/_J#'S>?.>7G! ?+=9-D[+M% MZ'@DQ"R!,<"^"/,9AHCA'7']1XXE>)P]_NDO!RGI9 ]1B] M;%98I@7F:%"]9$W&Q4LH4Q3R2&V3=A%_8TL2EM,M,,[6M>NO?7B+NA_:FGPFNHG=3 -",C"^ MTR3T[/< L]&+6UXNICT=93FEK+1-'OR0K@ETS/0'V L:3\-VG:R9WZ74D,+\ MHI+[QACZ183U]X9P.\-'ER^;J)4K!%0UN*L"F@YG-7P;#,%&$#&NJ:1R ME\P('IY)8 %C'8R)!P*F045J]=$C8%[KN1;F%N:CBX;7%03R=H*@-R746T*X M/_QP[D2V6[LTV/'XNCJXO_Q:12;\21S.M]B=+G921];,8V#XWI2:+679!:WZ M1PMA)<+L].*U]>JPJL:MC7WQ_*A5IYAO@.@OIX6I7AUF]?9F5#*.,Z6;B+WY M4S,CRJI$8FQ&4XF6V=!Q+.LN!RC _LP,/V/=Q'#(#_A;NCR0,85DO;V=A/[7EY"_/[ M@KD]+V_/RQMOT7T4A>KR/V_&)/\HOW&?@U%=;J$],V_/S%_@'.U$O%7[GYGO M'%9R8F?F*TK6O;T9E8^T;;5*6T[(?7,FA MI;UK6M(HCWKWC$1+$G3%.2MI] M7%$ ].U)@8_RSL=(IX:I*)R*=K<_JF)UI=ZFB[P3U_1^MQTO\6IA_W+;I=VO M&V#0[LU1[T4K.A$3OIW/#1'5.Y)^E#E]#\?0;012.Q_M?+3STVC).ZLNIV8F@H6^WM!5>N8N_N<6N?$SLZ)KZG( MX\C3',O[G9S@>R_&N;[STS 'MM9?RDG1"3P)^M*L)=NU*^:_.F$W%"[!SL*I^*$KXSAB?C>"X^S%O>+,,K0%\T.!S>U#GSDVE]@NH7'_4%L-YIR/3^8^TRUQE"\ MOCUU?8_YSZKOO,^8\>J.OAXBYTQHX= M/,?]86"(+?=E$#822:'Q._$#^X=&X:(IH&_N)_"P.P3W'P1C+![%&?? M!X2VZJ$];7X2U0[R(P#X3]J)QX>768N>]!G:\,;W_T3^7] 0QAC4EZ&'!Q8S M[#,4T5%H""1V#SKG;N G3BHV*4W8[Q]_?+T9\->75@^8+:=\S0/"1_83Y0%\ MGK+!/0*0"ZO\B<9V<;214(9-&9<'.W#\19B18QXX(Y)[*CSG+!AAY7WZ*5DR MX$/<&*@!GT#,XNEFMASC@&DR1W>+9Q( *8!MYGX8\=AQ"YO^Y :-1RE^%6<0D MXQ'N.QD[(^R(A!?9#V=<')\.0CLC^3$Y62>"/"!F'W".0=8']K!+N#LCM$0,42I2"B-I-0]!264 ## MLQ+.>I^,R.R.!-EM6:2"76'"@Z1>%'/6RQF7/,#Z,4LVJ(UC&<1,U#J@3N:SW66.YAJ;C7.?3<099.@YW3>X1_$W8 MR/OF>']2J<+$ PBD,9G0O^Z(!W\A62(G8!O,W 7)]#AU1E.@V -*(2:;JQDM M$2#QI(%\#1E@, 1A#=/B"S *+F'*MR!.)K27*2>:IG'.#283D/S. ^&&Y"Y8 MP)ZYX#;2/H^ MVR\]F*3<"["%7!*/"N?X:)V^FH@W(PV(^(8>LLMAG ]&?@T6WCZ-AS\5.1@_%UBT:<- M5-ECK9!E%VRV0&YH4\/9'+0FC]%V7IJOM=3$*7N)GI2:N(V%<\:.+JB"CP0% M24AG"SO_510V:3O^Q4ZTHN6U1\>_-:\DHL[%T30$\^R1Y?)R6T!D]SYG\*2+0(Z $+/0::MR^G"2_DT*-\HEH M/OOB:9Z( KLWGFVD[@:RL4TX:7X,8CL?[7RT\]'.1^N$V%@/_X'QJL6(C-H5 M[UU=5&\[#^XXI5H:@]X>-8%/ [_="P&_=[6Z325I9Z2=D79&VAEI(F3;[5#- M2("+H^DQP2<*G+L%GKK]) IJFJ#CTKP>EL!2CN6&]]=%'Q-ZC!?B4-GP-!EL M/'8BFD,&(_PDJ]G[N>0,UPZC)*K^?Q=V$)$@"=*/KV)V! (";\ X?UODH^%D M@0&R'$O^:>P\X,^_?EJ$_+UMSS_WG7#NA[;[>^ OYN'7)*FHGRN&<9&&O>-5 MUP\7 ;DA3U'7]4=_?H&1N;^.B?.Y[X\6& H_I !>TO22(5RC"501/']%)K^= M$=^]O1R((D__$0U1X/\3N%&ZO;[IWTJZW]-$A5=D6>!6C[[@J-4P9T"M0SUS?.2LJL -FOIW9 M^HY+U]C.X"X\A[WEA+XBB?KMWZ_[M\"=MR$.'Y[1G+R9[88T%*N,G&$8?4U5 M!5X4L6-5[6%;$[& A";]@'&HG 4)!B!P#]65N9]<'WKAO1_6SO<16*"_( MO"P6F;\ V/I5T+5#9]3T-:"\N 8H&MD,#6!"HV=,CPZCP/:B'_;L@!.DZ;HT MZ,,KEJ$:O"(-1-XP50!;M+JBJ0Q4S9!@@L2S+]=___'MZX__X/X86-]N_N"N M_^?Z9O#]FOOZH\?!+@%6 MAGOHN"3H 0/>^T']4 /+7 /? 0C<%4W,1&4FSG#-(U& LKA4L%\/2HDKEJAW MXW\#5>F>RH?K-,FS9H&XV8(1M;,OIJ+ I[,5LQ$VRP0(\1T27GB#)R3AP@FG M^.#%I$_N&HJ\#M)"DHTE[->B4L2*-) 4R"2+3-$35]%I"U2K* ;/5#@-#J>;Z,-^=Z"*)F_H_2ZO#-4A:"G*D)<4 MI6M8BJ3W=8T9K.C^B+T?1_8YY1UH;I*NZ(.](@KGQ7(.<0N F[3K29895$>& MOK;&-Y;K3I"62IAP/PG<1_C?A(R!$UQZ%YU=<(E6K^MRUQ8(RM*E14T:8V7EWK MR/WJT9)+P=CV1H1[=*(IG?RAX\$%!RAHL8),M-9*!*C8P3CDNC[\!]ZNO-GS MQ\[$&;%(Y%R5'>-7Z[J7_<2B.KHB8&4)&(E@?2Z<%7\18%D6$@2LW C@%;MQ MW6=T"8\)_#E#XCN3?.DKY':?OLU&PH_;6*B"(H;;24#^=^'@J'8 7<-0%*X65DTR]7V=^ M@/BXSI\$ 9[:'N?Y41YM9#]**D;NF"D0^L=?9'S.70"V)$,W027L<#9P)C NC@:#3.Q1Y.-E),\4S'<_<- 3'C,V/!F7 M:F%/, =\$DF.[R^B1;"BG@NK1S->9(7I[/G%9K0X[PC(V,,;(#H)G6#Z/ MB#BKH!07I?$]YM9/"QY-J:9/*Q&M8FDNZEU )E)4]BETX']+";R &HKCL7%SP;4QEW83! MS@K8_>$_@OD:,+BN![VXM!$5Q]9UE[OSJ;08^?=@_!(V)MZQ\[=8*G.DM,\CSQ^H"7H MF%4=,C9$$)TPQ)KO(/PGD_QNT%VX+HEH2<7"#G!M=8OS)\(&"0RZ;M;@'?H8 M_?Z8%N0+4B=DR(3H_<)A.YCOL8I;B-74?T0,XEIGA=F.Z9HG%+X%DII6]?( MG##$=>Q00C Y@\1*MH:&+!LK6J5V=-AV$$:T"%FRK]MW_@-AQ031<5#:?,?Q M;,9%;W*B0]NDVG3!_1)/(IO M!D<7LIWG=@1DAGS-$$EV890 ="!N,?<3H>!2=;%4HS #S_PU3)'+RV&6KIHH MWLGY-"5KY?&TSH#/?X_67Z/#4 #]T0@(R7+ :)FW7)W/$CS%0_%X4W/8NHHE MVHS8:(3&U=J83$ND*8KD#J4CHI*0G0+AP?J+M[" 3!:@\[ -"*?']_ZY\$:4 MM5+FA!D@=EI2;Q27NZ63=,X-$1/X @(:4F/BWO$\JG]-\(P_D2!T*+X.$0 M,)R8 OA+6A?P"1=:BA+[1&IAQ4\C[X/@9PN4?:KX EM\"$^!1^*5R.0AB&]& MH*04*=69G*Q29#R72>%,V$B(\X#T'93G="MN3DL;%[2-G]86KV(8N(I0LYJ31ZDU@2,P/94Y-@_LH?B(ZLP*6&;?RNN#=T05L2M M=[BLMLP7L$%3)7*U1.R4RC5/[3$:HX'_1,UX6-0_B7)'$01J"X7,N!]3GLR< M$SA#B0>!3UDGDYXX!XN02J1X(5,E(5])G4'A.C,GL@N^ALRHP2OT> 9H[0:SWP%:IPBZ1:#RI]89)U7J&*$H#PQI8,M^73)E7#/C+M$2=[_552S#@7Z8H8R",7HC/ M6H9ZVZ._+E5!<^-\=SP_@+T[.4NTO'%QE '8ZM'S=Q)-?;CS0&(/9R./7$7S M[ LO2^J69ZX'(\H.![%Q".(IG#%*YDY'L7D,]SJ,/2%2R=*^Q[$O40VC,MDQ M5#<^46KB@I0$&@.A52S()03*6+*E%S_32.Q$X^R++$@EY IP+R%E>_?H.V>Q M,4<]4N];HC88:AIO"$/88G2MRYN]+B"AP@M"7^I)EO#BD?K,#NX=CX_\^6>J MQ,6_6=H*NX2Z*Q^"S?=9S'Y/[)GC/G\NJ7G5Q^G&TFEZ0B7.RBJFO7"DG@-4 M6P$HDI5W:&>7S\K/.P&>@18F'LTTGX,6H@?AUV':T@2])VD1I#7UZ7-@H-Y; MHO@2'AOD]+#2]!M6DM>UG_.EXTO54],2]V_>$OPN(_2=P-/IP/M/J!-S&TV,4@UMJ+]*[>>W=!&7&H\E* M$$$122KY)JEPZ5Q065%=%#Q7/KQQA8N/3Y,E!_XR28Y=VGBIL-W!6%H45O+T MJO(<7%':/:=^E]P.LU,6Z5ZE MQE[KN4;#?#017 >_R@?FUYO 'A..)@65_9R/4RHGU%B%\AV9?Q4$P4V=^ M>E6CQ8Y@5!>.?H,KY4BHMEM/;EVD#22_.:-7*62V+YMH4G7)V3>W'HZ$Z*K5 MD..E^=.OS2R.M='JB:TY?(::HJY*VAOK&,D9F, M8058&R;_#@7;Z6U*[:R45^'J2KTY\%G@_7%"IPHMX>(*&C27XB?)9-4P9+58 M[F.;,KU5Y3ZJO@C#T&\:>ER!0]#2CVY51./#7S8JHU$5H_YB#&!U)"1&?#DWJRH?1Z\F"H;Q/9*1K'"NTT2Z&= M2!@>*<,A:>@"R2*-=HWKS"NO.PHG"A?FK 'CL.*,-%E]O!39R8U<^&+Z3AO:*6Q&I7<5[?G:GI";P!X1[JIOP7YCU^^QW[5364=6 MCN(F: R&>D3JT-S?\^>.Y'M 6ZUGNN^13=A>TK2SDGSYJ39ZMJKQUK<^+!?G=R>=$+ZVKZHZAU) MJ#74]"26P:$5MV]896CAQ3D\9,Q\9%ALDU:V&OEA='KI"1\EJ;K!]!L,/E+, MG1?)=J%'I[U]'&7=)%7A9EB=SHF;TA+U=&OU)YRHQD5P<6P8QR4/Q&51AH#IW'YFU53A MR:R^-FLJ%K>VQ!XF+G8CL!ULLK2BJXS6B<,16;^L"1:CAY''M*90Y)=H@IT& MON<;8\'G:;P6?OD?MH/U_PM$RS]<(ID=U^LG 2W]"]^Z>XY)DG040GHF'1KP M=WZT#GL6QIAA91F83;FC*MA?A<3$27IC%O[ >,W]5S]N<-]5,]U M]>YB-G(?R">S9J042QGE-Q)DY'"O-MNZ&>M@& !LKG' M!D3Q*##(@^,GW7B24-FX"5H2)UN./8D#9*_)/"I7>LYZAM#I1)HZ'BV-[SK% MKF_V+ G\S2KJI[BM[7OPE78?\TBQHP>R6 %W(%S&91ULK4&>G)!6N!X3V@2! M-F80.[ =T&X/,,(=1G*2<2=CC3M8W;2Z->LWE,'O$LKPC&OHH?T<+%B>8>[HD7D^RBK?/;1;E)N M'C_Q-6Z$!H-O:3NKD,08<(OM-$!I"!P?6Q. 4"[W>>O$_,_* MZV>LAI,+%,DB%'+UVAFA[YV)[;@+6I([[9Z!C1,"Y&Y[#-P4 DB3"8CCD'7%RVERE!TR&;XL&',"[.ZY ML*-^R!HYT BC^14QDTR,2JC],N!_&'(RIK#I(V>LUR-/>K?EZ/YI;Z@R*:A M\'UUH//*<-#%$LT"W[5T2Q3[ZG"@#YL1S:^4HOD'0 -_YHRXOCVSL5MAS[6= M668@;+0G'+%:,TJ:I0*;.;,"5VN 2OX(X6;:#8EQPK428^54JA.P.Y+Y(VT_ M]8QEWQ;"!VX)'G,)M4$^A*2/A+ MHAYC5ZY$<<01PA1#VC&4/9/VMD*[!_M79=V]74N(Z;5+Y@7:X MS>K?4[!P40=D&G>&'-@!]E4+N8^X%G^I2M:B]L>:=*W-9,&JA5X4"#]HDZF+ M20[F@PD"69 ' TG5^($E2+S2UQ7>D$R5UWL]0QJ8LC:PK+I[H(O&JB;H4DD8 MI IB1II-),'A6Z'GP5W@WZL@6]0-V1M<+[YOC_9GX4:Z?0^SMQMPF* ," M?W$_S2075=O\1^"]K$O3AZ2Q4]R8--\!"BYA$SBVO,*DTQ.*M=AN!/'[)^NR M%:_@A2*1W?0//D8D6'JK LR%'Y FHP+8#UJN*H HC3N4DG+MA[[\B8/)AQCP=ZWL()P?*WV<8Z8;T!$SA=?*XA MC<=P#TPAQWZ_$;FGBG&R>AUJ8TW\$5B::%N SNL'B9=I?U3T<:CW8X)6*74D$0-BZZ8 ML1.RMIMQ[[?,9@<-CQNC>*-68=[;1ZU9="GGK7DJ46F;Z04H0S;-K)Z!GL2Q M]D94P#.CT,>>\+2/&SH02-RY;4CN JI_XD!I&]NLS6^"Y@S HM[#!=5/4WYD M]G*N@R$^C*IC$7'6&J^$.)BR$XZ*)< @9L BM^=XBGH(4":/_A#,3,.^K2[J0^H^@&;C72(3O99:O5CP_/0 M'A6^6&"F>(3T0H<]Q?IXTH:M)"JMB;0W8L)EU \6MTW&'N"TN3*V>Z0>L0:N M_J2C+NOR)!'V(X2W)"$S'):=Z)V\5)IB(W&8?;=3'--5R>5 MX"6'BX(>'&MC#;ZR_^]]K W])!IRXN^-YX\Y3L,41"?,3NYBLRWIKKY+&9UM M6."IR +XNS3'3QO$3QR+Q82ULIKNVV#>QL3T?#1.8N?<*.^FRHYHPM1A15?>%% 2M$Y0HI;8[3 M1K08LN7:>%J(V!)5->2-B%&!5(D8"[3/+B97!(U-/&&,SSD.@7P\5![QKS^& M%9U&NUU#4H<&KTJJR"N2)O"6JBI\5].4@:3JDB+VF>-:RF&\$O*-IOLB.8)M M^'3C;,OR)G-=@=$2);(FPHTLF";)N-!ELXQN!G81HQ3EAN,E(EZF6%RR%<"7 MY^O18D%!\!#,M@=_CI@><0G[Y^B9_?L(!>(L5=:$OMSE#0E&4/J2QEMZSP+U M2>P/1)Z;58XK]JB+_/4?1-36 [,&CPA<=@J0GK2R\#CB4K(GI[K,9&=30 WQQ1S# M.=!)///!]$S= _%#5#M+9XJ[7X"66/)$)-#S2)2)$XY@5EDX[QVY=SR/?HTZI99C>;&GX#U5!O_$'M*)C%@N=CICKF'X*CVP8 M2M3=@W',7+YRJI/FJ,(-!WUUN/CHD0",,G?MV-:-P8[=$T5O [YGCVBD+KZ4 M<$R>%>8HZQQV%D#]?6,:11/'XL'4 .,%]HP\^L&?J0.$V;,4EOP'RC9(9JDE MWK9.:@H#7Q1/5*C+$?UNKO\8HKT>.@ C1H6B0RH.WX"WR!,9+6($G9@03AC[ MLP#^,(Y> &0=@J4A\= T&#%?;W[-E$@UAS^IAXBM;.JHF2]8@"U.VIA@E")& M-U!W!/+I/'#0735V,"+Q;I'P>SP2]8'3L4(6?XWZU 2(X[.@;)^(7XZ&G)?VNG85XT CLIFNE%&?HS&A*+8U%; M*0<9.L: R+@$E_"@,;,9*-0#2ID$6("_>^:3OV,O<)[]6:Q=QM EXN?)F0,& MUPH*C]BW1Y')HP[S:+O/&(.9K)C8S5OF_TP(Q6:@!QM*& MN1F*ZJHH\$-)# MU@QAZLWQ0^;$2X! MF0K%V"^'9+.SK2^CH$/E>DSNV+<< BGC- 8O[]4K>@E3)PYSI>6$ A5O!3% M0QJ\6!#0"<.])TS\?G?V.#DR @%"Q7\5 @G4G3B4\I]^$DKYB"?2\F"!:#1^-ML2Z/E$/#Q2,B# 5?&&D@HZJD;A\1D+@P[I MP2SCG#$] I@D9_$=JG4D6@JFK 2+>32*8R32,#+"YZX$U$)"!VZ&,T\3/F!U#W,\,)MR?,1V'3^[\+8&4: ML?Y LA43(U_D5Q1LRZN-ZBTPKS2B-X:TRBE:%+TTQ,23G[DCDP8#7E%Z [X[-(>\;$BZ M*:N]?D\2MXI]7I5@LG?LLU@.=Z0I&<#Y>0(V*_09ES1=D;BH%YX-DBUBL;A5 M4;GIU&,\8K:V:?[CVM8+Q<,FO(*QN=2<]$#[3"R:%SLJ4&.)"9L[ HH2C+@%Q4II(:"3YG[-8))&=A'&WRWKL@!DDLL4 MLT_9"ELJ0,TF],YVF;D_Q=26XHFEPT).T8B8P=9"(P3PL)O./ZK7#VB)X#Y/ M]ZR8@20A4#'>^7-T3*8L1\S8HDWB]-F!8)[ 2(C8'F)Z M]0H(*'W"E6'OF5^H$ ?3FG:S!VJ-O8X3C;X)VR'Q6R#!/D\R3_\I7H_+A\+ MKSO7*WN1XF?S$]\IG;&MO@<&<.%FQ1G;ZI=+YVNQ5'GA\/(7-">8ZX0=)*"B M,H2IW4(V_$PFTK[3*ME[)]I]C3:AUKLN.I\SZ66B8>K HU\ M-$R8&5MXQ2-H46 $!3H:V-:'"6#HV2KJAVG@4W)H6^6/22B=;!*PZ6%Z;I)R MDKVT;+$M;SE5&\[J> =*)Y0."4H.M?_I]U%CC@5%# *5G'9$PQYAJ3+SFV2; M'[K,@B+'4*?>?9&UTF':.B2*Z%[&F6$@#*_28."+28]& M U]'>ZGQ1SPOU<^^2*:N%)!^&95JU&]\:T2W<; P@4C1\R6H(I1R:2Y]K210 MK'[?DGLJ;X@J6CN"Q%N2VN/UX< <2%9W*&K#6UT0E%L16T^I@E1)AI?1*I$C M#J\=@B+5=VAT!8LVZ::1T(UDA:)%O $6J]&^MEV,KL'%P[JNB8W$6 8!)Y8F M?2T6JS&^2@I;A!ABP4H9D#'&'9Q*H R(/Y'58JJFQE88+A&*^>M HO3]Q5TT M6;A6XFQLXE:@ 6,H:ID4*W$H8ILG5#[GO9&S;L"F9ZA: =55")31I ;!&1X1827K8$YY(5A7Q$5U3#$GMR,Y'VQG+ ;TXNC M!./R%&N.&\OBQG%&2LG)C(=P-C=CV4EX[,:Y]B.']5B*:; L)C]. \I"7)D*&-$F M*T(IJJR;J6*(&P*9'$]NT_*T"D86:E_P-E2>OJ5>HZ+/*'8.43<((6O+.E$( M5OB8 +>?1"F9*MDH MFA#!*?V( D2>JP%&BRB4&VA80IBZ9D>UK9\_5P(DGH MB99E]$S>$C$:4Q2&O*$*,F^8P[XL*EI7[;\LDFHK(Z N2:6$5#2OXW5*"*P\ MN_+#3U;._Q2-4535BQ!X%7+@*6J]U7>LA2)%P5#ZRD]^,=XN9%OC=DS M,:U"9"F:6,?JQ-AAW"!WO6?NQ4(MZ2:SILON2]C2 \ 2/AOD(K%6N_$WMJ1> MN<4N*^8W#\G9IKU[3>GGI3:@62O?0NGF8C7<^'W-V+[;KOQZW7;;3]?:8SC' MSL;+W'QI_3[@NU<#ZS] %Q_[<-;M!S^!M7!CU>1NMC,.EG\<:EF3DPZXRX5 M1L_Z[&I5/:Q35>0&Q54&PW'PL2GVP_$:1K"6 M_==,YE*;Z<)D-JY==@T('[CS=?,1;F?XZ/)E$VUQI8!9[IY6#>ZJEC*'LP.^ M#8:@]HO866:]9<##,PDLN7H8PZQ81IS3N:S0'[T3V&L]U\+ M3C(D=7IJEP$[-YE2#'6C5TMMF8Z\91X20T$WWS2&>D?4JIL@OQ4,M8ZRHLWS MGAB^-SUG)VGFC.O7:+9ZHW+1F^)I+(G]495.18+OBZK6D:7J[KQO#E60Z<>9 MU59;R\DWA&63\G77<;8F)6 2/']R0O&]2$2CNMG]F\-3E:7W@:BL'F5&6^5O MO?)'$W0P-"4@I=G'_W$T-I?[ZL65FD].'.IF=7?E-[=\#/V="'Y0A?5WHA\" MJLI14&WUPYP(I"+NY 2;+%!J/A^W!EB1Y2/XJ[=1+#E2GFO M1K &(FXB!N/39"K%LJ/D)W:4O$M8X,D 5C]3-P+MQ@+6SD>S &OGHUF O;;* MW30_Q);!-ED@/JO95RP5.([30=,">B>GKJL=W7PG"KO:T=[+696H=V3SG3BB M$5>]/:TZMB"\?&."[Z,H[^R!_>6T5LA'T=C957%JJ,K:NYE56=K9*[,6U=97 M\5YT_W8^VOEHYZ.=CZ8 ]MH*^8G[*M8F!G%8;#+Q9IR;[HZH* M[^6X3>\(NUMAIX>K>I03X]9-D7=3) VDWX38TSNZ]DZ\LT9'--]+^)3.:;_S(=E]7 M+]\Q$UR4.XIX(FZ(W5'4S+==L4 1.IIZ(J;&KBC2\K6MUKW;9B'#9H$!#BYI MVC9V6,A.1Z]H9Z2=D79&VAG97OO^1.M-YR\LE33?IT)YJ=:Y[6)G-#I(4WN[ M26=?% 'T'R'?]Z4$^*H*[DG7&ZRB'V+!^M#RQFD/H*NT=_@1"KC+7<.2Y('. M&UW!Y!5#EGA#[P+7ST;CY:)6Z]4&+ M=N1@K&*5;R F*^O9"(K>J6AS:L?8/>OP)+0YM6,*;61;(WS"S87L=':J=D;V M/C_8VC^^RM'>=\*Y']KN[X&_F(>L[S.,@,U6P<9WO 497\Q)0+W*>-N?D>O( MC@A&O'=9I^=K;/,,G[?&8PX+Y;1\\ M;YG8U)N2$+TPA/O##^=.9+NU2X,=7=DG4F.@Q>[=82=UY-T#'UJE9K_F,]RU M[XY3879Z03/ZB>1J[ATQH^T<579BL4'OI9G81\DXSI2^A[/E-N:FG8]V/MKY M:.>C28"]MD*^7OUNL ET*EKLCNB=CO*ZZ_R=B,ZZLX4N&$?!\#VHJFW073LC M[8RT,]+.2!,A>VV5M6D^Y"T/Q@=VX#G>?W M,+\OF-OS\O:\O/$6W4=1.)5^@;MB*+]QGX-QE$(:[TW?>8]GYMJ)>*OV/S-_ M+_4TE'?2:N2C?*1MJU7:\M5UG GAPI%#L+849WMCCGCWCD=( *;>R4F[C_+. M&?PG)@4^RCL?(YT:IJ)P*MK=_JB*KUK_;CI=XM7R/"VV78/YX PS: MO3GJO6A%)V+"M_.Y(:)Z1]+;CA<['INT$4CM?+3ST)3R@LW#\Z,D[JRZG9B:"A;[>T%5ZYB[^YQ:Y\3.SHFOJ"$Y.<'W7HQS?>>CF1.3!>]D0J6.IK9.B";HSHT%K#6RF@58.Q_- JR=CV8! M]MK*^$D[(2:!/RN4CLX5CJY=*=^U(_R)."%V#G:53T4)WQG#DW$Y[-KNOB,9 MK^9I.'6UNTWF:F>DG9%V1MH9:2)DV^U06W6KJ:W)S*HN-]?D'L>Z(G,_@._= M?\U:I7>?XYM'Z%0S'$CF0!$4OF\J J\,!(NW3$GC+:NKR(IB*((IO=BI9F8' M]X['@QWRF7)"_)OQ#[N$T/*.-P8L/BL__\I- $^=/Y%/C,SA/Z>V#/'??Y< MLD(21OD'X0BPY@*HSL%44/)@3U-_POF+(#$FO'LN9-0*N3L[1"O#XP)6D1H& MP1CM[,EYX$^W1E(M\;D2"" ,D[3 D4=A! &" ^"R"=F8= MQ;US\&';'2U<1##&(7VM#'.,RIC, S)RZ CT@CU#]OD7O0 (N2X\[_@!A1AO MTHYZ4_L!L20>C#*:VMX]PNTC4X5.&,%GW6?$ ?Y-L8^?R&#E9B2:^F-N$=(F M/S!*GDKXJ7,N9EFXG?(Q((,47>X @9VSC9@R6+&=8H*MB'#8"%MWT"LP)00( MC6TG\(['$8\V) IA8'B3M1FJR*).^33'=-A)J,2V2UR[@81BG84V; 0D"L+/ M^=8_I>KW:8NAY(^UJZ*\A-9T0%G55TAL^PJUGUYEU\+?!<3^$\1VZ(S) M9^J"XC9F2B.W@#;1EHZL7ZWI&)&@S%9F(@#$K.B['.W*1_L3:37(LPG%W?0D5/2XQ\+_,.B.M>R0A7K44R%6E;)F";&4L<6Z>1ET_C. MJM2TD+YA2(^F IVB!,$&3K&Y'+(C.QB8!)[M@H$7 @@D.)G3.K6CJ=5'(:6C MC]?8;_? 2^_H6O4IUFGC]19Q$N6.(AZ%"5M5:*T@NZCV\M6OO>R;]R!6%_)H MR++8.^Q7UG9>'?L=R->%H*)75V!X,PCJNYP<]?&4 XL M#_B_"V>.<1&G)^G>N,:FO6D9\+8U-ODHZ*V2;CG9L"2EI@2A^NW,6'TDD3V2 MG;@JI_!XJ\'6>?3*I&U[]-I"^I8A;37(-WOTJ@I'L3E>^3C/Z(CFSN[\!N/5 M: 5Q]Z-7S:PN^=HZ\]JCUPU.MD2E.M_[S1S=R=+.OKT307#W7>@T$-17=%1N M#U_;P]=5^Z*^LU0[A24A&4?9\YN"7J.UZOT/7X_"FJV^]B8/7^6.N:)ET1M9 M#J+84<6W+H*0MOKC&SU\%?6._C:'KZNVA7?]JHWE#>-GO26D0.!+1\%P59?>Y/'KVWNZZDCV.:^MH>O M[>'KRW+ :+1_9E_T5.E-JS5O>N[$CBK4H[.UYZ^M#EO7^6N;_-I"^O8A;57( M-WS^JC;:<-S]_-7?8YOWH#DZ;K^ MZ,\O,"#WUW20TJM])QRY?@AR)7T!F\6CW+HBD]_.B._>7@Y$D:?_B&!_\/\I M"()T>WW3OY5TY193*@59%F^%,\X9_W;FC&]%059$53!NA[JL#0># 6\9FL0K M@M[E#5-7>T-+Z?6%OG&+;WY!C&.$R[(W)WI%(R=G\Z)WGU/-'WY$.%$Y M3WK! T+RK]S0\6P/K&*7RQ&7NWOF8@+2*:H^NZR"7%L!>'Y_4'[>"9&_P]L! M9UWWN!M_[HRX'_YYQG:2(702D+ETTCNSG:,7@>."'A[#M_$7&/4VBJ1WA%0++90%OC;F W"]<.W"?@;PP!AXGCZ8.F>2 ').1$^)0,_M/$@#X M07J)ATOXR'W@+^8=^"X,@??&>''J/W*1#XL:^!J^!9\*_44P C+B?NEX@&9( MPI#Z,$1+/ NG=(T5Q=]+ MBT0XWB+Y!TD9+C_3R-C $!7+@;NSZ81ZR\_^AA?M.0QLP[("O@4& MB>R82Z.P@P# 1U05R#C*N!(4/ZL.V.8!T!@C$.Z6MEF&-4QNLI>7/4'5WSOXMLWZ_)Z\#GY8SMKJ-04OF!W%96> M&!Q=_'GC"(GD'7GU*X>ZWGZZUD\?S40W5EKHA[(%MK,*TA!"J;Q4$I39RDP$ M %KZ\X@+?1>P_C>!_I/.!=4:L\VXJ$G>!=RGLH8Z!.G@.I%#PI+6V02#Z?"D M2?21=X%LSP] :*"OVM'41K=%W!$OO:-KC7;8MV&^^1 1:SA\*%5A=YJF*_8Z%2%O4-$ MY=T[UYY&#*RR>_3(:2"H'RF*^?]O[\MZ&U>2=-\;./^!\.T#5 -B%?>E-D"; M3U>/J^PIN]&W[XM!BVF;?2A20U)E>W[]C4B2$K79VD@FJ3R8Z;(D+AE+1D1F M1'S)X[+6EOBV_;CJ;36R@)?#K+4= (YR!(O[^7E MO2.L<1'VOZ1\@BRM:E7??^CW1E.YUD= MV6:ZSXVG7HNI5\.NYO1#'@JU,?7Z[@"(I6:D[E1E[[V]AA"XOQ=J!H&FR9.O M//FZFU\L!\*&E2E1THG'K)#'=%1]>/*5HROQY.OV\3U'5VHZA1Q=B:=?>?KU M[:"FW>?VE5-SQ0IY3&^N,1IN\^PK#V%K.^"&][WRD;9_I#Q^;&GR%0^X*6?) M47-&3U$[!MN1,$^_SO?RI(Y1#B8LCX5.(OTJRZW>&%(LIBW9X!Y9-8=5\WBM#>E7WOO:= )Y[RM/ MOO+DZ]MVP&)Z?^90\G2EU6%-JV4G=W2IFIB-YU]Y#%M5_I4WO_*1MG^D/(1L MS 9)?3G2L3!)3;;65:W5(*G>DF(A:MI-'IT8B+<8-XU M$B[O[[,CB+W9:.GMA0<5Z"[\?AE@KB;\1<9W$29YBIRA^9M.\+U-+CP M26 M,2CBB+B" PZ.OC7$M^;98'C,)!\5YHD%JK P8OC@)3&]'S[%./Y8238&\CSQ(AA:&-"] MC=$&:H0G+WD4U(ZIX$F2QM*84JJ(^U[XAH]Q1J,PSXO@;'6&'_@FRFCC!2_H0,DE(FC.?."\XEY&!>) R9=,$?/JS-W82 MXK\(1[Y4Q=WL>$ M28D@&&#$\"$B?KK!G81S6MYOI?2R4J;64VLF]D"I7,I5&.Y\BVI773\OHG;# MZ]XH7:"-XY1/Z4PH2!88-@H? B#.A>?\5:97_57OP/?QA(P2[Q?POB-XH%M( M@'!'"1@5"*"B"R=4@^ 17AQ/X0I@/QE/_/ EEY +:CU*PFBF9=D WL^(P2*, M8])B9K3851*#,_G>\2)TIU/4='@*7I!J>?9DX2&"H!<>_.0 H7%"5=P5IC%5 M7+BZYSN@+-1V+3=\$SG_!_)#HL4\&\VOIWP5.FU-;A M\X%ULC#(B!"H:@J7Z3NN(!X7W&F4#Z50&H-3;TNI%!F^.OO6! ?;^OJE$&$Z MF?@>B8?I]-\_$)@&7GJ7%X>:(INW_[P>G DN&8%H_/C+F:BN!@N690T,79=$ M^5S51:UGJV)/LTW1MI1SU>@9Y[8QO%5OS;.OLFK(\.H"N8OC3HERB??Q)G+0 ML%V_C.]"_WAQC6&:RG MW0MW1(U90AQC:W#4&4(:6QMJ!N6DL8UU]?__OQA M922+7/\7+4XC;O<7B6 U^V.*/NKR?N#Y4_B6^O7X@#JM'A4DF=R)$$ MHEIG7RW=T!8DLB--6S%DY2ZP_MZ(.7:8V[-C/44I,^+XY>.Y%T"8X3E^-W#_ M3AP_>1S!#=ZPJXH#!;BA6?"7W95-L3_0 MNY(%_V/+*E@#!0R7+BDSCAQ&XIQ5*3?[P,W+Z,$)LE3==^)ZR&%X3OJGYPY] M<"%1&'BC]):?!./8^!L$L@&ZEO@/QPLNPKAB]FVI4;)\]K6@3\>GNJ!\X$3@ M89DWN<&E> F+X[YL#7N*HHO2N=T5M:ZEB-V^V1.[DB'+=E<_-P=O+XZ_=W_^ M\>V'V+N\N;G\_E&@\?3YY8\;\?K;_QM^%.3Y%^?=[]\N_OU16-D*S1YQ@V,HAK%=&*#68J0V2?F4KQ:6#K_!Z.7P:*>3 M!F0.WG\?^G[X%'_WN7/P?#GV+_ M\N*B>W4--XV "F<2DS-A1'RL1<<8],N9E'Z>.*Z;?W[RW.3QRYFM_#[;B4*E M)=&9< _[J2E^]*8%24&?K;6V^ MZOXQ%'L_A]W_ @MQ_6T =]%\RX8,RK'V:E^_-Z,DFVGYY/\_$OU/D">)$(<^ MC'&%][->$&-Y@BWO.]R@29L/XSLU:?//0[1LBYN"=Y'P8?DIJZ9O:2.Q[#WO M6O@XWVD%;\ \#_D\>46^RJORG>$IMD>AWR38/#6"N81+MR_;A)4;#BN)B> X+"!EK'%Y?8XAP33Z6;R@#$B="/XRKKUS8MPUH?0O0\GU+ M*>*2I\81R5M?T=,6\K3U;=5M(6]#M>.^[1;6^L96Y^&Q?\DH)RY@A3Y;VWDMI!GUR*YSSB-;DQU[:R(DUUFDM-+"K(P0D;>\L[,._4B)=& 96 M0R]"67Q:H6,+M4JKH[":+._QC?5UJH8*5 MN=JY\GGRCVFQX%>5UK"D[.HZIL#/ZL8-NGITHK$S>A$R\)"B@]DKCCDHV577 M=4R/N=$X5^J1]16;IHGPPQD3.C"\(Q_;TZ.7$!$##O*QL.'R+@@#,8N$(/)( MH9CQOAFWFU2'('?DF@XD:@^I;'N$VJ=8/SMR0?A)D5Y@D?'H39I7MRAW)*L> M5+7VD,I=3V%>Y)WDPH4WJB65=JB:&$H]\,EM(72;8]&>/[&9GMEJ]F2+.0K5 MA2NYYS4KN>/O=-8TM.K5FA'"&1Y:LR*W)IA"I6/9]9SPV1Y2>114!,L?C:;C MJ4_A]+I-/@@$3\C97U^:U@@#Q$IZ*<3RJ.B4/#"7"7LR82LJ.MACE7&Z:)U9 MC7UK##MZ.2VI?5/N6(6KGJB9V>ZHL M#OJV)0_[AB0-SUE#[)S5B0E>+#A"/!V#OKSD560.HFQZR0MBN-//.5<1RQ.> MX&:(&MG&)]S#%\A!_&=514@DF=Z\,-*P<&K$*$; 4)_^\LB1.BI(8#* MDG0@!*C-(4 9>37'%]P;C&UN<^A7\SJRW +141VMEFRO.\KF06Y13X#4&SR] MYKATY^#:G9H 42HB3S779_*X=RUSYN/AENGD!Z_:X+G_KAP06U8F M1RE3@Q7B2I)=NSW\KE%TGHEZBKPD(0@Y?#_#0,# ^A>)O#K:60_5'6MOE*E& M3/QWBK'WW&\&@>K^!TDTVID-TH[;#I)H>X7!003:\*Y<#EP-+:[7N<&Q>"-E&4GDA9&V%D'AD/:^#;$XQ M1'-&RI,Z&^H@I_Y*$:19^9S:NPBRGJ-0RJ5*V?]@58:ITO7:CG5IDV?E19#M M]5'-&6F[O>E)%D&J!M-Y@4/)T\JIP6>%/*N<0^%.S;N>:!%D/>>25T1 6Y, K('D%)*^ W)TMO +R MD%&?VNJJ="C(Y9.\>=$&'^DI%VT<'0JR.560*M/YVSVITC8'TP>VZC1!]>PRAP*DE=![EU/(W,LR,9. M_;*$UVX?SVLA,^6Q6EX+*:M[]P2UD+P6 MV\%K(0T9]:JNKLM$@>2DD'^ENU_&LSO9HD$;E7@G)YL* 5T+R2DCVZJO8'1GKWI7+@K_PX^O[X1/Z_?,P&L 0D_NIG^^*W."=-^0Y MZ?GAZ,^O<+_P&>_YF285NX&;7_F3C(CW:^%R 3=0X<-/.,'+G"C[4RS$T[O8A9NEGP B&!>R &_>F-X@?\"]X,RQ5Y,M^6<<7JE"TR]C\(Q MO,B+7''B1,F+,'%>PBBF#)XXB4?@PO=(Q6]_>9N.XB^"<^?Y'CPP";&ZT"/!!?$4Q_&"4,.9QD$.K*1$S_" M$^YAYL'HNAD]R;:\AM<"Y6$$CT@BXB1CH!+?DA,LT&U+X@IW+\(#_AG@%3 T M8/=#Y(SQB2 )!U7O.W$]+(FEXTH_>"[]$,)XHG6\S6X6'FD]+3QC['@PTP.Z M> BC!P_?[\LL'CPZ6\=&!"Y)Q$.-=,$I.F51UQ=+3VB,%+0 MEE\.S#\OB*<1B:B"P=,>2 "\]_T7 02%3':"[3A=_ 6>0V*THU[\B'SU?!^3 MPB!3@@+,2C'P+1V4?T8,RDAPYM.\H-HPC 3$-/7A83!YQD28!IF:>?A[-GWN MI\F4R@;N=G)#31_K9J9Z]GS4P>(8:>V'.QWANY /(.3H!0<-;@TF#J@+E6-1 MBV>:"\^!F9? 4P*2T(&#*_Q?.G!Z=SI=(YP(E.+'PL1'@3BKDYD^91)&^-", M.+R*R@!'-0V<*7 1?H69[I(@3O^B>P,X$IPN'JJ8!WH,9"9D3%4=51?-3X0E MITQ$@YH]-W"R"*U_>7'1O;J&FW#F.9.8G DCXF,E^0A4\LN9 ME'Z>.*Z;?W[RW.3QRYFM_+Y<:"[-7"PG,QILSN-ZS?MUY=YO>HFV\Y MUO?\U96^FO?RO-+)8;S>R8'F:CZ&M+%@_IEV&-"+Y[T]JS9L*=8N.PE8+\>P M 8,MAG'UW[N1:79$4WNT]TV"ESN#6D\PEW#I]J55Z;X=6_/F[;#".02\/BQA MX>'7Y $75B?9+L#'?+)CYD61!;H7A]U>W#RPL,O2;^O3AQ M4IP?O&$6"3?)*)Z*1;3J.=RCSWXS MB]+'_QG(-RP9P=**QIE#TRZE.YP]0BWS1 P_A,(U]6S70:K&6YS+-H'4 MQ#7.L*EJ/;W]U1-JU(-T5CFA\NEL9\@=62UEN_84NIIXKRJ7!Y<'EP>7!TL# MJSOD9FT?8L=BFWDA/KD/\\:G&%O!UC9S-"Y39JK(-X57+#-\[6=U[!_8P%+(:2+5J.E2[>E+5_5%7&T=J23!Z?*_B M5&)_+@\N#RX/+@]6!E9W0-[PO8I7&X/@);3JI62,^39%<9LB.Q2S'6;/[)C&B>S.6AW9/I7R*;5C*">R M$PVTVEIM!;1\FZ() ^/+,+8&QN7!UL"X/-@:6-T!.6O;%#O6-=/#W.N-R_?L M!)?5CB8W9!MB?Q(-N]V(!9K4,?2&+#7V)1%/$>/',^SI+#@^)>7'B)$PN.@(#N89 = M1Y =>A \4!3V(":()^[EZ/LYR'N_ /(N7,^!W>$!EPNG)OR6GN 0D4>X$4] M&#I1 $^/A7<781S_;1=$]Q)E=#T=CYWH!0@%-H[I\!?. 2B> @ ,G$.QGQJ& MNFDE-0SA:+U5 M)J37G8_T+CNG?,&MYZ?$Q'_;*SBK89?!Z&AZ0ZHW#J"0 UV4/44N\'RG-TY) MJGQ.'%R>KQM[;Z,VK1-!U_EI]_LNCGG*C,N#/7GPH.[U*L/TP,:U>P,96],S M1"'0:THTIW>L_=L$&Q'-Z1U;XJ5H3&SBLCNRYG@J+I$#-_R;>SPH;ONGN\^X M2X^[T4*<;5]GF05GE'B_\!CD_,S6XO(*GK!Z#&U^H&BAB^@Z/_)YEIX(W$TY MA5?/(]UX&FFV17>RYY'*DG389KII[[Z9KM6WF=[F5_-]_+UWK>H)T JK0 ]+IU\P?KF61,IZZE[3D^1%8:OG1&^))\3.U*0 MCW3GZ]J=T]BQR+WG^#3:=A+A'TXPA:M?54 MM-4&S_UW-8&P5D1>/3@US99=NSW\KE%TGHEZBKPD(8$0 MWM]WLAX8&EC_(I'70!"G=U8YU7',S UE?XRJ9A"H:KR^<1MCP>OIRE9E)HAE M=F!<"BP,C"]WCI4Y>"TSUX3$@^"#DU':Q3+E4'=*N<>H3#ZS#9\*Y< M#EP.+,EA*]N7+-F^1X(F^X5KYA576DW7\ZK'(U4]SFNM"O6/LVMY M(60;2>6%D+450O[ [@1>!]F88HCFC)0G=3;404[]E2)(L_(YM7<19#V(L>52 MI2CU=/R62]4!04DKX#@M#%WH%IMQ(4PZ]O=:'J$PVN_ MV/"N7 Y<#BS)@=="\EI(7@NY.UMX+>0AHSZUU579:)"\%)*/=+?K>%9G>S1( MH_(YM>?ZV&@E;J)J,'UZYYY4V;9I>=<3K8-43::S9[P,LGK9M=O#\RI(>O\[N2-)>[O] MAI0)[A_7-(- N7- 20>OA.357T=49B:(979@7 HL#*SNR(>U-0^OA&1S8< K M(7DE)'OU5>R.C'7ORN7 Y<"2'!9MWX?$@?>6&V]08F1EL;QRBG_CM=DF"Z91 MKJ(P@+]'9$R"1+@/(^%GFJ"$?VD6$[=9Z:BG,^L[J6#LQDIDI/V>T_(M@'CH M!0,@K2,DCT0X]P((E#S'+U)VG3B!ZT1N+/1"^ ?N>Y?)"&[L?SKO7O?FGP>? M_B9X<8R;RVL?\<^)ZR1D^1G=ZW\N/@*')$IV1WAZ]$:/0CA-?"\@F ..X7D^ M$4;A>!*11Q+$WB]\W#ATB4_9GB>-\;U9CEB MPOQ=$*BF+CPE'$8)P)Y]N*D MBX&C1W!"T;^U,4K\^^$>$)&WKTWPCPT\NUQ5H )3_$"=QHG MT;1BP6@39A$X2\/WXS#=@(/_L+;P@E]57@O.).)_X*O<(3[J>_#4X 2 MH E> IR,2!*%^,X$B,5KH] !KDPG<+/CID\IO,V+X7YR?Y]=CTRY]^(12/6% M.%$LW)$'+PCHV^X3$@D# EI[1Z)"38V>AL4=>-"3ESP*<)__,GN7 )PJ&[\GAXQ,87&#AJ(O0I5UY )$ACC%REKP(F922% 3P&ZWZ$ M#,:=BA1^'$VC""8<_."-)SZ=?/AF#YXR@: _'5\V;'@$WD7 _$T=>AD* >YS M1@F\@=Z4:TQ1%2:PC!N!S) ;P/H1<:<1ZB(\"U,I40B*%SEC\A1&?])O\;%P MQ=1/QU)\ 3P"[J$+0X?R;S;C)F%,7]?);HU1+\)9@B9]G1,_PA/N_? I?B]T M83+ &$$/'3 Y)*4>[R+/9#3-"/0R1GBIRM'QQS@,N@W\RR-/>%T<3B/X/OMR M-F>66#6!/_$53CJSD1WA9.H[>4F&2Q)4C(#0JZF>3B(/Z!1V!.&*=Z%WMCSWHGY1786 M!H-S!8T'4I7K5Y%TD*/CO\"[9C,&:76!]B7]GQLA> ;^$(!#B3/#G;*8SJI% M'8#'1J1 ,(PB>0QC0G4C'^2&64YU,]7'5#YWJ5WW08W0S?@H(GPB3OCWE7E, M]/8;769>G(2*D_K,F5$$#N9L<^:N;\Y!C]KUC-WI7"0QL#*=/CB#YDR:>T/[ M4XS/2/+)C3-W;A2H>5LP \C ,,@, 148^IX87X$7WSG(69?<)6A J/E?1T ^ MZI3$L?.?,$)=@BN>8,ZE'F:NJ2/?B>/453DS,[/XTO25N9BIK[U'+D!CH1XOS!0+;B$^R@@,.*TF:-#HXX\2KES@C^CZ209@8+B(V=5=*DA2PU;G/%R+BGT*PNR2I^8 M1WK]1-Q@F$A(1)X;)B>8%)FXOV? M*:BRAS/C%YG/F(SX17U%P[8ZVVC< G)]=. !V4CGKG8VYCC7^6R8JT;F@^O] MPH^?/\3QR\_3D3[PUY3GI^./KS*]PJ?,;++\+@X08\XN4=K+=2 MKLRNHBH''WZ2^R]G)/1OKX:R+-+_9$N6Q/^&U95R>WTSN%5,[18MH*2J\JUT M)GCNES//O94E59-UR;H=ZK;2MW5)U/M23]3Z4E>T5,T65>/ M^14)RNA9MJ%C)X*H34S"R4>Z8L@^IRO$CU+A*Y_<)Q^UWS^!M@2)&(->?4PM M+/U\[X##?OFX9&!SZXD,$3%&H"HV<[MN+@9P%Q#:@"!7BSIG(RV\%@UU8>#2 M_.-\W%NL0NDR$J:CCZTV(WC[ES-@,WZ>.*Z;?W[RW.3QRYEI_'XFW(41>%#Z M]6)G3__RXJ)[=3W\F/_Q*EN6>;BNQ6>VS[>XA,]&8TF_;[V9E]^C;[[E6-_7 M]NI-FZ,3YX&(=V!]_A0]&OY\I(D-86OQ6"L-EL?.I.^64]_<%Y:3G.IH/A/D M]Y*4=YGEFSJ?4(0FQCKRAH>9 "DNS^GLHOU"W M]O>="43.ON!#J VQ[SSTI(N!$!=+E4^)?[$ M9L)XJ]F4N7"\AOKOYS7^^_@9LIJ&5KU6,T(XPT-K=KBVL\=2CQVOS< KFN23 M&A2O'4JJV5&D];U:/' [WC2XP#S(-'#&8930GF>Z1X:[P#3G/ KCI('M&LJ& MPQRVT)S#>AFJ)U6S]YXDN_4T--M]E#)OLF04IG6GD97P;9PJAB= M3=6Q1Y\L?+73XLB:RX0]F?"@;FW&%I>PH MGI+O45-CDM9^,V;HCC6VYGD?+I7E6;C2)+!8T?-:B?UX R6^R-O[/CQES-17:WRL75E:"JV(795 M0Q6UOC$0NX9NB);<,Q3-,/6^(J=5/K*)C$W)6SOPE*YI+#XXSN3C@$PB>#.E M'0N;TNV'M"AQ3PIO%4T%NM1G_-?6K/THUKJ#05?MZT"B/A0U35+$KJ+W1?-\ M: ^5;N]<-LYO@5;U5E;/OBJ4YBV(6J3^,B]L^Q:,PC&Y"..X,50K9U]%6975 M!K!LD@;:'VQ*VN::)\/^H8V MD#7%U.%J>#IH_)6L_[LX[Y>'^1H9W[*,[,!)B'PL>E"8BFG(*%S5-,T]Z5.H M@4I9UM\T-Z7D4CM=>,IAB2^;5HQ.3RVER19NI>[2M+;WYQGD^ M%G=1V21#DD#Y;%"V/7=KRF,2<+E?-;:5BW?[#\8*"T.C; M+N_77EJ!/AOP78D<5I'#UME7T7Y;G_=G3*,M2A42@.A,5"UN4BIB=[K%=-JN MTI1,U3!+Y+2&G#9Q3U>J0;-GT#^PCIF?)YB?%IAC&1W 55NU%8QN+]KJE9IJAK5D_4]*$EVD9O*/;DX: WT ;24.VFX1ZX1%U59CYQ*UHK9XVA MVZIF5\@:)8N$%<6T6.>-81E2E;RA9D^#!:]DRZSSQ@)"E IYHV4NP5 5UO4& MC+9DJ17R1D?>2!B!&^8^O)DOUBGB28\$\$>"&TQ#"IM#W)\DF4;!98#?=>.8 M)(=$%7\%#C_*M SO[J#!8#M16 MLV&1^SH\MB^)NC7HBIHL]\5N3^J)/1V^[_9-;="C3$B+7J3%#:9UY&Q8QL6O M+V-BW.&^O$^-$%[AA_$TFL/]',PD50(_:J_9\>WV-+MG= VQU]55<#A=2;0U M92">6XH],)2A?-Z7W@3V.38XVA(0"H6T^!$F1)#5]WD5%Q"I?A*0;PCLDW*. MEE[- 3#JACZ]#(1_.,'4B8HGR6;8DAVA[T1C;_3H$'\1B*WOQ(]/SHN0GRR. MP%N@/>\[@B,\/8:^_R*$3PA4%D_O8L_UX/%+"%,=++].$2*=U'E3V"P\VS)Q M/%^89$^> VD)8++3#R3#>T,@P&>*G07O^ZLF2^^%;L9*K#3-N?FOOW^[&8K7 M5]T^\*X +CZ)B)@XSU0,>#U^)SP@T%D.Z06"^^TO^*1) MX"A"Z#?,E_1>YI=DB<#NDQ/!^^C+_H +$QA1:F=A? =EA#5=436PGIIA*G+! M>L8XA+AH.+_].%]C."1%LG3;$E5#TD1M*%NBU>UKHM'3Y=Y T<[[ZCPD*^;R MCL^$NCYO#N">H1GJLV)+DJW( M\]C?LG3+*FZ5P0C>9.6@U[,4_=P2=46714TQ)+&KZYK8,PQMJ.BFHLF#U G) M6(>4JNF.I*[R"&[X%OR81@AV_/=P3"I@E(:?+5O6<>?+-A6K"L8IR#@:PDB+ MG-N% [D%^$D0=!7F=I2\W,!LCAV*1=E-,2,O M[PO?'<0X6[&048JU;[F3U1WT^UJW)P[[VA""0TD7+4,>B$9_V._:MFS:O>%L MC:7(B\'A#E2N*E>VP+B@>.0'\"!7%KBPL'FS4@*6[Q(<1V,TU!@-5IV+"E.D M:5$AN@C(B'4"YV$T"*=WR?W47\6^_%?D)>!K[P]BR.$U<)(U-(;GMB$:N@U* MH?:PJN5<%?M*OP?+)EVS!KU;A=: V, #7#$CZ[['X1#]K.K4Z8"R- M,B<9+40R89(M%7XU]F.V7T8,39%N/5RGH=V8 LOE_E0-KPT*XY[@#BJE=*]^VLGAF5K"E M&HO>\4#*RZJ(K90MYM8%L!7ZP&I(UY%TU3::ZP-3/E7L V74F>6IU!8?N(:C MY?M F89C;>-G=1I)K9BUE#)J$0?+UT"U# U$DPJ_(SBY\X#;UGY"HH >@/'= M"[SQ='SC/*<)32!L&KCIF04',,PP< M&->R%\L')-")%3JUIM)!U_=P<&(JH MPJI1A.^Z8J^O*&*_VS=563[O:48W74QIJA](UR5K]^_WQFNP):0)>8A: 5;92 4W&A871Z^34I%:Y/#@\EUKAH[ A7-#DK6N.A1M97@. MVJ /Q>Y ,T3;,@?6<#A4+-M*M4%=4H=7:5BDMU\\$3(M<*6EQSL5 Q^!6,NR M!H:N2R+(61>UGJV*/(?GQ"61 MX\//V=3(ZCLJI5CN6@.YW^^+NF6:HF9*BM@S94WLFN=#JZ?)BF:#+\ $F:@N M^LTWJ%@6< R<^",,W?@:<^@,"A7FL*XKZI)(%X:]CJ9\U<0B21#K&+:RAJ)\ MT&OU\AI/V(*5X058\V9H)\(G:.N4\W522NB3KTZVV/NM&<9^/?!,-&\<@U=; M-=;A3J*(>XJ5-F:4\2*FG6(*:51>K^AZ9SIT(CRO.(9K:-PY\/PIGDIW3 [= MPK!N5^MWUJROMN25B@&$]%Z6YYS:0,<6NH1VC1X8C5'67IQE<<[*$%&*YA;: M=#CYKRL4+&2\$>/JI+VI3I2*4M/>%;H^8R&3MD-ZNWA+C/>0^!(6I@B7,O7B M1[SP\GZ0'6_)'-GF"MFOTE!3]JM"AIQ]E:W%N.^HF:X%#M-445Z2RB0W].6= MSXTYZPO"\^"O06Q2 M9OI/D$=,K(<6UK:<#3R8J]1-O"L!=ING#NP@CL2+8689@TQ%:US,6 M[9G8WB^3:"'AK+Z[Y7Z.A?.C;(]"^%8PKB%BCTE:L17^T+[+M;/]C38$" MBZ(WT!4OYKM>(^%(1&^BM![/9U,?(_$#$<9V$6B+X&5+XYZ MD:1_$3SEB;C=7S"!'TC>XU:,D^/+:1(G3N >Q42MK@<.H%:U$/=$731/.Y*T M%3]6[CI2DN*XW#"WY\9Z@DJKQZ]N J![5BU+W1=K:_V&]G?B>G@;/"/]TW.' M/ADE41AXH_26GV041BYN78+EAZ HSM,D+'))GH-4'I_@LLL\*CPT1LDJF!<7 M =4JY@*&?W6>:5 K\4;%1R5M(K;JZO M=];7P@5J!98J_9BR K5PA2X*#>THB\*CFX9:. *FPI*7\D/,&(S2#WQ1LD8[ MV=RS.K0*@U$-%R@BMV8TQF!4PQ5J,/1&V(MJ&&)@Z?]2=+FQ-;RR8P166%3= M(3L*]KB)QAPANGU'![S*W6J/?:$.2S2V.)6DL4=B,,5MI6K=KN*4G:TY7/Z9 M(\M0-^T_8(PW6H*[3V MP@6JCC%U'*U#XU^KM9KM-['*FAF-UTK-;\V/^BJ7*D1J-*DZ*:OEJDU#:MR>H>4"-UJ4H6K3 MX+,WL*]T]&R#YOC0G%G2X>:L7OR :J&2TR+S,B$%CI8OK90KYB[YT6I\7S6$ M8Y.:M5PA]7(4Z$/Y;, MRN"/JR )X8_-FN&/JU!,99UBU@1]7(5<4^CCI0*G!D(?'\:KK4IY*6#"4AO M*0$?5^((E5)Y7"KL\:O\.3)@EIS#'DM6,V&/JYBO2RV>S4$\KEB3M#W5 Z MV'$EFJBN2<*4BW5W#+4P!"R%22%^6;07I0.WTBY7%2OO&+87U7 !E],R,ZCHC#!%7U4- M5LU%-0R1,;FC;['G4@.48X%%U8$<4_-AFK/E:EOA&S#R45]I;Y&X!6!W"U&.&1& _G:=?/M-216,;C^^\9N, MK@+?.#VL1*VX5ZOLA$.]^,;4#]ILH?BN,*8.?.,T]+7W/I6R(L[4@&],&Z%5 M=>\D5D6*Q489;/+&0#W[@F M?F"&?+EMG35\XYI8DP,T-0/?N"8F(;[Q\IE^^^ ;,QE[IYQ4)56Q[#TYJ0][ MW:$B#41M@'@90U,6>VB^I6Y?ZBE]P]8'PQGR^G+G8&6X""6B2Q>X61VZ=.K] M%HOK6067+C"H(G!IV-)$<.D5]I4.+BU;V1K9.B+27SU(#=6""=,$ M6*G@#4=+4U?*%7.7M'0UKJ\:PA%;FIZ(U%#75SFV-+J^K'=$;:/KJQQ;&BTX M752*;8"6+O*S.H6D)=LT%&LE \M70+44!42#FC?<_#V,)UX"(]T1>E56D"N: MK"SUA.3/*[+@VX_S51[8YX8^M'5;-&55$K6NK(M=LR>+PZ[2TXR!/#B7NVG? MC)JZ@+4C3@G*ADW?L1/$]\;^0EWPG*7G"],39VA\&7LUDTA$BN%.0L+^KL MCA+OEP=!8GR=/JW[[,5G7VUN(EM8?>FL1>0.)=PG(IXWA6(L?^Y,_+\HAZ\ M(5YN46I5.O8M3".5CMNYQ6V)TU.Q=HISPTYW4\5[]>A$8V?TPHC5X*[JK1P5 M5S3NGHZO9B>B5FT3X4*U"),BW%!1$O=>BK\L3M'O3N \D!,4YT(I%9/B3&NC MYO/2\7&_]_J1$&S$[;JNA])U?/3C?AA/(P*27FA B5_O0"E,[3[,;&_TZ! _ M[COQXY/SDD]V>,0I:D9>KGCRFG'AW9/KD4?@!3'V?P M26U97T&19]![:NM$:Y/)4DJXIM6G:>N[-EN@:>FBR>VG$)14[[X%&&9%;^UK<'TK3]\VM$\W7-_F M>VG^_97#[5D=^O4JY &3^K6PV.O[3AS#(TL-#Z6 MUO&%*VM*G &D<"5F4XG[CR3&%Y&\WI$K[1P@C"LMFTI+ V*LR^5*RVBFJ%HE M;9M\7X4H95+>?1!:Z'MNVK /)F!I<3%+Z.>K +[,8$:O6"X:8%FO3KI:8?$\ MAD;J3C^,)B%H#_D1!JCE(Y]"]-(I>-VK@$[ \PNT-D5)^]*XJZJ+D5KLJMB3-&X>VK !B-3 M^WPLBI!W);5*G.Q7%IU*"0^#VL%[3]J2?617N7CO"5>N\I2+]YYP3:M&TWCO M"=>W"O6-]YYP_2I'OWCO20,KH/G"=1LEYKTG3"MQE;TG35):WGO"L-)6V7O" MNM)R)6V??'GO"5]F5*=7+*>&6=:KD\Y)\]Z3ALN0K=X3!KBCF-HRGJ]AT+(+ MN)!1\WCC/%]1RA.6K@F;<2SOB;$J M3][OQ;U5;9K69&_%F*9Q#]6$;7W6=M?9DZ%ERWJV]ZB&M@BV3IV:HSXH-,E"THEU0=:N0PK4LW;(8W>V^BD+@ M3/)RY3L!E@(-_V?J3:B=>+EYF9"Y=?@QCJ+RU]@;K M]/WZY+59M4W%XMK" MJ@AG5;LX( C7KA*UBR."<%6K2-4X M) A7N"H5CF."< 4K2<$X*,B1U(XO7YG38HX*PK065XP*TARMY; @#&MMQ; @ M;&LMU](6"EC7#!UWZRPCW:U33$.FU4"FR6I(2.X26*LDOSA)$S(C_) M YW\^7S].8W $L!ZQ ]I5KH[31[#"(BY"-_,&&X]HHLP>$A(-,:1S9/>LTJS M,$H>8*%]:D7#"ZIUXJK4.MER/"&^15&A8K% M'.2$>ZO:-*W)WHHQ3>,>J@E;C4SM^#$I0PY6T2YY\H;5]LB2_6K34RGK9%$] M>%=B6_+*#&L7[TKDVE6B=O&N1*YJ%:D:[TKD"E>EPO&N1*Y@)2D8[TIL8&<, M7[[RL\J;K\55=B4V2FMY5R+#6EME5R+S6LNUM(4"YNU%?*U1H6*QG/-G6;%. MN]B MQQ '>'J^ZRJZY <:1Z/+^GD2E2W,[ ZZ4.$\-R9+M8DE: MNDD+GW5)DFER59%M1DO+6=X=W9J(0MWKXB$QW3@F2:Z5W8>(5%#T:HFR_99. MSBZK6">Y#E:\0U^W,H &2(HB&:HTZTF@O2ZF):6?==W _0K;9#7BG*G%]8@$ M#C!D*=.>?7L>1F3DQ$=K?+EQGOL1 OA!C>_*U[#[8FP? NK@8(2=(,K O48?8-5[KT7 M> FY\'X1]UL +'KP[GQ"EQT@N^_.?\*(9FL7)0<2=@DV>5697&FSZ55M0\<: M/UQQ-T1YSG=1G&*_SX4'(6]<9=O/"6B.INJR8;50';_5QS#M(RGJ3GE0O _IRXOK1#(%QU N>2#I46UA.6["L+6U<]W!\ M"A8EPU)U0NDT9T@2S?!FC#J5&:)%94)BV8DP9,NK$@Q+%J-\FGD]TS%*&K2:8DPU9L6#+-!E]-'J$)H^0 ?D5( M+#L1AFQY58)AR6*43C/'9"QARP.A%LL4&(=:/(:02MW)UF7&+(DE2CI%=RU/ M,66NF(P C%O_WD]N(7+;V,]Q&>]_E#_N7L]@_K[Z>/'9 @''O!I@>G ]OTS-6; M/W\HC#V]:(GT)5)?>]':^T$-R,K=^.46]Q;8OO*(C2Q<^Z0L?EHE \M/T]^V M>$J/N&N? -]O-8;HES=:QTLZB/3'+9Z3.^&US\E_W/"<=%Y]_'-D[5W= M<]LV$G_O3/\'GEXNF:DL*T[2QF.W(\MVZQG'TMCJ7>]>.A )2;A0@ J MG5_ M_2U 4J3X 8&4[#!S?+$I8G>QB]_B:P$09[\\+WWG$7-!&#WO](^..PZF+O,( MG9]W?G_H#AZ&-S>=7W[^_KNSOW6[SN7U@_.'BWW,D<3.!#TSRI9KY\%=X"5R MNLY"RM5IK_?T]'3DS83+CERV[,T(1=0ER.\*S!^)BT7/Z79CD?\(,S]U/AZ] M.SGZF$JY9P'U3IUWJ5=#CI$$:L>#_"'IN/]3]_A#MW\\Z7\Z[7\X[?_X[S0U M6ZTYF2^D\\9]JXA_="X9I=CW\=JYCK7ZP;F]'1XY ]]W[A6Q<.ZQ4A1[1Y$L M$9H'147%>2=EX]/)$>/SWKOCXW[OC\^W83%TOO_."6E/GZ?<)UL>3DU1!Z([1VBUH9\A,=7444)/ M%5/WN-\]Z6]SR?4*BT(VG5+,)\1Z2S,14*7/ B-?+K1S* B/3[:8*& 4+(L+ MP9.\I_+K 5$7J# G;IIU-U^.1]%XV"4TJ^WB87V#V:L\=> ME%A<%F[ .=2M,M8HM9C7PZ28#1(4Q_L0ZYXB4LD)+ED8C/L;Q#2RQ6R,55_! :N"6F M\IKQY26>H<"'0ODK0#Z9$>QU'"0E)]- XBV"@"8D/RLI9XA2)G5[I7^K-ZL5 MH3,6_8072HM3SGP\ >=TU,/O]S<[5)51L]M3Y+U+Y@9*642]*RJ)7-] !GRI ML^TXQ#OO&"DVJL3*>!C::Z*5[A_WH4V/V=./(,H)93DI86>]K(2L\$!@;T1_ MUL\N\MW UXRW\#MBCBA,C"L.[3.5-3@3S$Z@%TUHXUFFUZGS$3 M6J&ACX2(_$N!=@\,?UHRF#$\ > V@AS5*U(/4S!:/0GF$]67>LX%\E57Y#PL M,):BA?(04(X1M.ER@26!$JJ,J^;> >[[.N Z;[84>]N";0WV#0R.EWC@2\PI M&/*(BU'-DYEA_& 'XX9$.&SFC%9J& X"A&Z/AVP));P -LC/N4*L+YE M0KQUWOQ.4> 1D-+";0_W$(G%M<^>Q WU",>N+(8[3V:&^V,=N%4FCLZE!=,> MS#LFL9BP33.;E.F(SQ$E_]4F)<4./P;4&Z?,3;71"?,E$:[/1,#Q!#_+"Y^Y M7U*N\8J9FAWM1S5HVW#!CPLDB/:F=&:M#]7UH3LDH5Q'LZ0IMO*" C8SCC_E M< P$H5B(5"?0HE@712C9%1/(_Y6S8 5MN.L'*@"F"IS!)(<&H.*FF.O6_+TS M,7O(IZR'I 6W7G( +U'CJ*$NT;D*U"2%;5?G#>Q&9/O'662O7*4O<9U+M$1S M+!R8,I!E"VQ=8.^QD)RX,)H:"('K]^TVOV(\8NC\86@]<'9J' M-RXFCVCJ5Z[:-I+,8)_D*[<6"O]=-@_)]$0^SL))\FB[[=I.<*,"WW,"A;A? MZVXCQ^P [[,.D(AT0IDMRO4'9W0^P6HU9BJKX5K,:4;R0Q9)):2KI#A*3 MC M_2I;:Y="VO_4A';+EDDC]"-UG,@,BN'937%&D M&?9<$0%*IU219_: 7' M$NUHV4Y: M> O_J\38'I"/1[/]QFL'S=#L0+G8FQ*G@NSMJ&[/63N>J__W>,6XC,"K-5^W MD&.$^%TN"+?));T!QIFNG2BO%O07G;6/F4]4?WRXV?M&HMD1"D)T]K-XYTV< M2[MN^]56:R8:BE=9LXFR,GM4+@A8LG+CO G%M:[SLDU+!?^H(L_L!'L%!UO/ M>(TH806_L)=F]HK=$<,6^I<)'58 V\1OAG='&+'%]I6#3Q5 KR78[ VY^*,Q M$-4ZQVO,+BMXA+TTLQODXI&[9IJM)]B>E-F4:KQ[+AE<#SQ/*X;\_/&9RFQF M@&WV\L';1/06[F\NL42DW;-O#W9)Q,]=8"]04;_B]"SV-:687<%VTYX**48Y MJ;!BZ02Q]8V#^(958U"%U>@%)[G88KD7M(W"BP*OCM PJO?IS\;J( VC5\\K M=3+##GT#O]D%T*\FS;:3*OWTEHU /:,9NQS M\;_B_;UM[3\?$0+)>(KT>SB"$WR*\OR.P1N4!?I>@^.%"8 MG^KPXQQ;-WDI-XD*.U4EKQG/D]7T'5OI9H?*Q0HK.%3*G]+-#CP54K=^]K)^ M-IH-?)\]J<\S@"=L!X(Y MO62\::K3+[,0[V8PPOL^%V+,K#1O-=?95>@6WCW@G7#DXOO+P2U#JJO6/__) M^!="YT.T(A+Y.L6FGA]*K-E53LJ"ST""%]%^3N1 CKY;=ML M'+)WB XW8=N.80>]V1-R@-%85/P58]RO')4"UOX.X'.!QQJ1*>?-1D>G__\ O?JC;@&YQS-'7_!QJNZV M..\(LERIE*NXC=?#=);<;;"7,) NA>+C07DN+?O(M&.E"F_2*M8PH+C M&:@EUMWX?H4_@>'H>>G'%))(E,H.3#)0[[?Z377\&T4=]L-] 5V7VZD M?"-F^VB*?3N+@;3 XELEX!LQ-EO'=]L,' 4VIS^V7&3Z62]],0C\VKXXY PL M9UPZM/ NDY(KA9SPUJ);YFI!!A;UJQOS==6K;O]=]Z1_]"R\2,4J&B0%74V# MF*^J!L:KB,ITT/D7WGW4P[X4&UG=1%;UXBB\K,BJ5-*<=R&C*I9/JECZ'_?1 MI)X6]50HO$K)UBMB!I7IA\J.D+W*:@\_4&^JNL&N6Z&,ZA3QQ3_V4Z3@CBD[ M3=*,FU][Z9*YN,I*C9A'/703YNJ99Z_ LLI]PZ2?]C(^?YF6E08IMNBYFXBH MKD7N;BXK)1*N\'&O@LA<]66E0,RC'KH)&V>4>,^FGDORC^\.T N>= M@>OR 'MC3&$RMMXZ4 )CAS]+DL-!C[Y!\'3)*,QT^/I&XJ6:#G0<-!5Z:>2\ M,T.^'M1H0ACL$.9--*L7\&CB'J9-PSN SCLNQQZ!AI@2WU>;M]FDX#.[VMX*/&$AA!<"GLKX?D1/JEK*\M(>T0ZN G1>50VC:5RF&SW@YQ7R7 MJ3'5%K0>6R)"OYH]\0E<@"%]00N,U+'2220V[:9L$$PERDZ2[KR 5\A=WU WZX96Q$WRQN$">G9H M"_!O3.B=-#F+R@@:9<5FS3:[)%Q0K:R(&U2SRO7-5*Z=A,VL7QNM4S>6)'U4 M?H4WU\W5E] PE!G5I[?B;FR"J8?Y:#;#/%;01MZ#KR76["2,K *35 U1ZU=5!IIA!.TPX^K"X^7A M]CMUC] U9\M"D@L\8ZE]?_EZ>7#!#:JN6U]K-'^L,3K*TG MZ)N8NQW^B\RYLMM;:M/F?Y=$15U(>'M?/'#&(F[OQQQF;P/O/X&0X;>@M@\+ MAN535\+>3K5IH#(^Y>'IH5PJNA]\4'#3>$%;9$7=H 8FOE-7M91CS'57'PYO M GB=^@A,SM3JG TWN^3K-U:&[^)MD.F;72C@H[_IO10N&/" ^2-4T_CSKXFU MEN3?1/>0Z'^-7.(3M8@:[;C)#A,M2)LT8 S5'8*ZZ7C'9R@Y90) %SX2[\K' MKN2,$C=D40=?N:0P;-%HP;+C$,[(A,VVBF M^P8&++$)(SH*I,I,CU5AGICUVIV$3?+:6_ Z/ED@FK4BE] HK9"F919JJFS8H^(XKFZL-8NH<;R07F-U3- MY+C(8F9!VB2TXMXZ9T;F??-TYCA:22Q6/9?<1 O*5&^BSBH"%,YEZ%Q?]8TX M7\-T]@EQ[^IY1<*L_@5=96)/%9YT9SI7K[Y>=0>UXXLOS)C5U$'G;ME,;9L"FPF0; M]H*D)K7M22.-D<"Y,4U)-:IG*UBU+"9IDQ1BM M=1!@P@;N7P'A>!P>5EB/89JK@^+P=I4LH6]'BA-C]Y7S3827MK^F7;:UT$S5 MM&G3.%QDAOF0^DY?>("-/.+/A))EL)R@YZ$NOWL\"ZBWO8I4@W6_Q>W#&A[M MORJ9UYB"_BCM&AWA^?&A3;4;]8N.R U=#J MPKO$<$ORIE7,Y',XJ2\H%01Y=]$U:.)3J&IFKYJ)YI5-L=NFEE9X^Q.(5\_1 MOH-?&?.>(,^R'F,/$8WSVA562X]RO:-YW477I';V04*1WN-5M#O"NPR4ZXW# M[)+-=4*O*Z=K9D6^+??6[[XBCL%J%;Y OMJP?.VSI]3."/5JC(AWK7:O)=]W MHUZ\1)$/RAQ.8H-:M/ +B'BN>]5XG'\/.?B7T.OX3(]X!X%<, Z]K?H68;8B MU)?0I"HR>6*3!0L$HFI-&?K;2Y@"N))Q70=&*R5*S01RUE?D^XHVG_7"DUGP M^#]02P,$% @ N4RK3+50 O^>$0 J?H !0 !SR9><\XT0:RVE[]]*! M24C"A")T!&E;]]??@A\B*1$D^"4 ?DDL"1_[6RR W<4N\,L_7S;.X E[C%#W MX]GX_.)L@%V+VL1=?3S[NAA.%E>WMV?__/7[[W[YRW XF-XL!G]8V,$>\O'@ M ;U0EVYV@ROD6(&#?&AD<$?<;X^(X<%PL/;][8?1Z/GY^=Q>,HN>6W0S6A(7 MN19!SI!A[XE8F(T&PV'2P6\1*1\&/YV_>7O^4^:7>QJX]H?!F\Q75QZ.^K2! M&OCI8OSS\.+'X?CB8?S^P_C'#^-W_\F6IMN=1U9K?_!7ZV^\\+O!E+HN=AR\ M&]PD5/U]<'=W=3Z8.,[@GA=F@WO,"<7V>=R6DP $UKGLXUD&Y6-%5"P(&P!/\T3(H-^5?#\9OAV_'Y"[//?N4=_N)1 M!]_CY2"DX8._V^*/9XQLM@X^B[];>W@)W['=D(_0Q=NH^@]3:@4;[ )2^]KU MB;^[=9?4VX1$GPUXLU_O;W/4L\#E#:XQ,\!ZN',0861)L-Z->LNT3XI@C#S<.CST79. )MX9RW&+7-%\AMKYQZ#.[=6WB88/*%'![-%L-D@;S=; MQA5:+Z;-.SXY^)B$S #<4.^XV(DX(DN-*C;-EF"EEX5.KI/N0-U1=_6 OTUZ@.S![)V*F^+U M_$)]S![HON^]SY+-O!5RR?_"OF!=8-0A-HI5\;F'&7?Q\X\9WW):.47U@%_\ M2X=:WYJQYX3T]G1G%\/H;-$-Z[%5/7,NSO*6*J?[%(Z.N='24\]8TS=G=&&?H(I(]-E MSZ@7/G22\X?RLB? +M]Q[^,>^KL*G5P]CKQ,ISH@[V?9J].U#ER8@X;3W ;N MJO.>.7'H,CS!*B#3I7K4_LW>M>-&/R#>BH??=O-C7>!)M7KYKG6S=K!=3-S]!%6U] M6T>1Y^\>;ZGGQT3V;1=)=*D>=3\+BGS',0>L-.S^#KK,<0)J8-?FL);KW^%!\=3+"TC'/2(G8]G%85' M:NCV8-&Y(^B1.,!'S"I)%Y171'VP"<*=9XJW'@9YX*( ?SLX"=[9\.D4>>OG M'H7%U=_-'>3Z\!MWO6PWI6"[:5XQ;V;^&GL\[-3#:QYP^A2?QW-_XQ<,DPE4 MVFH62+6B!.G^.&Z.B'WKQG$37$.C;NAJ$X&KKJ@$3QS354QS-B!+!5T5ZT.N MC HJPWA=-PS;Y1/P"90HKJ/[5\CS=K"O_H:< NHEZNK!%59:$HQELJPD=,C MB&=5Z1 <%E-!ZS7HD72'D^ -Z=VQNIX*-)G@J]3!^H6Z5BF6JEIJD.2]AK#M M7+_$-M0G2NUGXCA".!)5U6!Z G92;P<4"6G/%%%!8T:082TY/KT2T%U933&6 M\LFLR>S-D%$Y9XO+*J$ZXQ&N8'-!2=445S.ZN+ *ND.U/%K3/A-F80>L#TR# M:F&1J*@83QT(.E MO;2(2NM N1S3]5EIYM 6AN[M2M6RJ*0BBK=@;\9)G[ S M9L2X7&YD:M9#=.0>A2^@&[K$C(66<3+0NWO"OO&Q+J90NIH:A@L<,Y\\RD3V M4T4EK7"(5SB6QB'@X*BNJP'-L5^S/U>;<.4O=B0^C\!CX86 1Y?L53[2A#I"R KL0 M>S!, LP=-;[G2^9X9.+E680\*R$"_CPZ&\E?S1.7&#&>.\=;&Q(?;Y+Z2X]N MCER&26=4Y*T;4 ]@AO= _71Q<39XQOP*I/ S?-IZA'J _^/9F[-!P( XNHV< MI[JB*U\N4[#O7P-8&3-@#WG\UC3(!QM%%KFDPS<=[_$K E^],:6XW[PJW(5J M1 KV-4EXWD688OS'*\(H912ET'\T![JL\S3+C2)/0KIZ&[1AM01?N'N],6AN M-\%?>M:7&VKA64**^6 MXC?(<)4>];+CIQ2Y0::K_'ELWL23B6Q)%P"#ID)3AE0$+:6\,&A:-..%X$@\ MY8!!TT/F#$O*B1N?W:4N 8/T@+I,Z"[./6573H48ZLVO;H]X#MQ.Q]$#Z;YC MD#W1'X^.(W=3!AEDEJ=P.+;V&1:>#Q)7>-&)X%_AS#NE*2OA1OJD!*^.3#)6+$$H N+JL#U5/B!#X6K0*BTAV$O^ZW'I#_?X6K MOP4=)/,XOK6J(/Y5KIX*UGX"78N+<'R*\$#O8$N-KI=>8-]W<$D2M%Q=5:C" M.Q,QF[G7+_R4-"!L'6W)T:W[0D3E]92CX5=_L.3N#QD8^0H=3()(@*] @+/W MW7[&-N%"#1(>_4GL:P=;H+ZZQ(JJ\+/K//?I$N,=_2;U+9'-I$XUOVU;5I9HFNV44NA# _$HOM;G$ M0&/V/8#/Q T-D<3T@5'/MQ)949^QOZ8VCX1B46B$@&NGI$!/#G<8_=Q39WKR M#32)4/D)U8G&#,FWHBW26%UJC377CGJTQ1=I)KT6E5YN M$$>.7F(7+X4I+*+2BBXS")?#_6.3 HKSI92D1J-'ZL&N&)L Y00+"JN@&^0T M%6**VI.1M,2-#CAJSI*:A:F3LC )7:&XQ+[(JC$P 5\S( MLG,9(Q.M-."GQ%FDD3E=&K"VXD#4R&0QQ6P];"VZ$>QW0CYS8@ES"UX'V,&3= MS$Q 2;#E)UJ"J_]>"?3RPUE!"KG9V/L*6#4SQUQ.3DI30P2IY9I+B>#\-)$0 MR;A^(R^*+('>692RX"9)6:%0G*/'+\:\<>@S3'2;@.3[2G+T"B_IC.PGF*X> M7[*G./I?<*A>JPE%45>>N)A:LLN%=+^*0+-D&-,(7 M.:5:X"MJ0"-\^VVE*;ZB!I1$"J%=Z#H$@^<>;P//"KT8R^KG B4J=O'X0MS+ M YU8,+\]++S-H\BY=4!Z!PTJ"N:R,+9C_U,X+?P ]JWE9<"(B_D!ASBFJ[*F M:D0@//&0S);Y^YOEU\CF[:E&'[UJG;G2:"P!L:"2FJ<34DYGKZL3(! 65QL5 MUD '.8B,D]X?C-2E>V)0H8)@Y(W6/3&H9@"%?-K%#FY^)GCE85N8(=RP M,367>QV2R@>![_SW&%8F=^:&Y)?=(5.K"3TP)B%9G/G2J'*5], !FU%D,1$K M_K86(D%UI?MK79#YX\CR@3;2D] M0\IFMYDZ:K?\D5OUVVFN:G?C:XM_3:PI MVJ 59E<.(AMM58>#IPEU)3/,,Z+ C'+YY M=/A9Q1I_0X"S^(X\<<=@GIS,_?L2]V@W:$C%*EE"9OS 3EUT434U%ZK9W"80 M$5;PGE8AMMK-*+H\[ICK\@BE*NN J_@=-"E4A5459WW6&;1\5F-=T39RVV_. MH.IU3+#UF\60LNE0]IR@B)%&'N,U94J3O;UEPJ->"I:VCHUL-,=>?"B) MU0]?\0K3J&:/3GQ'B?"Q%T%I)?>U4N0FCX(+R,T544-C9?BD/B&31<3FGR[. M,MS(K;<*HG VM-M7-5]WDB>]\%C%"M1XCBBBL=S)5E12-<7'[^Z6$)TIK(+N MKRZ*5!,<)N3=,A9PYT[Y%:P5E;1>2@@G5+JS, *2%[UHW MBHG79T=Y\)"%[Z<3KAU,7#O\^#OUOH&9DNRF_!==E?+,[5S:TLACXDET$QA/ M2 @CU5;8M0C.! /RKX'W?H"(U0Y:KJA6F!+>K:C3!EJNJ%Z6%-O&:0TIK: M(+H)>*3Y9^*23;!)TAFF_"AP@P@LI1Y_+YG!FEL7<+V&%5]F7[) YB\Z:L]! M(TWX=APZ6@F,=)AWP(/,RF&D>[P#%F0W.2--C]8\.%1@3+9)2C1=;17[^ [& M.?+\'1A.+H,Q(CHGRD1)[I MW=\^Q;(W;L$$9-0A-HHCN.8>9E F#ELOJ)QRX@%(O'1X KB&&+^@*!U2AWP[ M,97 S"UER/GDT6";W@5=G.=F".?;8GH( RUU1,8O+TPWK%U*NY;4IAD/T3Y@ MB/B$5TKD,B!X64.(CX-B"R-AS2=2!$ M!.QUD%TU)7X9\;X?$R)89'P 11," !0 M !S>_F;M+[AP=#B$$,>T_@#45HL>K=P&D0!3$=HS<,HM^? 8&]\]X\CI7U_?^5/BH7<>6ES0AB#R A">$XA? @^2B][Y^7K\WS)(/O9^?/?^P[L? M2[^,41+Y'WOO2Y\&&()T3I\"0W^ZO/K+^>4/YU>73U<_?[SZX>/53_]7;HV6 M*QS,YG'OO[W_88U_ZMV@*()A"%>]NS54_]L;#@?O>OTP[(U98](;0P8H]-_E M8X5K!"GE(O+IK(3EVS,.WR$\NWA_>?GA8MWP[(]_Z&6-/[Z18*O#ZX=U\ZN+ M?WP=3KPY7(#S("(QA6:K(QN,U_7JYY]_ODA_+;>FR.F?K>?DAZ_ZG&^0E"QA1NOBW41S$J_MHBO B M!?JLQX;]=7R_!3U)(C;@'((PGJ=;+\ZWZP5K?B$=\:(AN&/:\=LDION233&: M;O;7(R+I.1F$@)!@&D"_'O2:8Q\0CT> 8B7WD1]@Z,6-8=X?L2G,-P'Q0D02#*\3$D20 MD-&2W1YT:4G?]],U!F'STUQY&G.(L7\ARD*B!/K%K(R9^TD(1U/^[TWQK#EK MVVBWLJ95IFH;P0%:+%%$3PL931]AQ,25V[ XAF22+!<"KT33OT)B9 MUI_XX,CG()06X [A_68'HH@N-+;(-)I250Z],G6* G:#DN=XFH3KYH=5FJ%EG"@9EXB \#-&R9+*]%Z8,#<@WRIU@#W1&!['Z?646A19U 7,VV%[5:9V@0J/5,*IKP.;FKQE2NS:U0[ !72FM(]U M.V= ?^+6;_>2+:ZME>9/8@.S=E93-E7K.SBW+![DP$KF:AE/B;WL )A7G-TI M6K2SY6O!T/IMSK#;K_[86!%"Q!$M4'->K<):3K#^0(NGB&N".96 MUQ9AG-,AL)<\P_,-9:I!RAL@A]??I( ,*61;,-.C!B.?1;IG7]E0YD+UL^DO MMN=O'R;- 'RGH=N.J+BTGC90T>1@_>40&0]1 B>89B.H>YRT1I83UG M!-X%A$F>JIOK4T(6HNIA8SMDQW!SHU^#D 5@3^80QLQ+LKDY2Y[AZU6E5>^_ M!;LWX8$G/\A6&W*WVK#J5JLY^]<);W;ZUN(C0\>G^J >Y[@@VSO$: MQLR8DZ959+Q%=/8D'0P2/6=T3+[EB;V-@XK60JKH*^.UL M;)Q'C#P(_5R$>X$D#K+0NK5>L+=P57I:PHB>RGCU2&\3=H^P<)=E>K^LGNC< MDOM(IZ=3&#&HI/*93L^CPZB1=%D?I_PL2Z'?;M,)*.U2\S-$,PR6^PWTA0VSC[?Q -A;#YL[!/1\ M67F?*;U%-6V$ZVF1A@&OA[ /\:>SJ\O+=Y?T?[1SZO;XR!0JZ'\ZBW$"BX]4 M@X)O\6V84H$.GZW@66^) X2#>/7I[/U9+R$4-;3,=+.V2+/C,6I")!T9>4VF M=Y=7C$B=QK>6UE,0X/U1$:":UEI0X<-146%;#RNP_'/GL:RDQQ2(_W TB+?J M#"@(]J,=@G&=\IIDV_)XE4FFD&X*I"^/"&DMM3A'_?UQH2Z1 W.$/QP7PH>R MZN?4^[,UZDGXJ2&'U_HFU7)C;SC'E2UZ[$>O\6AR6*_/SFU5;S6L,^7]8+NC MH.RW]V[15K9M*UAVM6Z^LK'1)1I(]E=[)'!C(ZCY>073\89WBZ)\"GQ_.B9\ M.>ZOXF9R3[V7FJ;7. D\:\4*_MQ-O)1A),7*N6>9TC9WI]BN Q6*-?O+$6#$ M8HR*-7+/;%0=H^$61K9,1'HB@9:C8DL7W#Z,]F\\K6N_&9IN7.T5%U3DL^%@ MR=O3+N&KL["-T*VSP#9C]&M69S<0[SV'A%$]9.!-=3\! MY1K$>#>8Q4 X55W;]@XH_6>25KGD++/I&9S9'J=T $L4?(#Q:'H8TFVF;HY_3*]7K%LA3/(9Z@T%>:*$0M[<2NM:2K*T/=FMA![,=KN$E3 MX^&#UGQ7>D9G36U%&&[!%Z0[8H)N WDW/ X5@\-DZI#RR @M'UWP=IJ*D1-9 MUUV.NS9, ^'U;3V4^G TT!;Q[,??'&=0GP/,=R^US:(J>MC0Z.--O+.\A"+% MS.7+A%/'030J?(AX.&/&05PI:2TV$^3!X00_<=E9J2&;J MVY9H(]@LW*:G:JLF,"H]O285+?;;=0I:2W482W H:M?R6G;>D:CA4'8W<=^> M,]56*OS)F7IRIIZ% MNDLUN7+:A3A(VWS4H,O$>LCER=N\YVT^N?YEB\'5]UWVTRL-*^NK1.Y/MA\D MKY@NL*"ZX=SI)B>BRF(-J8QS:%U#IVMPJ*UF--$=LBZ]-0M7%UP4# MND'D99)-%VS9!DFA)[)WP0YMD"@B::H+AF5[;GU;-N.36]^V1;*6\-(%(Z]- M$]"MQSX'W@U8@!DD@Q $"P/9-&;$U755HS$,V2N53VA(X9JEX$Q@'&?BE$!, MU>MK0PAG4 W2O3.CC"^ RAAJ20_H8OUTG7AT_ME>O M#Z0#J@]8^580;>S#=DM/& MD,0X8.8$]O"F,Q+:#7R.[R,*6L((*RMJOM_0CD^C#(;:L"]J;@/VG2T0I?]A M#^&]@)#M>@$.RFXNXI)>1BJYN.(@=@WN*F#U3.YZHQB0KI\P\"C3F:5,9AWY M.$XPU8[A"PQ1^OAB/XGG*L432GIOIVZXZ"49/KBQE+]^R*$ZI9P#D**<2$ MX1NOG)%9^V$Z./13&*\!/7LLY(TN: K2.M:-?Q5K=C91[ /8587/E'IYN5K&_F\J)7C$1)V&IB$T:I4K#3J"-P6LK=+E@A_\#T,0;1 M++WCR/6J:/,(5BGC>P78UQ.-FXYOA3HJF$4@JU0C P-WBAZC].8CGVE#*FQ$ MF5_],T;$.($D,UFC6)K;)T,T:V -OC%<;K(0V:N]"YDK0=S!'?CE+AQ9ER/ MP=9-$B/O]P(D/\\93L]?"J[8.:7L:$! MV/96;0"[>64\#6$KG7A'ZK5O8M.R)%9#JRN/!O%5D(W%L.+&M5ZVIX9MQY!" MP]L*CKB7W2"*3(2TGA4LM"^;4^WX-N?&A#YB:W1+M"^I6M9MT0>G0AT9U[KW MQ]Y>T5!6NI#N<'CJY'I$%Y(@#D(<@5IB/R'"%GUTW3?6Z][8O:A,6U'M%QO5 M4R+5!D>U;-DQ!=,V*.Q')LEB ?"*12&D'8B!%W'N@@A$7@!".N67%%2/$C9/YB3Y1!Q#E%X_ M R:S8O [X 4A)0\DJA01=1\;]LD,J@&%:H1G(,K39Q_I_U.X=%1W*%'L=+JG("B).'=5K93 M!,IGF7_>==,$=$+9S8W=O:OGE;S]I852-3[Q6^1F#?**=EB3P,.;IB MI:RN\JUY[*Z^T05?1E-L"X7.OJNA+6P%LJ7]PN^M+J_:D& ]_*M5 DA5^0WJ M5]T)\JJLJ':IILJAZ:%_9UH/=FM:;D;#-].)P*I329WC**FCY4;-O:BEI.4[ MA/>;G74,G]&4!=*\L@J8%)\;E#S'TR1<-[>5ERV"IP!_D& LKOI8;0P;!CL] M"+/0F_O(PQ 0> .S_S9"6C"DNS3X.^4<]'*=BLR8547+/*:#,*1;-^EXG*VJBA<42^R[SISET@BM:K+_I6V:592 MPZP[9DZV:D?HH;H4OR]3M;L1+LU,U>Z&H.A*S!Q3M4SO[)#WH0[J5-^OE* 6(V!',/W>O45 M_ OA00B(S%)3903',)35 U5V#W N"Y6W*X&\XZ'@<>*&BG3C[?;V0UG4&QPO4@&K4&.T4G.KS&]A"SQ M+E[IAKDH.IR\PW6Q>,+ AXPSR]7=O69V34HUM+^R2:6RD-X1*]-AR=*5[+6: M*EF9,E+[4!=L[0UH(+F^73*TR]A%346UO -JRL"4 MQ3W#-Z=T(=6]@9&O3)!]'=%ZQ%"->+$J9AS-X[(O&5D7: Y(F,IBH_58N@,2 M1R_@\H/+>K,TY$YEP;-?",/)&"R7 F\D[UC;!'.(HMD3Q M61VR3XEW^:"5 M""R#&(1#%F4_>@Z#668&$@4'"5K;,/#RWE_G LUI:!_>/4%-"O30JL-\&Q:E MWU38O,.P6W+L;H,C<\CQ6MJ >(A 1![!2@+J5A,[,)9XK@C&4A/;,,H+:O!: MVH;X 46>-M"EQB8>9,6 %?"P!<8HF5Z"23Q/)5GV%X4 M/\U:=R@;Y/\U IEA Z:%2N\)25CBV.:Q)>XR*#K9=6Z(+_BRW"IF\-955CU) MO1F:;CL;%#*/&,'C=QI4(,WVG6K?-VD4.:$"8MT49WH1RT)'%QPW%9!373Y= M\$+47$M.5K^[GH2:.);%N2ZX!U1*W^8-]-JRHO70&&V+KT2%%%^_]6S^KAC7 MLF6]Z;,%ZT=^^N??$?X]B&;KVX;](K82G@Q9^O!> Q*0R1)#X(^BWP .V X; M@QA>:6$AZ6X?MQM(/!RDFWPT+0.70JV%GV((^SC>T0Q./T$>4]G5S5PSY!R^#<3J>0936SLC8>_0W,].QWJC$_3AP8RNM4M6M/X#HELOOZN3RZPZ2?!..]80=S1 XF0%*AJ4S M2J*>+MP,32="X#18E-S"5<9SSZ)4\!X]-N4. M4C*"D,*61R9=PXC21&3_4O6R8<++84K3N_J1/Z0S5<5'T=>.KV(**6P^A6:= M?O@VH'\'\0!@O*)[YQ5@G_1#>GXBP$2QKW0G+Y(%;2?T:C08T@D:_ ;")#TQ MFU= =%'E]+2!T2W 84#E2@K7/ZEH*36/\]O:*3J8\R^M,R5J;;+DJ0O:' YN10L$)G&\05PB9R M0THZ&"!UH?^RMXDYC#-CL&,X32*?XR*O-X:=(IE4!:92UAW"T .$7[]1T=@F MW+]&A.6Q3P/HRPM@"MMW&OK*GF!^,<]2L82-3+MG12D7\Y1W: LD7C2*HK'5 MNJ+K9=.I)[K5UDH=49[8*(%1X.)I8@1"E7F+Y+OHU(;JU"J M*+S5JC.0EM?^\"5H5#?==JE%OC!BW06Q%P*B?VMNRNU(+K0C# 2I1B"E2NIR M*$@]5)66.I8]WKW@** J.& M_3*8%9^PY=ED>#H(1V&QOG,K5L2LC:H;@09Z"ZLT6RG9DE/)!GI+;!)I-Q9; M;4G0M(NM;^ ]IZ+]X#[M#;UO,^->-MW;M)40Z]#&Y!GERI@) @2L1UJ:P8[K M&>]2)-< +19!G%6-COP!BIC8#B.//>V^$9+89PR\. %AJ7R7I&NU^"^N%ZP8 M?7?P/>1N2G4_6P$F?&6U917!FWK3-0WR2P/Z6WWETPC>>< M.)"*G5W"ZSZZ0PFNA=565[=PFD /17XMG$I=W<+I:1[@>B@5/9W!Z"Z)Z?60 M&^GRC#="@1U#=A?2"VXTO:.W" BK(EQM8"LQC6^,.R^.2ZM] X\B4Y MRW5'H7'M3@#UPR=NF=L0E@Q,GRM@RHE_P(,H 7@3<',"0#0.:O8/4XIY^ MM[J//*$_5*>7E;I6E':I#2&!?FX00E&66L%2@.[H_N,VN4E8,5** X&C)*^O M? TIG8L*5A^MI5T7G0'[XC5/P-45"+ M(;NL^QNB0ZL2KG6#00W=4>1=$E C!EFYYO9ID_,11/ZP4 MYOP_MCVQJ>8NSO5SI<84E:1WE*4QR\0CH/_R+(,93T,Z-!?4O;F $ 3/AR\BJU\=JT>A"!!&0E-?2*L0Y\>0OJ8I:6[%)Y.D'3ZCO4:$'0RH3 M4_#BU2,589CPPD2AY4(VLF$A ",D8OD JSSU $15W M6]DUYN14&\,E8U'L=.U+0WJ6'?V1K&"< 2 OT;W5QB*4/!J*+**5NEHMI;W6 MM->L4*>D-K>/76^S7/K=R8 0R&S6#55Z)L#FJ#KA4=:P_ZK$:VX)Q%T)P.4D MKCJ(2J1VZRE;-2P]E:\Z^09W)+?GT(10L'/K=1-U"IKS9(&U"T=#MW(Y84\+ M1X%H;3TU3Q@[644NXOM-*NSY(W2B-*;CKF;CLJ>D*;)TAOC:PNUQVH2F.5:P^]BLP5*N.*],HM]C7]F7HOFOM <60KMC&1[7!F(SP M#$3YX=R22>E*/F)(6(%Z]B>K*[+7N?!^/5$0KZG2_[LM1YP8PP>0.>8+AZA[ M,%;RYW:"ZDTQ2F4G!UE;SR[L$ZAB3&@1=#/[N8.K%Q)C$%:XY" MRE))%DO!VG8"]%R@92)/GAPSAAX,7MA6[CK8KIY'+> ?Z:U6E-]U"?Q[>KU& MLX "VZ$CJ@&TJ]NE7'O$80ISP725IIN O4YL7DF%CR.$W]4](TJ1Z\025))M MRTES0NQ.*7.=3OCB+HO17;*_?D:'/^6WN9#?9C@^8L^,)PJ*&+H1SR$-"]IN M]+TE=MERBIP2NP[NF12>7J[3_#MP,4H)8OZBM>Z8TP_ X#+.4VY117OCCA^L M$QJ(!M *S>^7"S;U,R"0_O'_4$L#!!0 ( +E,JTR+'H[EL5< .+ ! 4 M /'[]___YAO8E7X8=5N/VX\0(W6'FN?Q;CZ-5;X?@C.CO+:?\U ME>)7-/O@C#_,*G^Y#_?!^E?D5'YU&6$W(4^C-1&$_&DX6IP-IV>CX>-H^>MH M^NMH_O]7GPYW;Y'W_)*@]ZM?Z,-S=!4& ?9]_(8^YU(-T,W-Y0=T[OOHGCX< MHWM,!<7K#QDM/U>06"V(__*NHN6/I\C_$$;/'YWA5B]X*U[Y@5Q0J2IO4B)\5X=+9?+C^ROZ=.Q]VO,J-R$ M*V8??@1K]_]"V7XSU'HXWN\04R&7Y.W'?[+ MN]C;[GS\+OO=2X0W?"G\*/I(W_\8X&?R"=>4PY)R&,THA_^:_9IYUCM$G_S] M_EJHT+)&*WWI8RJD3_]!/;,F)OZ1X&"-U[F@]'6)N1AU9FE&E)(-5S6"/K5Y M&'$59[0V;OS$".[CLV?7W7VD;O@1^TF<_^:,_N9L.,J,_%^S7_]YOEH1 "3Q MG?OF/OGX?AC(3=]O"9YA.-P'ZVPEBG2SZ(AP9_^$WUA MZY/':6S!P=GO#^^0M_[+.V_]YV@XGHRFP\6?SF3L+*?.GZ,_1^_^):>$,E(# ME!'[YU2 ?G5*2/S!-Z=6S*DIMDM)\?0YC^H.YD:K7"[R8XM"V1,?5R&));OD MK/:]-E&X;768G'>HI/]'>%C<8Y]B_\Z-$@_'F7#GP?H;,8$.8A3HP(&I73@- M=YR.9R*<97Q0QL@*O/6N>PK%+>61 Q$E(?+=[VCC15NNUD"H5'=N"6 5#0B) MY7N\PMXK%?9+%,:Q6JH3O 2 4KXD6AEBWH!D27* &%%+DF OJM:385201.\# MG*!P@PA2DLA=)7O71Z[OA]]I;1S_8@,RY:[*@Z'$9$"8B_:D6/;<)\_W*B%! M_.4%SYM%&E\(G=@_FQ0@H\10A1H\NGI1CP'K:L_R6?+B16N2X*+DC::Y,(). M;'*O:R!'8@X]T,3Q&T7"8CC.<$!^D3.XPX'K)V^??NQP$./&MQ$_U[/?K\/5 M?DN48V-W52%4'6,Y'#F3X9_CJM_O4DH(IZ0^G,3G>6CN2YN11!NS .Y+(^=0 M(^+U,IU.#=Q6F%# RM4'RF[[[9X5O%=X1TH+C\&*_.QC^@.I>TGI3RKAO[/? MWT7A#I,(>4>^$JV)/_W'WMMMI:,J\P$JV",W M6*.J .4BT!^HD(,V".%'& I&L**+##RF-1"J60@$ M=SXCCM'_':U!H:GER#9[JIH."*)NT M_QQ&5^'^*=GL_\%S^C)]2F7$RKZD+A1 J7JE*IZ@9^](#B9MKQV M*0 7GY1S&C5'7^>.[F:/ZBE7E+-%[W/&W#5P,Y6:(5O51E)QI5!#+@D8Y-_K_8J5 MKDE(_O&*@SV_4;37R4EY54K L6A6A:8Y:E M?GQ@C,Y"PLGN"J&S02:U%J'OA$R" T04'J"L1X@&AE>"@I\!_0>.KP_XNB7[ MZ(&0L'VD'!_QC^3"/YS%U'S9=+>$LF2J+CF?.6,G;Z&0%ZR&6RE.I6HC''WF MAJ,_& M$>2#&Y/\"M%Z'?#63^ Z8ZP]SQ M* -13@!1"F8!9ZF?!/6KF8L,[+7,O+"UHQYG).9 MQTCU>V1 *6KA8XQ]LL#X%6^?<*3L&]GC5@2X5!957YQ-G=%R5@UBN]P7W9RB MX8%U?UK) ] ?*4UK DPG%>5!1*8B7)"H@TL>""I& 1E82 <0Y@<*NG7R:%1- MPU!5?Q>IG5-+'2:NW[O4,RKUX^WC^0TZ?WCX]/@ .A81CSFZCBWZ1)5@B"%X MR#C*M*NZL3-;3JMH RMB>U$D!: E3LRK'B5:PCEU2U==[1GC+JW?,C1;SJL> M?>*=VFHAN9L6:62F'%!V\ 9RA=G%K'/+^I@.- 9W;:6PW7P6RM7U8]]XY#A< ME[(\@P?)4QP'C<.BT,9=+;:#!O)H*1F M"3B.5H_AHZ*6-1 1^]HA2@16Z&&R[&(?>P&.X_-@?1L]NT&V;'%#?GF=X&US MH*STBN%)LS9YU"=QR8!OD4Z(PGUM3LM#IX@/K:5'_<.GC=L0%)HORG.QD.5D,6V,"HVE%..BB M75LH.*%V7:) %Q7;(H!814#PUT#6 OS2*!#5<[:;^88VS=\^^=XSDTDTRRYZ MVF#M+!!!8^PUGF2#RHP48K10A1A,V=R/9DY5,Y]I%I;$V %"[+0,R#*ZQ>FJ M5;3,*#TDR4LWVGJK%Q?[\:4;OWQWW^Y>R*_K^=79ZT-E$=M5 9YYD M58T%DVOC%Y+\Z7_HH5ROKD\ W;;TUO*2TK.&<]-;?:R"*4)20R1&]>\/Q7U]^+=FRKO0N/N;I &NXX M' ];H#= ;H)R\HC1ASM2XQ3J3^1H_$0+Y$VV[QSRC(U3Z#Z5ZUZ>NG%:"W0- MOT?I7H_"*_H#+FE;&'KY$4LA G/,9$\@UCI!0XL$>%@^]M0'4BPL6J.SZ0,Q MVOI 3F@*UB9"3S+U"F77N;+I,8H"*]D'9O53+[3MV<R&8Z<%'K):!F>T>A%E5%=E9P6Y*Q%+WHY'?0R M,C,A1TPQ&R$Q0A^X#;=;+\GVZ%R&04)R/@Y6'HX/5A^K7T;A+=-X;A=).7?, MYT,GG[TLR+*%HQIAN': _I4=P2LKCP6]:^P%KJV#[2$A)+' M6[G_E]Z<^?88N4'LLI,'16L71Y$""R)Z<<6JU@&HBLO7OEA MO(]P6_^$%@T[@'8HF(9C3F=#!>BAD@=\L\4)+>'T: D+D"MV>T4L"PQJ+;I% M9^]V)&(;OK6/925N/5Z.=0$.=C:M$6.T8]QZ-'./ISW">#W-!80!NU4I/PGH M$0=K'-UN-C@2KQ"JO 8PQF^32:>%=KXLQ_-A@&)*N#RK*V&DZ1'M.#*\EMB_ MGJ.*GHQP>;152AHQVI +C?TK[?2@M*G1M2I$JR-I)7-!E039I8K?0C*HE_9J MQ6I9S(M"UVMF7WYU@!&",-P?!W'>[QN_Y*UIV%04A5!RYWF/)P\9%Z5T@-' MRA'*\;#B";4" C/TP00.3"#%2"YW2=QXK+K$U6_9/452+A4Y-"9G9R/99BI M$+4$.-W5Y*$GE.L'!B&.'TIQU+0*,)@4RS'(2DR[5ID,>4!A9*S)+5V4.AC# M\ JP7S,-TVWAI;,-T'Q P)7AB>X(^DK<_@6-1P-$)PK8\\O!:#:F?_O7?8#1 M>,C^-+<$;RKE7-=*3CA=L@^\Y*V]AUKP),"D"$<,53=;#H=+9U3.@S!24#W4 MO:@RJJMB0P]U+WHY'?0R-7LA04QUPD)D!*!\N(OP"PYB[Q5?!ZMPB[_AY';S MZ/X01W+A&V:SI$@,G=PR+1-F20ZE]-#[FS".?QF@;^G5E(3T )TG2>0][1-V M2U["9C? 3JWMSP:S0QM\3+.K "<"=N!AE,YHV+(5J&4=K"C/R@QL+6['C1S]#4SAQ69H]5A(K2$ M'0BY"K>NURSV6A\'14DJ@\[.T/%2@I.4G#5(Z:2=&"L2[>#04G9B8^&-RGC6+E4,!-%QI.2IZ, M"E5/NH JPXY6:-96J'' W0*M& M(\C*GD80B?,U8".PD368N=KC\PV)AY^]3?+R;]AMSG-HO@R-J@.)U#UR.IU* M839 A#AR*77$R"-*'RP_]:\[RU9W[EN*N#51U@O0]+^C-T+*/KP)';<5@'P[ MV83(Z^ S\9E.>*R]:@$:J_)H9(?9>-:.1>*>*7$+D7B$WEP<3NR%(<];54!X M8"*[(/B B4W6G2!8>=4*");R:+GB0@F"*7$K(=A9;RX$'9LA>.BM:A!LF,@N M"#Z^>%$W!)9O6@' 0ARM =)$"7^,MI7PZZHU%WUCF]%WX*AJX*L;R!KL??;B ME>M3N;ZZR3[RDK>'U0M>[WW,SBAHW\ES#$UHO*H*JC6X:D%RRI-A&.5<4[<+]0"MUCBB97][(LR>R(J_>H&WW6_S M2$]"XCVFL\IL#T.IF)8[:A$&CS4ZTNJ4L&4OG"#@,,8HXXR*7'M%>^4*[A1W ME=!D4]0YH>&XU<>(51_VA9,N.&J/*=K6A0DLT2Z,W 1_"\DHYID*R>W4:W_> M:!@0"*%3(D^*@7E&C%T:>I;1 VISZUM#IZ8A2^VW]+HCT&XW9=^K8TQF$1CH MQ,GMYDL8KN.'T!?O.:H_910F-=8:Q>.H7"N-6><:(X(H%2@\'*.*4U7EF:D2 M"U0QY_M(8SJ3MY3@/2Q3OJD99; MV0;F-8HEFICU\*;;'#IX36,H_Z8G27SZL<-!C%MOH!(];MCG>3)H>,UD6 GQ MZ: _IV;!"4B]J.?PU8,&A%*S35K\%(P3W>4Q7CUX3E\_;C&'@78A/Y <36IX(K\JI"BF GX%*RO MR"BG\4VECQI D(R_AB/-BKN&<]A4YNSI56.4GEFT]*B9TT6S4R-$Q[JZQ72V M-1^I.2XG*RD8"@:/<1)N<<3.F:8KAR_>+I;/%TO>,(H]H1@Z7C?+YXPS^.S#"?6OT2<5R+."X@X.$Y0VMSPQ*P1 M,V[VP+#=J\7@;#$?/&2O<+R*O!VM.6\W50&9Y$HNTD("#+IRN;3*IX4 OA46 M='6VAMX4VS9@N%=#<'&\+CG8@ULUUQ9C5\%L\/C][*[P^3;IO&'X ,<6<50=9KY<3D?9A=G-,0PCBG*JIRLC>7#O7T7N MP-.4BM*#'OO5DY=4!_7J&&TH#ZB3'Q6AEY\ J6(=^-Q9%>G39H-7B?>*[S!Q M$P+A9]&QR7HTP+)LBV ZH[?%2)!Z:Q@NS+L]B=+1+*>?EG#W@$OBG M&&$\6\'#C!T"HO2MTR?!(,78:]4WV>);]9"8FS!X/B.>M44->,79(3I69*9)HM8P2L@(;^@IQ5YZW M^2E:.Q:6+<)"Q;$D4,C- (.$#8XBO'YT?YS',4YB\L,E^;>77+I1]+8)H^]N MM([/??)M Y?._V5'Q8@O3CJ*I%%T=9=3QVT7Q1I6RH]M>$DY#MC/*5-4XSI M%;[%V4WD:2C@&K-5;0>G6S'"-C-"0J^GHEMI5DP T(W2?<"G'AF.M+,5,81> MT,5^*\6HP&! 4/0"O,XVX-V1SW6^#:/$^[N;MK#=D0(IRHXR MH0WTOMXZ<9@G9.3>V0 BO2N4FN,/A0%SRAYP2ABG.F_-JGEH(]B[A^@\N!TU->Q M*X+=8Z)" M @5K51*=*:SE2 ;/HN']4C"FA2 M_58+5X+701'&ETG# :>CL0QKA'[9*Y7_R<"T6MM]V">R!+LBF^J<5\?987%V M 5+NQW)H2LP$ ])=A%=>.GD?K*LS><(O+W[#*!2%8FA47[>V07A>O]ZG27T;=GO[YT=YJZ,X7="D%8Y+4Z9QUL2W#[4=,W<<49,H/4I2=6>>C_,S M5BL3M^P>O9(GRIBR]!D/$.-[QAB75X*!GW)GTF#.R0UF+%+T K-:,#G^0T#% M&W8EY!ZO;W!VI6%LBJ MYB/!B_""'3:V9KI.Z$5WTC/,(?N!A./X5[-R?TP2TXIR@$UC?FMI308\KMOA] M1V_$N]UGLV-'U*$]<82N2?M10Z.06DRF\OHT"U:-"I47W5+!$)/L+-SG4]AV M5ZL@!E>-?=95LOWBNK6J[?'C_.RA\1M.;C=F8F+!ZB<-AKG\&O-BH]'DY%&0 M+G"1(?T_1/CK:&)NW).,.$YSA/0KCIY"ZVTU$AN+[WGQ 6IBR5\%_L9,T4R');S87;P^NCZ67]VF1 $;CC6* MCH_UP TZ8ARO@DYCQ+QE&HS=ULO$H9 Z>CAH43@R;N>L\[HX'L&&;L_3(K8U M@O7T#8""75E77?IN''L;;Y6VXTENA6QYRVSPD8FBDY:=LD*I5->H3A3V]LA> ME76.4=8@ME4CG47M2B4CDG/]_9KD5&ZZO<>OF/R"31%^2FN59EKK@Z+Y=J1C MQ%7UV1D1:#HMVH]2GWUF/NOE3$7]1E'*-Y_6SNK$V'C7D4$[\8)9P50TQLCX MLA6FVPW*68-T%!FTE9-O&\O\!&2YO,=84ND,.MJ*X-5)+!><3MEDG?:/^$=R M0<3ZFTKZ[$(6JK;I(*M._3V=\:)%/&B-%^GT8''0$66.&'<;ZJ/3&TTV<6I- MO70$?(3E5%?36A]+VF^GZ4C-ULC1Y>Z7V6(YXI87-MQL8T1YWKC)GFMOCG/X MSJ _ZM*<]I%5&WNZ6G.[24^ :2\)>B8Z4G9%YQ\/9Z/%>,@;@,6#UB$8 M>83NJ**CK_0T(L"QEUE[=2ZM'C)[I8+846D!VS*]V*5F%RN&:CT%)^ZXK0\+ M]Q*,7W&<> G;T7RQC[T $Y;Q'7$MNGQT%WDK?+[^]WV^5-!MINH616S!$4<'1=# U8I=1TRZW M&U1R0SD[Q/BADB$J.4($1R.V88'P3N@9ZSVF9X2R=H*7,-YY"4D]3_LW#'(2 M:!_AHPR-1]BWCS"8Q8SS8/V)A.+D[3K8A-$V7=&3[#A6>%.027E@-)U. M1J,LE&5T67LH9I1)>5B0-ANJ^M=Q5-.1$$8I950A#;L;MW^=G>-U-A)D-,!9 M!!15:W6?O(KQZL-S^/IQC3TZ;S6A/]#(,JE,5Y%?%:*D9Q*GW3B?R>^::X3R M9PU,-4D%T)E$73H-.&6G?:?D$*-G%D!]JN9T4>W4.%%R- J.=DN81@0]I5L- M#^63(&@HV&LYS)B/!4K,#B1T58N+ [E:YE%PX%Q\#-1M8 X!*?8^!>LK-VF. MJ<7/&?;^&G,-)YF,%PW?SZ+D)[K!B-""\_QC5')T53+I]5R':OK\H?;F//Z1 MD)5\&/9GP_Y->6K%OGG#K2D!.%_N(+ZC)+Y)OZVZ1=-="P4A%IH_N9'OX3AY M='_0)"'=<,=_UN B,5< C570Y22K5G)";%L+R^FP^^3Z4"R]0#>,V)X2>GU. MC)[PLQ>P6W7<#9$!?25>^X+&HP&B,T1LIB,[=>5?W6#O1F^(_XI"<+HY)/=8\ZY$S< MB:W!XA17:["C[KIB/)^-ZV2Q$\4FP0$ >M&IA8@%\4DNH;I+SB:+65N$$O2& MP,>H7HT@C5*"=@_KXE2O%I%UREH5J]0P+XM6"G8#&ITP47,Q6X[_$3YN=HS" ME4%G%F8V::"Q!"+TN3T]J5?L76D<\ 4"*U5O:XPYQ':P 2H7;NRM%#]B^BP@ M2)@ 6BXT%2%D@!@QF O"^M"+W08FU $*"S5WD@&A5-D&%%QY_C[!HJ-C1$\# M(B$30<-GG)$P6]"-3HR<'6CHIMLLK<*$>D AHN%:,DQ4%0=!17J=-,ZN\;GQ MW"?/]Q(/QY?[*"(C+]$';'W/)%+:A-'PJ^$PQTQ&]"S*;GVJD!V@C#!0I=6S MOJSD.E^M(CJ0V;EO1 J?30'GJH,?N:WLIC6L*9GI] N :1O6)6$8N?YUL,8_ M_B=^XRQK\9\SM"3(9:[A1\M)UDF8-=)EE! CA0@M\\N$?:CDZ*ID8NE0ZE#Y M&J)8>V,>'VZW8?"0A*N_L5P7W^Z3."%QA21 \>>2O606"Q))U+UHX0P7=6 P MLHC1S>X0C%&%-!A.^E/7.5)=@QA2<-$&H-K,9 I=GST?1Y_GNE#=W0_5-N7?]_C9HQ-G04(W M8@N_2^,QHQY>YZU16SG>DNIMS- <9C?_' MG@C3MI11?\CD.+O&6<,_IM.\!F(4X)D/R5_&-//K@2 -2I&$>(LF@Z@]'YI :AE >J,&$S M-HP-ROE8 K13VE95@2D%92&P=NF<;PAI&ZJ'E];,7 MN,'*TU'X^E\F?:R MYB@JE60 I]3PO]%Q5U

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end